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Abstract 
The pericellular matrix (PCM) is a distinct zone of matrix that surrounds individual chondrocytes 
throughout articular cartilage. Although not much is known about its function, our group has 
shown that it has a role in mechanotransduction by controlling the bioavailability of perlecan-
bound FGF-2. The aim of this project was to determine the other structural components of the 
PCM, and to search for other heparin binding growth factors which might be sequestered in the 
matrix.  
 
By confocal microscopy I confirmed that the PCM was rich in type VI collagen and perlecan, 
although devoid of type II collagen and aggrecan. Isolation of individual chondrons (the 
chondrocyte together with its PCM) was performed by partial digestion of the matrix using 
dispase and collagenase, and proteomic analysis using mass spectrometry was performed to 
identify new proteins. As this method was only partially successful I looked for the presence of 
a known heparin binding growth factor, connective tissue growth factor (CCN2), in chondron 
preparations. CCN2, which is an abundant secreted protein of articular cartilage, was present 
in both the chondron preparation by western blot, and was visualised in the PCM of porcine 
and human articular cartilage by confocal microscopy.    
 
CCN2 is not commercially available so His-tagged recombinant protein was stably expressed 
and purified using nickel affinity chromatography. Biological activity of the purified protein was 
investigated in a number of established assays.  No biological activity was demonstrated when 
purified CCN2 was used alone on murine mesenchymal stem cells, but was evident when 
assayed in combination with low dose TGF-β.  The effect of exogenous CCN2 on fibroblasts 
was limited by the significant release of endogenous CCN2.  High constitutive expression of 
CCN2 in articular cartilage may limit the effects seen by exogenous CCN2.  However, the 
results presented in this thesis support the role of CCN2 as a modulator of TGF beta signalling, 
and suggest that, through potentiating TGF beta it may regulate matrix turnover in articular 
cartilage.   
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1.1 Background 
Articular cartilage is a paucicellular, matrix rich tissue, where the extracellular matrix is divided 
into three structural domains; the territorial matrix (TM), the interterritorial matrix and the 
pericellular matrix (PCM).  The PCM is a relatively poorly understood hypodense matrix that 
surrounds individual chondrocytes and is likely to play key roles in chondrocyte regulation.  We 
became interested in the PCM after the discovery that FGF-2, an important regulatory molecule 
in cartilage, was stored in the PCM.  Upon mechanical loading or injury, FGF-2 is made 
available to cell surface receptors where it activates chondrocytes. 
 
These studies suggested that (i) the PCM plays an important role in sequestration of 
molecules, (ii) it can regulate release of such molecules and (iii) it mediates 
mechanotransduction; converting mechanical signals from the matrix into cellular responses.  
The aim of this project was to define the structural components of the PCM, and to identify 
other regulatory molecules that might be bound within it. 
 
Before presenting my results, I will give brief accounts of cartilage biology, and a more detailed 
review of the pericellular matrix, including its structure, function and changes associated with 
osteoarthritis.  
 
1.2 Development of articular cartilage 
The formation of cartilage is essential for development of the vertebrate limb skeleton.  
Cartilage development, called chondrogenesis, can be divided into two distinct phases: 
mesenchymal condensation and the subsequent processes of differentiation.  Multipotential 
mesenchymal cells that originate in the lateral plate mesoderm receive signals that determine 
the shape, size and number of mesenchymal condensations (Shimizu et al., 2007; Tickle, 
1995).  The exact mechanics of the condensation process are unclear; however adhesion 
molecules including N-CAM and N-cadherin are thought to have important roles (DeLise et al., 
2000).  The condensation process is followed by commitment to chondrogenesis; a process 
controlled by a number of factors including the transcription factors Sox and Runx genes, and 
growth factors including FGFs and BMPs (Akiyama et al., 2002; Minina et al., 2002; Shimizu et 
al., 2007). Chondrocytes then undergo a process of proliferation and maturation which results 
in the production of an extracellular matrix (ECM), characterized by the cartilaginous molecules 
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type II collagen and aggrecan (Archer, 1994).  The fate of developing chondrocytes varies 
depending on their origin and location.  Some cells survive and persist as active and functional 
articular chondrocytes whereas those that comprise the epiphyseal growth plates go through a 
proliferative phase and eventually become hypertrophic (Pacifici et al., 2000).  Hypertrophic 
chondrocytes then undergo terminal differentiation which results in cell death, followed by in-
growth of osteoblasts and blood vessels, and formation of a mineralized matrix. The process by 
which the cartilage template is gradually replaced with a calcified bone matrix through the 
invasion of osteoblasts is termed endochondral ossification (Shimizu et al., 2007).   
 
1.3 Structure of articular cartilage 
Articular cartilage is an avascular and aneural tissue that covers the opposing surfaces of 
synovial joints.  It plays a key role in synovial joint function by providing a smooth surface which 
results in frictionless articulation and is able to absorb and distribute loads.  The organisation of 
articular cartilage reflects its functional role.  Cartilage can be divided into four zones which 
vary in matrix composition and cell morphology: the superficial zone, which is closest to the 
articular surface, provides the highest tensile strength of cartilage allowing it to accommodate 
the forces generated during joint loading and articulation; the transitional and radial zones lie 
below the superficial zone and exhibit a lower cell density and an extensive extracellular matrix 
(ECM); the calcified zone contains cells expressing a hypertrophic phenotype that are able to 
synthesise a calcified matrix which provides an interface between uncalcified cartilage and the 
underlying subchondral bone (Akizuki et al., 1986; Kempson et al., 1973; Poole et al., 2001).   
 
Articular cartilage consists mainly of an extensive hydrated extracellular matrix and the 
chondrocytes, which synthesise this matrix, contribute between 1 and 10% of the tissue volume 
depending on the joint, species and maturity of the tissue (Stockwell, 1979).  Both cell content 
and matrix synthesis of cartilage decrease with age.  As there is little cell-cell contact within 
cartilage, communication between cells occurs mainly through the matrix (Mitrovic et al., 1983; 
Poole et al., 2001).    
 
 Chapter 1                                                                                 Introduction 
 
20 
 
1.3.1 Articular chondrocytes  
Morphologically, chondrocytes are normally rounded or polygonal except at tissue boundaries 
where they may be flattened or discoid such as within the superficial layers of articular 
cartilage.  Chondrocytes typically contain an ordered rough endoplasmic reticulum, 
juxtanuclear Golgi apparatus and often a significant deposition of glycogen. Chondrocytes 
possess cell processes which extend into the surrounding matrix, often branching near the 
poles on the cells (Stockwell, 1979).  Although thought to divide rarely in adult tissue, 
chondrocytes show typical features of a metabolically active cell that has to synthesise and turn 
over a large matrix volume.  Indeed the prime function of chondrocytes is to synthesise and 
maintain the extracellular matrix (ECM). The fact that articular cartilage is not vascularised 
means it must rely on diffusion from the articular surface to obtain nutrients and metabolites.  
Consequently, the entire metabolism of the cell is geared towards operating at a low oxygen 
tension (ranging from 10% at the surface to ~1% in the deep layers) with the majority of the 
cell’s energy requirements coming from glycolysis and, as a result, chondrocytes normally do 
not contain abundant mitochondria (Archer and Francis-West, 2003).   
 
1.3.2 The extracellular matrix of articular cartilage 
The territorial and interterritorial matrices are composed of two major components: type II 
collagen and the large aggregating proteoglycan aggrecan.  The combination of highly 
hydrophilic aggrecan aggregates embedded in the collagen fibrillar network creates a complex 
architecture, critical to normal articular cartilage function.  The matrix also contains minor 
collagens, glycoproteins and other of non-collagenous proteins, which play different roles in the 
assembly and function of the matrix.   Figure 1 shows a schematic of an overview of the 
structure of articular cartilage.  (Chen et al., 2006) 
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Figure 1. Overview of cartilage structure.  Cartilage matrix can be divided according to its spatial relationship to 
the cell.  The PCM resides closest to the chondrocyte while the TM makes up the majority of the matrix. Three 
classes of proteins exist in articular cartilage: collagens (mostly type II collagen); proteoglycans (primarily aggrecan, 
but also perlecan); and other noncollagenous proteins (including link protein and fibronectin ) and the smaller 
proteoglycans (biglycan and decorin). The interaction between highly negatively charged cartilage proteoglycans 
and type II collagen fibrils is responsible for the compressive and tensile strength of the tissue, which resists load in 
vivo. Modified from Chen et al, 2006.  
PCM
TM
 
 
1.3.2.1 Collagens 
Collagens account for around 10% of the wet and over 50% of the dry weight of articular 
cartilage.  Each collagen molecule consists of three α polypeptide chains coiled into a rigid 
helical structure and can exist as homotrimers or heterotrimers.  The ability to assemble into 
the characteristic triple helix formation is in part due to the repeating tripeptide motif, G-X-Y, 
within the polypeptide chains.  Collagens within cartilage can be divided into fibrillar, fibrillar-
associated collagens with interupted triple helices (FACIT), and non-fibrillar collagens 
(Bruckner and van der Rest, 1994; Eyre, 2002; Gelse et al., 2003; Lane and Weiss, 1975). 
The classic fibril-forming collagens in cartilage include types II and XI collagen and are 
characterised by their ability to assemble into highly orientated supramolecular aggregates.  
Fibrillar collagens are secreted as procollagens containing a large central triple helical domain 
linked to N- and C- propeptides.  The C-propeptides of all the fibril forming collagens are 
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conserved and involved in triple helix formation.  The N-propeptides all contain a short triple 
helical domain and an N-terminal non-triple helical region and vary between collagens 
(Bruckner and van der Rest, 1994).   
 
Type II collagen accounts for 90 to 95 per cent of the collagen in articular cartilage and forms 
the primary component of the cross-banded fibrils seen within the TM (Buckwalter and Mankin, 
1998).  Type II collagen is composed of three α1(II)-chains arranged to form a triple helix and is 
synthesised as a procollagen molecule including the N- and C-propeptides .  During secretion, 
and prior to incorporation into the matrix, the N- and C-propeptides are cleaved by specific 
enzymes.  Covalent cross-links between individual collagen molecules lead to formation of 
fibrils, with many collagen fibrils forming fibres.  It is this network of fibres that provides the 
cartilage with its stiffness and tensile strength (Bruckner and van der Rest, 1994; Buckwalter 
and Mankin, 1998).  Type XI collagen is formed as a heterotrimer of three different α-chains 
(α1, α2, α3) and differs from other fibrillar collagens in its processing, with the retention of its N-
propeptide domain (Morris and Bachinger, 1987).  It is proposed to form the core of type II 
collagen fibrils (Bateman et al., 1996).    
 
Cartilage also contains type IX collagen.  This is a FACIT collagen and its collagenous domains 
are interrupted with short-non helical regions.   It is a heterotrimeric molecule consisting of 
three different α-chains (α1(IX), α2(IX), and α3(IX)) forming three triple helical segments 
flanked by four globular domains.  Type IX binds covalently to the surface of type II collagen 
fibrils in antiparallel directions and together with type XI collagen is thought to play a role in the 
formation and stabilisation of the collagen network (Wu and Eyre, 1995).  Type X collagen is a 
short chain homotrimeric collagen with a large C-terminal and a short N-terminal domain.  It is 
characteristic of hypertrophic epiphyseal chondrocytes and is thought to play a role in 
endochondral ossification and matrix calcification.  In articular cartilage its expression is 
restricted to the calcified zone (Gannon et al., 1991). Type VI collagen is a non-fibrillar 
collagen, present in the PCM, and will be described in section 1.4.1.   
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1.3.2.2 Proteoglycans 
Proteoglycans within the extracellular matrix of articular cartilage provide the tissue with a 
swelling pressure necessary to resist compressive loads (Knudson and Knudson, 2001). 
Proteoglycans consist of a protein core substituted with glycosaminoglycan (GAG) chains.   
GAGs are long unbranched polysaccharides consisting of a repeating disaccharide unit.  The 
general disaccharide unit consists of an N-acetyl-hexosamine and a hexose or hexuronic acid, 
either or both of which may be sulphated. Members of the glycosaminoglycan family differ in 
the type of hexosamine, hexose or hexuronic acid they contain and the geometry of the 
glycosidic linkages.  For example, chondroitin sulphate (CS) is composed of alternating N-
acetylgalactosamine and glucuronic acid sugars, whereas the most common disaccharide unit 
within heparan sulphate (HS) is composed of N-acetylglucosamine and glucuronic acid.  
Sulphation of GAG chains leads to a high negative charge which is responsible for the 
hydrophilic properties of the ECM. 
 
Aggrecan is the principle proteoglycan within the ECM, contributing about 90 % of the total 
cartilage matrix proteoglycan mass (Buckwalter and Mankin, 1998). The aggrecan core protein 
has a molecular weight of about 230 KDa and consists of three globular domains, G1, G2 and 
G3.  The G2 and G3 domains are separated by a long GAG attachment site to which up to 130 
CS and keratan sulphate (KS) GAG chains are covalently bound (Knudson and Knudson, 
2001; Watanabe et al., 1998).  The G1 domain of aggrecan interacts with the GAG hyaluronan 
(HA) and this interaction is stabilised by the small non-collagenous protein, link protein 
(Hardingham, 1979; Hardingham and Muir, 1972).  It is this association of aggrecan with both 
hyaluronan and link protein that leads to the formation of large proteoglycan aggregates.  HA 
binds to the non-integrin receptor, CD44, at the cell surface.   
 
Other proteoglycans of cartilage include those belonging to the small leucine-rich repeat family 
of proteins (SLRPs).  SLRPs can be divided into three classes. Class I includes decorin and 
biglycan, which contain an N-terminal domain that is substituted with one or two dermatan 
sulphate (DS)/CS side chains respectively (Iozzo, 1999).  In adult articular cartilage, decorin is 
reported to be present in the interterritorial matrix while biglycan is found in the PCM (Knudson 
and Knudson, 2001).  Decorin is associated with type II collagen fibrils while biglycan has been 
shown to bind type VI collagen (Knudson and Knudson, 2001; Wiberg et al., 2002)   Class II 
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SLRPs include lumican and fibromodulin, which are primarily substituted with keratan sulfate 
(KS) chains (Iozzo, 1999), and PRELP (proline arginine-rich end leucine-rich repeat protein) 
which is devoid of KS chains (Bengtsson et al., 2002).  Fibromodulin has been shown to 
decorate the surface of type II collagen fibres and therefore with both decorin and biglycan may 
play a role in regulating collagen fibril diameter and in organising and stabilising the cartilage 
matrix.  Decorin, biglycan, lumican and fibromodulin have all been shown to interact with TGF-
β and are thought to play a role in sequestering this growth factor within the ECM and therefore 
influence TGF-β activity (Hildebrand et al., 1994).  The class III SLRP expressed in cartilage is 
epiphycan and is thought to be involved in organisation of the matrix in growth plate cartilage 
(Johnson et al., 1999). 
 
A number of heparan sulphated (HS) proteoglycans are present within cartilage, including the 
basement membrane proteoglycan perlecan, and cell surface proteoglycans: members of the 
transmembrane family of syndecans and the phosphatidylinositol linked heparan sulfate 
proteoglycan, glypican (Iozzo et al., 1994; Knudson and Knudson, 2001).    
 
1.3.2.3 Non-collagenous proteins. 
The ECM also contains numerous proteins that are neither collagens nor proteoglycans 
although their functions in cartilage are not as well understood. Fibronectin is a high molecular 
weight glycoprotein that exists as a disulphide-bonded dimer joined at the carboxy-terminus of 
its subunits.   Fibronectin is localised to the PCM and TM of cartilage and is expressed at low 
levels in normal cartilage but appears to be upregulated in OA tissue (Rees et al., 1987).  
Synthesis has also shown to be affected by factors such such as TGF-β, IGF-1 and 
biomechanical forces (Homandberg, 1999).  Fibronectin can exist in multiple isoforms due to 
alternative splicing of its gene and chondrocytes appear to produce a characteristic splice 
variant known as the (V+C)- isoform.  This particular isoform has the (V+C) region within the 
type III segment of the protein deleted (Burton-Wurster et al., 1997) 
 
 
Fibronectin is easily degraded by proteinases such as thrombin and cathepsin D. Fragments of 
fibronectin have been reported in OA and are suggested to have a role in matrix degradation 
through the stimulation of MMPs or inflammatory cytokines such as IL-1 (Homandberg et al., 
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1997) or induction of  type II collagen cleavage through an IL-1 dependent pathway (Yasuda 
and Poole, 2002).  
 
Cartilage oligometic matrix protein (COMP), also termed thrombospondin-5, is one of the most 
abundant non-collagenous proteins.  It is highly expressed in the developing growth plate but it 
is also present in mature articular cartilage.  It exists as a disulfide-bonded pentamer linked 
near its amino-terminal region and the projecting carboxy-terminal regions are able to bind 
collagens I and II in a zinc-dependent manner, suggesting an involvement in collagen fibril 
organisation (Rosenberg et al., 1998) 
 
Tenascin-C is a large glycoprotein composed of six subunits.  The expression of tenascin in 
mesenchymal condensations in cartilage anlagen has suggested a role in chondrogenesis 
(Mackie et al., 1987).  It is expressed in normal articular cartilage, is upregulated in OA and 
following stimulation with IL-1, and mechanical loading (Jarvinen et al., 1999; Pfander et al., 
2004; Pfander et al., 1999).  Surprisingly, the tenascin-C knockout mouse does not produce 
any gross abnormalities and is not essential for development (Saga et al., 1992).  It has been 
suggested that expression of other tenascin family members, or unrelated matrix molecules 
that share common receptors may exert a compensatory effect (Jones and Jones, 2000).   
 
Another structural glycoprotein present in cartilage is fibrillin-1. Fibrillins make up the structural 
backbone of microfibrils, which unlike collagen fibrils do not demonstrate any well-defined 
banding pattern.  Fibrillin-1 has been localised to the PCM in human articular rib cartilage by 
electron microscopy (Keene et al., 1997). Mutations in fibrillin-1 results in skeletal abnormalities 
associated with the connective tissue disorder, Marfan’s syndrome (Dietz and Pyeritz, 1995), 
possibly by changing the bioavailability of TGF-β (Dallas et al., 2000). 
 
1.3.3 Cell/Matrix interactions. 
Metabolic activity of chondrocytes and therefore maintenance of tissue homeostasis is 
regulated via the interactions between chondrocytes and the surrounding matrix.   These 
interactions provide the cells with the ability to ‘sense’ both biochemical and biomechanical 
changes in the ECM environment; resulting in transduction of signals essential for cartilage 
metabolism (Knudson and Loeser, 2002).  The importance of cell-matrix interactions in 
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maintaining the chondrocyte phenotype comes from evidence that culturing chondrocytes in 
monolayer leads to the expression of a more fibroblastic phenotype (Holzer et al., 1960).  Most 
cell-matrix interactions are mediated by transmembrane receptors.  Chondrocytes express both 
integrin and non-integrin receptors. 
 
1.3.3.1 Integrins 
Structure and ligand binding 
Integrins are transmembrane glycoproteins that exist as heterodimers consisting of non-
covalently associated α and β subunits.  In mammals, 18α and 8β subunits have been 
characterised and through different combinations of these subunits, 24 unique integrins are 
generated.  Both subunits are type I transmembrane proteins with large extracellular and short 
cytoplasmic domains.  
 
The extracellular portion of the integrin heterodimer consists of multiple domains.  The integrin 
head piece, which contains the ligand-binding site, consists of a seven-bladed β-propeller, 
bound to the α subunit, and the N-terminal domain of the β subunit.  Integrins can be 
categorised by ligand binding specificities.  For example, a subset of α subunits have an 
insertion between blades 2 and 3 of the β-propeller, known as the I domain (also called A 
domain, indicating its homology to von Willebrand factor A domains).  Integrins carrying this 
domain bind either to collagens (integrins α1β1, α2β1, α10β1 and α11β1) or act as cell-cell 
adhesion molecules (integrins of the β2 family).  Other integrins are characterised by the ability 
of an A-domain within the β subunit to bind the specific amino acid sequence, arginine-glycine-
aspartic acid (RGD), within a number of matrix proteins. This cell adhesion sequence was first 
discovered in fibronectin and is conserved in a number of matrix molecules including 
vitronectin, fibrinogen, von Willebrand factor, thrombospondin, laminin, tenascin and 
osteopontin.  Integrins that recognise this RGD sequence include α5β1, αvβ1, αvβ3, αvβ5, 
αvβ8, α8β1 (Humphries, 2000; Hynes, 2002; Leitinger and Hohenester, 2007; Ruoslahti, 1996; 
Takada et al., 2007).   
 
The cytoplasmic domains of the integrin heterodimers are much smaller than the extracellular 
domains, often less than 75 amino acids long. The β-subunit cytoplasmic tails show homology 
whereas the α-subunits are highly divergent except for a conserved amino acid sequence next 
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to the transmembrane region, which is important for association with the β tail.  Both α and β 
subunits of the cytoplasmic tails are able to bind a number of cytoskeletal and signalling 
molecules.  The ability of the integrin tails to recruit several adaptor proteins, allowing 
connection to the cytoskeleton, is essential for integrin-mediated function (Hynes, 2002; 
Takada et al., 2007).  
 
Function of integrins. 
The function of integrins is not fully understood but they are thought to be involved in a number 
of cellular processes including adhesion, proliferation, cell survival or apoptosis, shape, motility, 
gene expression and differentiation.  Evidence for the importance of integrins comes from 
knock-out mice.  Disruption of a number of integrin subunits leads to either embryonic or 
perinatal lethality.  For example, disruption of the β1 subunit which is present in at least 12 
integrins causes peri-implantation lethality due to failure of gastrulation (Fassler and Meyer, 
1995). A mutation of the β8 or αV subunit leads to embryonic and perinatal lethality due to 
placental and neuroepithelial defects respectively (Bader et al., 1998; Zhu et al., 2002).  Mice 
die perinatally due to severe skin blistering and other epithelial defects in β4 knock-out mice 
(van der Neut et al., 1996).  Disruption to the α4 and α5 subunits leads to defects of the 
placenta and heart, and vascular development (Yang et al., 1993; Yang et al., 1995).  Although 
mice with mutations in other subunits develop normally and are fertile, they do exhibit subtle 
phenotypes including; reduced tumour vascularisation and glomerulosclerosis in α1-deficient 
mice, mild defects in branching morphogenesis of the mammary gland and in platelet adhesion 
to collagen in α2 integrin-deficient mice, and defects in the growth plate during development in 
α10 integrin-deficient mice (Bengtsson et al., 2005; Chen et al., 2004; Holtkotter et al., 2002; 
Pozzi et al., 2000).  
 
Binding of integrins to matrix molecules is known to induce cellular responses in vitro.  
Maintenance of matrix assembly and organisation may be regulated through integrin binding; a 
study on fibroblasts showed that inhibition of fibronectin:integrin binding using an antibody to 
α5β1 integrin inhibited production and assembly of fibronectin within the matrix (Roman et al., 
1989). Another study in which α5β1 integrin was overexpressed in CHO cells led to an 
increase in expression and deposition of fibronectin within the matrix (Giancotti and Ruoslahti, 
1990).  Hering et al. (1994) showed an upregulation of aggrecan, link protein and type II 
collagen mRNA following enzymatic matrix depletion and resuspension of bovine chondrocytes 
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possibly as a result of disruption of integrin-mediated cell-matrix interactions (Hering et al., 
1994).  Degradative products of matrix proteins are also recognised by integrins.  Treatment of 
fibroblasts with a monoclonal antibody to α5β1 which mimicked the effect of fibronectin 
fragments caused induction of MMP-3 and MMP-1 (Werb et al., 1989).  Xie et al.(1994) 
showed that fibronectin fragments binding to α5β1 caused an elevation in proteoglycan 
degradation by bovine articular chondrocytes through the enhanced release of MMP-3.   
 
Integrin signalling  
The steps involved in integrin signalling events are complex and involve a series of reversible 
events that depend on many factors including the specific integrins that are involved, the 
nature, organisation and mechanical properties of the ECM,  the cell type, and the presence of 
co-signalling receptors.  
 
The regulation of the affinity of integrins for their extracellular ligands is often referred to as 
integrin activation or inside-out signalling.  Activation of integrins is thought to involve the 
cytoskeletal protein talin which binds to the β-integrin tail via its N-terminal domain and disrupts 
the inhibitory interactions between the α and β subunits (Wegener et al., 2007).  The exact 
mechanism by which talin becomes activated is unclear; however it may involve the activity of 
a number of molecules including phosphatidylinositol (4,5)-bisphosphate (PtdIns(4,5)P2) 
(Ginsberg et al., 2005; Goksoy et al., 2008; Han et al., 2006). Interaction of talin with the β-
integrin tail leads to conformational changes in the extracellular domains of integrins increasing 
their affinity for ligands. As integrins bind to the ECM, they become clustered and form an intial 
talin-mediated connection between the cytoskeleton and the ECM. This promotes further 
assembly of the actin cytoskeleton through reorganisation of actin filaments and recruitment of 
additional cytoskeletal and signalling proteins (Ginsberg et al., 2005; Guan et al., 1991).   
 
In addition to a mechanical role in anchoring cells to the ECM and a role in cytoskeletal 
rearrangement, integrins are also able to transmit signals into the cell in response to changes 
in mechanical forces acting on the ECM.  This can leading to modulation in gene expression 
and cell differentiation.  This is known as outside-in signalling.  One of the first integrin 
signalling molecules to be identified was focal adhesion kinase (FAK).  FAK was found to be 
tyrosine phosphorylated after the attachment of fibroblasts to fibronectin, or platelets to 
fibrinogen (Guan et al., 1991; Harburger and Calderwood, 2009). In response to integrin 
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clustering, the autophosphorylation of FAK generates docking sites for SH2-domain-containing 
proteins; these include Src kinases, which in turn become activated and phosphorylate FAK, 
promoting its kinase activity and its interaction with other proteins such as paxillin (Harburger 
and Calderwood, 2009).  Paxillin mediates binding of kinases, phosphatases, actin-binding 
proteins and regulators and effectors of the Rho family  of small GTPases which are involved in 
inducing actin polymerisation (Deakin and Turner, 2008). Binding of Src kinases to FAK, or 
indeed directly to β-integrin tails results in cascades of protein interactions that transduce 
signals to many downstream pathways, including MAPKs and NF-κB associated with 
promoting cell growth, survival and proliferation (Miranti and Brugge, 2002).  
 
Another key molecule in integrin signalling is integrin-linked kinase (ILK) which forms a 
heterodimeric complex with the adaptor protein PINCH and the actin- and paxillin-binding 
protein parvin.  It is unclear whether ILK has a role in kinase activation; however in its complex 
with PINCH and parvin, it is thought to be essential as an adaptor between integrins and the 
actin cytoskeleton, and as a hub that regulates several signalling pathways (Legate et al., 
2006).  Interestingly, mice carrying a conditional deletion of ILK in chondrocytes show skeletal 
defect and develop chondrodysplasia (Terpstra et al., 2003).  
 
In addition to signalling on their own, integrins are also involved in optimising activation of 
growth factor receptors.  For example, the αvβ3 integrin has been shown to increase cell 
migration of endothelial cells through synergistic activity with the platelet derived growth factor 
(PDGF) receptor and vascular endothelial growth factor (VEGF) receptor (Soldi et al., 1999; 
Woodard et al., 1998).  Also, adhesion of fibroblasts and endothelial cells to β1 or αv integrins 
leads to tyrosine phosphorylation of epidermal growth factor (EGF) receptor (Moro et al., 1998). 
 
Integrins in cartilage 
Adult articular chondrocytes have been shown to express α1β1, α3β1, α5β1, α6β1 and α10β1 
integrins as well as αVβ3 and αVβ5 (Loeser et al., 1995; Salter et al., 1992; Woods et al., 
1994). Integrins have been shown to bind numerous ECM molecules within cartilage including; 
fibronectin, which has been shown to primarily bind to α5β1; type II collagen which binds via 
both α1β1 and α10β1; type VI collagen which  binds α1β1 (Camper et al., 1998; Loeser et al., 
1995; Loeser et al., 2000). Activation of integrins in cartilage induce MMPs and inflammatory 
genes including NO, IL-6 and IL-8 (Attur et al., 2000; Xie et al., 1994).  Another role for 
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integrins may be in transduction of mechanical signals from the ECM to the cell.  Holmvall et al. 
(1995) showed that expression of both α5 and α2 integrins was increased in chondrosarcoma 
cells exposed to mechanical strain.  An increase in certain integrin expression during 
osteoarthritis including α1β1 and α2β1 may reflect attempts by the chondrocyte to repair 
damaged matrix (Loeser et al., 1995).   
 
1.3.3.2 Other cell surface matrix receptors 
Chondrocytes also express other non-integrin cell surface receptors including the 
transmembrane protein CD44. CD44 represents the primary receptor responsible for binding 
hyaluronan (Knudson and Knudson, 1993).  Through binding HA at the cell surface CD44 is 
able to anchor HA within the PCM and is responsible for the internalisation and intracellular 
catabolism of HA (Hua et al., 1993; Nishida et al., 2000). 
 
Annexin V (anchorin CII) is expressed on the surface of chondrocytes and is described as 
binding the N-telopeptide of type II collagen (Lucic et al., 2003) as opposed to integrins that 
bind the triple helical regions.  Interactions between type II collagen and annexin V are thought 
to regulate mineralisation in the growth plate (Kim and Kirsch, 2008).  Expression of annexin V 
is increased in osteoarthritis (Mollenhauer, Mok et al. 1999 and overexpression of annexin V in 
normal chondrocytes has been associated with inducing apoptosis (Ea et al., 2008). 
 
The discoidin domain receptors, DDR1 and DDR2, constitute a subfamily of receptor tyrosine 
kinases (RTKs) that function as collagen receptors independent of β1 integrins.  Interaction of 
the DDRs with collagen leads to receptor autophosphorylation and subsequent transmembrane 
signalling.  The function of DDR1 in cartilage is unknown however it has been reported to bind 
type VI collagen (Vogel et al., 2006). The importance of DDR2 in cartilage is evident from the 
fact that DDR2 -/- mice show reduced chondrocyte proliferation and shorter long bones. Xu et 
al. (2005) showed increased expression of DDR2 in a mouse model of osteoarthritis, and 
overexpression of DDR2 in chondrocytes induced expression of MMP-13 through its ability to 
bind type II collagen (Xu et al., 2005). In addition to binding type II collagen (Leitinger et al., 
2004), DDR2 is also able to bind type X collagen and may play a role in endochondral 
ossification (Leitinger and Kwan, 2006).  
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NG2/human melanoma proteoglycan is a transmembrane CS proteoglycan expressed in both 
foetal and adult human cartilage with decreased expression in osteoarthritis (Midwood and 
Salter, 1998).  Studies from rat cell lines have suggested a role for NG2 in binding type VI 
collagen (Stallcup et al., 1990); however this has not been confirmed in human chondrocytes. 
The ability of anti-NG2 antibodies to enhance binding of chondrocytes to type VI collagen is 
therefore likely to be via modulation of integrin activity  (Midwood and Salter, 2001). 
 
1.4 Articular cartilage matrix turnover 
To maintain the integrity of the matrix, turnover of matrix macromolecules by chondrocytes is 
essential.  This is achieved by a balance between synthesis and degradation through the 
action of proteinases that fragment the matrix macromolecules and their inhibitors. The 
mechanisms that control the anabolic and catabolic activities of chondrocytes remain poorly 
understood. The most important proteinases involved in cartilage matrix degradation are the 
matrix metalloproteinases (MMPs) and the ADAMTS (a disintegrin and metalloproteinase with 
thrombospondin motifs) enzymes.  The tissue inhibitors of metalloproteinases (TIMPs) are 
responsible for balancing the catabolic activity of matrix proteinases. 
 
1.4.1 Matrix metalloproteinases  
MMPs (reviewed in Nagase et al. 2006) are a family of 23 proteinases in humans which play 
key role in ECM turnover under normal conditions. The MMPs share a common domain 
structure. The three common domains are the pro-peptide, the catalytic domain and the 
haemopexin-like C-terminal domain which is linked to the catalytic domain by a flexible hinge 
region.  They all contain a zinc atom at their catalytic centre and are synthesised as inactive 
proenzymes that require activation before they can degrade matrix. MMPs are also involved in 
the increased ECM breakdown observed during disease processes such as osteoarthritis. 
They fall into 4 main groups: collagenases, stromelysins, gelatinases and membrane type (MT-
MMPs).  
 
There are 3 specific collagenases found in humans: MMP-1, MMP-8, MMP-13. Collagenases 
cleave fibrillar collagens at a single point in all 3 collagen strands making fragments that are 
susceptible to further degradation by gelatinases (MMP-2 and -9) and membrane type (MT1-
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MMP) (Knauper et al., 1996a; Knauper et al., 1996b). MMP-13 preferentially cleaves type II 
collagen over type I and III (MMP-1 preferentially cleaves type III and MMP-8 type I collagen) 
and is produced by chondrocytes. Overexpression of MMP-13 in the mouse leads to an OA 
phenotype (Neuhold et al., 2001) and inhibition of MMP-13 blocked collagen degradation in 
cultured explants of human OA tissue (Dahlberg et al., 2000) indicating the importance of 
MMP-13 cartilage breakdown.   
 
Stromelysins have a broad substrate specificity including proteoglycans, laminin and 
fibronectin, and they are believed to play central role in the activation of other MMPs through 
cleavage of their pro-peptide domains.  MMP-3 for example has been shown to activate 
proMMP-1 (Visse and Nagase, 2003) and proMMP-13 (Knauper et al., 2002). Much attention 
has been paid to MMP3 in cartilage due to its ability to cleave aggrecan within the interglobular 
domain (separating the G1 and G2 domains) (Fosang et al., 1991). 
 
1.4.2 ADAMTSs 
ADAMTS proteinases are a group of secreted enzymes; many of which are expressed in 
cartilage.  Nineteen distinct human ADAMTS gene products have been identified and it is 
thought that the zymogen forms of ADAMTSs are cleaved intracellularly and that secreted 
proteins are in the mature form.  Like MMPs they contain a zinc-binding sequence within their 
catalytic domain.  Although also able to cleave matrix proteins such as decorin, fibromodulin 
and COMP, the ability to cleave aggrecan has implicated ADAMTSs as major enzymes 
involved in cartilage breakdown (Kashiwagi et al., 2004).  Several members of the ADAMTS 
family have been shown to cause aggrecan cleavage, however, ADAMTS-4 and -5 are 
considered as the most active aggrecanases (Abbaszade et al., 1999).  Both aggrecanases 
cleave aggrecan within the interglobular domain, although at a different site to MMP-3 (Fosang 
et al., 1996; Tortorella et al., 2002).  In the mouse inflammatory arthritis model and OA model, 
induced by destabilisation of the medial meniscus, ADAMTS-5 was implicated as the major 
aggrecanase (Glasson et al., 2005; Majumdar et al., 2007; Stanton et al., 2005).  Malfait et al. 
(2002) showed that both ADAMTS-4 and ADAMTS-5 were expressed in human OA tissue and 
that inhibition of these enzymes blocked aggrecan degradation (Malfait et al., 2002).  However, 
the activity of purified human ADAMTS5 has been shown to be at least 1000-fold greater than 
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human ADAMTS4 implicating ADAMTS5 as having a prominent role in the progression of 
osteoarthritis (Gendron et al., 2007) 
 
1.4.3 TIMPs 
The control of enzymatic degradation of matrix is controlled by tissue inhibitor of 
metalloproteinases (TIMPs).  TIMPs (1-4) are endogenous inhibitors of MMPs and ADAMTSs 
and are thought to regulate proteolytic activity. TIMPs bind tightly and inhibit most MMPs 
(Murphy and Willenbrock 1995). In addition, TIMPs can inhibit aggrecanases (Hashimoto et al., 
2001).  TIMP-3 has been identified as a potent inhibitor of ADAMTS-4 and -5 in vitro 
(Kashiwagi et al., 2001) and was also shown to inhibit aggrecanase-mediated aggrecan 
degradation from cartilage explants stimulated with IL-1 or retinoic acid (Gendron et al., 2003). 
 
1.5 Osteoarthritis 
1.5.1 Clinical disease 
Osteoarthritis (OA) is a degenerative form of arthritis and although it may affect younger 
people, it is mostly associated with the older population.  Most people over the age of 70 will 
demonstrate some pathological features of the disease.   
 
OA can be defined as either primary or secondary.  Primary OA is an idiopathic disease mainly 
associated with aging, whereas secondary OA is caused by a pre-existing disease or condition.  
For example, repeated trauma or surgery to the joint structures e.g. the menisci and ligaments 
can predispose individuals to premature disease (Lequesne et al., 1997; Lohmander et al., 
2007), and pre-existing conditions such as diabetes and inflammatory arthritis are also highly 
associated with the onset of secondary OA.   
  
A number of risk factors are associated with the onset of both primary and secondary OA.   
Obesity is a common risk factor and may be due to increased mechanical stress on the 
cartilage, although it is also likely that there are metabolic consequences that also contribute 
(Felson et al., 2004).  Many individuals with OA exhibit a family history of the disease 
suggesting a genetic contribution. Single mutations in key matrix genes such as type II 
collagen will lead to premature OA in a minority of patients (Reginato et al., 1994), but for most 
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individuals the disease is polygenic, i.e. a number of gene polymorphisms are present, with 
each making a small contribution to disease expression (Spector and MacGregor, 2004).  
Other risk factors include occupational activity, for example, an association between the 
duration of knee bending activities and knee OA has been found in male carpenters, floor 
layers and painters (Kivimaki et al., 1992).  Also, nonoccupational physical activity such as high 
exposure to sports, including football and weightlifting, are associated with a high prevalence of 
disease (Kujala et al., 1995)  
 
1.5.2 Histology of OA 
OA is characterised by progressive loss of cartilage.  Initial fibrillation of the articular surface 
gradually extends into the middle and eventually the deep zones of the cartilage.   
Cells are arranged in clusters especially around fissures or disappear completely as the 
disease progresses.  In advanced OA, the organization of cartilage is completely disordered 
and replaced by fibrocartilaginous, scar-like tissue with fibroblast-like cells or in some cases, all 
the articular cartilage of weight bearing surfaces may be lost.  This is accompanied by loss of 
proteoglycan, indicated by the inability of the matrix to stain for safranin O. The tidemark 
representing the boundary between calcified and uncalcified cartilage becomes unclear due to 
presence of osteophytes at the joint margin. Finally there is invasion by blood vessels from the 
subchondral bone, which penetrate into the calcified zone (Lorenz and Richter, 2006).  Such 
histological hanges associated with osteoarthritis can be seen clearly in Figure 2.  
 
Figure 2: Histological changes associated with osteoarthritis.  Histological views of Safranin-O stained 
cartilage knee explants from (A) normal human tissue and (B) osteoarthritic tissue. (Images courtesy of Dr T. 
Vincent).
A B
 
 Chapter 1                                                                                 Introduction 
 
35 
 
1.5.3 Pathogenesis of OA 
The pathogenesis of OA at the molecule and cellular levels is not understood. Over the years, 
a number of theories have been proposed.  For example, Maroudas et al. (1976) suggested a 
weakening of the collagen network, resulting in a swelling pressure and increased water uptake 
of the matrix (Maroudas, 1976).  Walker et al. (1969) investigated a reduction in the lubrication 
of the joint which resulted in increased friction and tissue damage (Walker et al., 1969). Simon 
et al. (1972) proposed that OA was initiated by thickening of the subchondral bone leading to 
abnormal transmission of mechanical stresses through the cartilage (Simon et al., 1972).  None 
of these theories, however, could be said to be wholly responsible for the changes associated 
with OA.  More recently, studies on the pathogenesis of OA have focused on proteinases in 
cartilage loss and on the possible involvement of inflammatory cytokines in the process.  
 
1.5.3.1 Inflammatory mediators in OA 
OA is not considered a classical inflammatory arthropathy as there is no marked infiltration of 
inflammatory cells into the joint and synovial fluid. OA is frequently associated, however, with 
signs and symptoms of inflammation, including joint pain, swelling and stiffness leading to 
significant functional impairment and disability.  There is some evidence to suggest that 
inflammatory cytokines such as IL-1 are detected in the synovial fluid of OA patients; 
supporting the view that inflammatory components are involved in loss of cartilage (Bertazzolo 
et al., 1994).   
 
IL-1 is expressed in OA chondrocytes, especially those in clonal clusters.  
Immunohistochemistry has demonstrated both intracellular and extracellular staining of IL-1β in 
the superficial layers of OA cartilage (Melchiorri et al., 1998; Tetlow et al., 2001).  Incubation of 
normal human chondrocytes with IL-1 increases expression of a number of MMPs including 
MMP-1, -2, -3, -9 and -13 (Benton and Tyler, 1988; Reboul et al., 1996; Tetlow et al., 2001). 
Also, IL-1 inhibits synthesis of cartilage proteoglycans and collagens (Benton and Tyler, 1988; 
Goldring et al., 1988; Martel-Pelletier et al., 1992; Saklatvala, 1986).  The increased expression 
of IL-1 type 1 receptors and caspase-1, which activates the inactive precursor of IL-1β, and 
decreased expression of the natural receptor antagonist IL-1Ra, are thought to further enhance 
the biological activity of IL-1 in OA (Martel-Pelletier et al., 1992; Pelletier et al., 1996; Saha et 
al., 1999).   
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The effects of TNFα on chondrocytes are similar to those of IL-1 including the stimulation of 
matrix degrading enzymes and suppression of matrix synthesis. TNFα expression has been 
detected by immunohistochemistry in the middle and deep zones of cartilage explants taken 
from OA knee joints (Moos et al., 1999).  Both TNF α and TNFα-converting enzyme (TACE) 
mRNA is upregulated in OA (Amin, 1999).  
 
IL-1 and TNFα also induce chondrocytes to synthesise prostaglandin E2 (PGE2) and nitric 
oxide (NO) through the direct upregulation of enzymes COX-2 and inducible nitric oxide 
synthase (iNOS) (Goldring and Berenbaum, 2004). Expression of COX-2 and iNOS is elevated 
in OA cartilage compared to normal human cartilage (Amin et al., 1997).  PGE2 has been 
shown to oppose the effects of IL-1 on cartilage matrix synthesis by stimulating type II collagen 
expression.  It has been suggested that expression of PGE2 in OA cartilage may reflect an 
attempt by the cartilage to counteract an IL-1 induced dedifferentiation (Melchiorri et al., 1998).  
NO is a highly reactive, cytotoxic free radical.  It is thought to mediate a number of processes 
associated with OA including apoptosis, possibly through the interaction of NO with oxygen 
radicals resulting in formation of toxic products such as peroxynitrite (Amin and Abramson, 
1998; Blanco et al., 1995; Hashimoto et al., 1998). 
 
1.5.3.2 Dysregulation of matrix turnover in OA 
OA is thought to be a consequence of an imbalance between anabolic and catabolic processes 
in the tissue. Degradation of aggrecan within the matrix has been suggested as an early event 
in the course of OA.  Increase in expression of aggrecanases is seen in both human OA and 
animal OA models (Boileau et al., 2007; Roach et al., 2005).  Degradation of collagens, in 
particular type II collagen, most likely follows the destruction of aggrecan.  Catabolic activity in 
disease is attributed to increased expression of MMPs;  MMP-1, -3, and 13 have been shown 
to be increased in a rabbit model of OA (Bluteau et al., 2001), and  MMP-1, -2, -8, -9 and -13 
were increased in human OA cartilage explants (Tetlow et al., 2001).  Another study on human 
OA tissue showed increased expression of MMP-7 in chondrocytes (Ohta et al., 1998). 
Expression of MMPs may be driven by inflammatory cytokines such as IL-1, IL-17, IL-18 and 
TNF-α (Poole, 1995).  In addition, fragments of matrix molecules such as fibronectin and type II 
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collagen may play a role in driving cartilage degradation (Homandberg et al., 1997; Jennings et 
al., 2001). 
1.5.3.3. Growth factor expression in OA tissue. 
In response to catabolic events, chondrocytes proliferate and synthesize enhanced amounts of 
matrix molecules through the action of anabolic factors including FGF-2, IGF-1, TGF-β and 
BMPs in an attempt to repair damaged matrix (Sandell and Aigner, 2001).   
 
IGF-1 enhances proliferation of chondrocytes and controls proteoglycan synthesis and 
degradation (Coutts et al., 1997; Hickey et al., 2003; Schmid, 1995).  Expression of IGF-1 is 
increased in OA cartilage compared to normal human cartilage (Olney et al., 1996). 
Furthermore, OA chondrocytes possess an increased number of IGF-1 receptors; however, 
they appear hyporesponsive to exogenous IGF-1.  This may be explained by the increase in 
IGF binding proteins which are able to regulate activity of IGF-1 (Chevalier and Tyler, 1996; 
Olney et al., 1996). 
 
TGF-β has been detected in the synovial fluid of OA patients and expression demonstrated by 
in situ hybridization in a murine model of OA (Chambers et al., 1997; Schlaak et al., 1996). The 
role of TGF-β in OA is unclear. Transgenic mice with defects in TGF-β signalling, such as 
mutations in the TGF-β type II receptor, develop degenerative joint disease resembling human 
OA suggesting that impaired TGF-β function is a possible cause of OA (Serra et al., 1997; 
Yang et al., 2001).  Indeed, Boumediene et al. (1998) showed markedly reduced TGF-β 
receptor mRNA levels in a rabbit model of OA (Boumediene et al., 1998).  In contrast, van 
Beuningen et al. (2000) showed that repeated injection of mouse knee joints with TGF-β 
resulted in formation of osteophytes on the articular surface and cartilage legions associated 
with proteoglycan depletion in OA (van Beuningen et al., 2000)  
 
It has been suggested that the increase in growth factors may occur at early stages of the 
disease, and as the disease progresses reparative events mediated by such factors are 
outweighed by degradative ones (Chambers et al., 1997).   
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1.6 Basement membranes 
Basement membranes are sheet-like extracellular matrix structures of 50–100 nm thickness 
composed of type IV collagen, laminins, nidogens and proteoglycans, principally perlecan.  
Other proteins e.g. fibulins, type XV collagen, type XVIII collagen and BM-40 are commonly 
associated with basement membranes but are not considered defining for this structure (Timpl 
and Brown, 1996). Basement membranes separate different cell types and occur for instance 
under epithelial and endothelial cells and around nerves, smooth muscle cells and adipocytes 
(Erickson and Couchman, 2000). The molecular composition of basement membranes varies, 
e.g. different isoforms of laminins and collagen type IV are present in different types of 
basement membranes (Yurchenco et al., 2004).  In electron micrographs, basement 
membranes appear as a dual layered structure referred to as the basal lamina. This is 
composed of the lamina lucida, lying proximally to the cells, and the lamina densa. Basement 
membranes are important for cellular functions such as compartmentalization, regulation of 
diffusion, cell attachment and polarization, regulation of growth factor presentation, 
maintenance of cell phenotype and regulation of cell migration (Li et al., 2003; Miner and 
Yurchenco, 2004), (Quondamatteo, 2002). Cartilage is not described as having a basement 
membrane. However, a recent study by  Kvist et al. (2008) detected a number of cardinal 
basement membrane proteins closely surrounding the chondrocytes of both bovine and murine 
articular cartilage including laminin, collagen type IV, perlecan and nidogen-2.  The zone of 
cartilage directly surrounding the chondrocyte, known as the pericellular matrix (PCM), is 
thought to represent the functional equivalent of a chondrocyte basement membrane (Kvist et 
al., 2008).   
 
1.7 The pericellular matrix and its components. 
As mentioned, the PCM is the region of matrix directly surrounding individual chondrocytes 
throughout the tissue. A chondrocyte surrounded by its PCM has been termed the ‘chondron’.  
The concept of the chondron was first proposed by Benninghoff who identified a structural unit 
comprising the chondrocyte and its pericellular molecules, in a range of hyaline cartilages 
(Poole, 1997).  However, little research on the chondron was reported until the observation that 
chondrons could be isolated following high speed homogenisation of horse nasal cartilage 
(Szirmai, 1974.). The majority of research since has been reported by Poole and co-workers, 
with the development of novel methods for both mechanical (Alexopoulos et al., 2003) and 
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enzymatic (Lee et al., 1997) isolation of intact chondrons.  These methods have enabled a 
number of new biological and biomechanical assays for studying the properties and function of 
the PCM.   
 
Ultrastructurally, the PCM is described as a lucent zone surrounding the chondrocyte, distinct 
from the type II collagen-rich territorial matrix. Within both middle and deep zones of cartilage, 
the chondron is thought to be surrounded by a pericellular capsule.  This capsule is described 
as a basket-like enclosure containing a randomly organized fine filamentous material (Poole et 
al., 1987).  The exact composition of this capsule is unclear however it has been suggested to 
consist of type IX collagen and possibly type VI collagen, and may be involved in anchoring the 
PCM to the further removed TM through interactions with type II collagen and other PCM 
molecules (Poole et al., 1984; Poole et al., 1987).   
 
A number of cartilage polymers have been identified as structural components of the PCM, 
mainly by immunohistochemistry.  The PCM is rich in type VI collagen, but lacks type II 
collagen (Soder et al., 2002).  It is also enriched with perlecan (Melrose et al., 2006), 
hyaluronan (Mason, 1981), type IX collagen (Wotton et al., 1991), biglycan (Miosge et al., 
1994) and a range of less abundant glycoproteins including link protein (Ratcliffe A, 1996), 
fibronectin (Glant et al., 1985), laminin (Durr et al., 1996), fibrillin (Keene et al., 1997) and 
possibly decorin (Guilak et al., 2006).    
 
1.7.1 Type VI collagen and the PCM 
Type VI collagen is considered a ‘minor’ collagen within articular cartilage and accounts for 
only 1-2 % of collagens present.  It is unique among the collagens for its monomer and 
microfibrillar arrangement (Wiberg et al., 2002).  The monomer of type VI collagen is a 
heterotrimer consisting of three distinct α chains (α1, α2 and α3), each containing a short triple 
helical region, rich in RGD sequences, and globular extensions at N and C termini of the helix.  
Prior to secretion, dimers are formed by a staggered antiparallel alignment of two triple-helices, 
stabilised by disulphide bonds (Ball et al., 2003).  Dimers then align with their globular domains 
in line to form tetramers within the cell.  While other collagens are secreted as monomeric 
molecules composed of three collagenous poylpeptides, and their assembly occurs 
extracellularly, type VI collagen is secreted in a tetrameric form that align end to end to form 
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microfibrils which become incorporated into the PCM (Engvall et al., 1986; Furthmayr et al., 
1983) (Figure 2).   
 
Figure 2. Domain organisation and assembly of the alpha chains from collagen VI.  A diagram showing the assembly of 
collagen VI microfibrils from the three α chains. The formation of monomers, dimers and tetramers occurs intracellularly, while 
microfibril assembly occurs in the extracellular space. Modified from Furthmayer et al
 
Ultrastructurally, type VI microfibrils have a beaded appearance with a periodicity of around 
100 nm.  Although found in the extracellular matrix of many connective tissues, in hyaline 
articular cartilage, type VI is exclusively concentrated within the pericellular matrix (Poole et al., 
1988a) and is commonly regarded as the key molecular marker for chondrons (Poole, 1997; 
Poole et al., 1992). Type VI collagen has been shown to interact with a number of components 
within the matrix in vitro, including biglycan (Wiberg et al., 2002), hyaluronan (Kielty et al., 
1992), decorin (Bidanset et al., 1992), fibronectin, perlecan (Tillet et al., 1994) and also has a 
low affinity for type II collagen (Bidanset et al., 1992).  As mentioned previously, it interacts with 
cell surface molecules such as α1β1 integrin, NG2 and DDR1 (Marcelino and McDevitt, 1995; 
Midwood and Salter, 2001; Vogel et al., 2006) 
 
Type VI collagen has been linked to early events in chondrocyte differentiation, regulation of 
mesenchymal stem cell proliferation and ECM stabilisation during development (Atkinson et al., 
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1996; Quarto et al., 1993; Sherwin et al., 1999).  Indeed, Alexopoulos et al. (2009) have shown 
ubiquitinous expression of type VI collagen in cartilage growth plate and a deficiency in type VI 
collagen leads to a delay in secondary ossification.  The same study showed that Col6a-/- mice 
exhibited intact chondrons, suggesting that proteins other than type VI collagen are important 
for the structural integrity of the PCM (Alexopoulos et al., 2009).   
 
1.7.2 Perlecan and the PCM 
As mentioned above, it is likely that other abundant PCM proteins are important in maintaining 
the structural integrity of the PCM.  One such PCM protein is perlecan.   
 
The name perlecan is derived from the ‘beads on a string’ like appearance of isolated perlecan 
molecules exhibited when visualised by rotary shadowing (Noonan et al., 1991).  Perlecan is a 
heparan sulphate proteoglycan present in virtually all vascularized tissues with a distribution 
that is primarily, but not exclusively, confined to basement membranes (Iozzo et al., 1994).  
Consistent with this, in articular cartilage, perlecan is localised primarily to the PCM.  (Melrose 
et al., 2006).  It has a large 467 KDa protein core that consists of five distinct domains (Figure 
4), each of which are repeated several times, that display homology to the low density 
lipoprotein receptor (domain II), laminin A chain (domain III), neural cell adhesion molecule 
(domain IV), and epidermal growth factor (domain V).  The N-terminal domain I is the main 
region of glycosaminoglycan (GAG) substitution in human perlecan and contains a cluster of 3 
potential attachment sites.   In growth plate cartilage, perlecan is mainly substituted with 
chondroitin sulphate (CS) (Govindraj et al., 2002).  However, unpublished work in our 
laboratory has shown that perlecan in adult human articular cartilage is almost exclusively 
substituted with heparan sulphate (HS), and is the major HS proteoglycan of articular cartilage 
(Vincent et al., 2007) 
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Figure 4: Schematic model of human perlecan protein core. Domain I contains three Ser–Gly–Asp 
triplets that are the binding sites for heparan sulphate (HS) side chains (another potential HS attachment 
site in domain V is not shown).  Domain II contains four repeats that are similar to the low density 
lipoprotein (LDL) receptor class A, followed by an immunoglobulin (Ig)-like repeat. Domain III has three 
globular domains that are homologous to the laminin domain IV, and that are flanked and interrupted by 
nine laminin–EGF (epidermal growth factor)-like repeats. Domain IV contains 21 Ig-like repeats (only five 
are shown) that have homology to the neural cell-adhesion protein N-CAM. Domain V/endorepellin
contains three globular domains that have homology to the laminin G domains and that are each 
separated by two sets of EGF-like repeats. Modified from Iozzo (2005)
 
 
Perlecan is reported to bind a number of matrix proteins including type IV collagen, type VI 
collagen, laminin, fibronectin, PRELP (proline arginine-rich end leucine-rich repeat protein) and 
WARP (Hopf, Gohring et al. 2001; Bengtsson, Morgelin et al. 2002; Allen, Bateman et al. 2006; 
Melrose, Roughley et al. 2006).  Through these interactions, perlecan is likely to play an 
important role in the stabilisation and organisation of the extracellular matrix.  Perlecan also 
binds a number of regulatory molecules including FGFs, VEGF, CCN2 and TIMP-3 (Clayton et 
al., 2001; Iozzo, 2005; Knox and Whitelock, 2006; Mongiat et al., 2000; Nishida et al., 2003; 
Ornitz, 2000). 
 
The perlecan knock out mouse shows that early events in skeletal development, namely 
condensation and differentiation, are unaffected by the perlecan deficiency.  However, the mice 
do exhibit skeletal abnormalities, including defective endochondral ossification and 
disorganisation of the growth plate (Arikawa-Hirasawa et al., 1999).  In addition, the cartilage 
shows fewer and less organised type II collagen fibrils and decreased levels of proteoglycan 
staining (Arikawa-Hirasawa et al., 1999; Costell et al., 1999). Interestingly, perlecan substituted 
with chondroitin sulfate enhances collagen fibrillogenesis in cartilage (Kvist et al., 2006) which 
may in part explain the chondrodysplasia observed in the perlecan-null mice.   
 Chapter 1                                                                                 Introduction 
 
43 
 
1.8 Functions of the PCM 
The functions of the PCM are not fully understood. However, a number of possible roles have 
been postulated including; maintenance of cartilage matrix, regulation of both biochemical and 
biomechanical signals within cartilage and chondrocyte protection (Guilak et al., 2006).   
 
1.8.1 Role of PCM in matrix organisation.  
Interactions between the chondrocyte and its surrounding matrix are essential for successful 
maintenance and development of cartilage.  The fact that the PCM directly surrounds 
chondrocytes suggests that it may have a functional role in maintaining and organising the 
further removed cartilage matrix.  It has been shown that interactions between the matrix and 
the cell surface have a significant effect on proteoglycan metabolism and gene expression 
(Adams and Watt 1993; Boudreau, Myers et al. 1995).  Signals from the ECM may be 
transmitted by several different types of receptors expressed on chondrocytes including both 
integrin and non-integrin receptors as discussed previously (Section 1.3.4).   
 
A number of PCM proteins are known to interact with integrins.  Type VI collagen binds 
preferentially to α1β1, fibronectin binds to α5β1, perlecan is thought to bind α2β1, although this 
may not occur in cartilage, and laminin to α6β1 (Loeser, 2000).  Although  type II collagen is 
also known to bind integrins, the absence of type II collagen in the PCM of articular cartilage 
may indicate a preferential role of this interaction in development. Indeed binding of type II 
collagen to integrins has been shown to be important for chondrogenesis of mesenchymal 
stem cells (Chang et al., 2007), possibly mediated through α10β1 integrins (Camper et al., 
2001).   
 
Another important cell-PCM interaction involves the non-integrin receptor CD44. Binding of HA 
to CD44 at the cell surface retains HA within the PCM of cartilage.  It has been suggested that 
the interaction of HA with CD44 also allows retention of aggrecan within the PCM (Maleski and 
Knudson, 1996).  However, this study was performed on chondrocytes isolated from embryonic 
tibia indicating that this may only be the case during cartilage development.  Indeed data 
presented in this thesis would suggest that retention of aggrecan within the PCM only occurs in 
young tissue.   
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In addition to integrin-mediated cell-matrix interactions, CD44-mediated hyaluronan binding has 
also been implicated in maintaining the integrity of the cartilage matrix.  In addition to binding 
HA at the cell surface and anchoring it within the PCM, CD44 is also responsible for the 
internalisation and intracellular catabolism of HA. CD44 mediated endocytosis and degradation 
has been demonstrated in bovine articular chondrocytes (Hua et al., 1993).  Further studies 
have shown that IL-1 treatment of articular chondrocytes induces an increase in expression of 
CD44 and uptake and accumulation of intracellular HA (Nishida, D'Souza et al. 2000).  The role 
of CD44 in removing HA may be important in cartilage development. Depletion of matrix HA 
during limb morphogenesis has been shown to promote condensation and subsequent 
chondrogenesis (Toole et al., 1989).  It has been suggested that degradation of aggrecan by 
extracellular enzymes may be a prerequisite for HA-CD44-mediated uptake into the 
chondrocytes.  Aggrecan fragments (G1 domains) that remain bound to HA have been shown 
to be internalized by bovine articular chondrocytes in a CD44-dependent process, whereas HA 
bound to intact aggrecan inhibits the internalisation of both aggrecan and HA (Embry and 
Knudson 2003).  Disruption of CD-44 HA interactions may be important in maintaining tissue 
homeostasis through removal of degraded aggrecan. The use of CD44 antisense 
oligonucleotides in bovine articular cartilage, which inhibited CD44-HA binding, induced a state 
of chondrocytic chondrolysis as indicated by a significant loss of safranin-O staining and 
prominent staining for the aggrecan neoepitope NITEGE (generated following cleavage of the 
N-terminal G1 domain) (Chow et al., 1998).  Knudson et al. (2000) showed that HA 
oligosaccharides, able to inhibit CD44-HA interactions, also caused depletion of proteoglycan 
and prominent increase in NITEGE staining.  The same study showed an increase in MMP-2 
and -9.  Interestingly, mRNA expression of aggrecan and proteoglycan sulphate incoroporation 
was increased (Knudson, Casey et al. 2000).  These studies suggest that the interaction 
between CD44 and HA within the PCM is essential in maintaining homeostasis of aggrecan 
within cartilage matrix.  It is possible that disruption of this interaction may play a role in 
cartilage degeneration seen in osteoarthritis.    
 
1.8.2 Role of PCM in sequestering regulatory molecules. 
1.8.2.1 Sequestration of growth factors 
In addition to facilitating matrix-cell interactions, the ability of the PCM to retain regulatory 
molecules is likely to be important.  The PCM has been shown to bind growth factors (GFs) 
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and is likely to act as a repository, while regulating their activation, synthesis, and degradation 
(Macri et al., 2007).  Regulation of the cartilage metabolism may be mediated by GFs released 
from chondrocytes.  Therefore the PCM through binding such GFs is able to indirectly regulate 
chondrocyte metabolism.   
 
Fibroblast growth factors  
Perlecan is an abundant PCM protein and plays an important role in sequestering GFs within 
the matrix either via the core protein or its GAG chains.  The heparan sulphate chains of 
perlecan are able to bind a number of members of the fibroblast growth factor (FGF) 
polypeptide family including FGF-1, -2, and -9, -10, -18 whereas FGF-7 binds to the protein 
core (Mongiat, Taylor et al. 2000; Ornitz 2000; Clayton, Thomas et al. 2001).  Of these growth 
factors, FGF-2 and FGF-18 are present within articular cartilage. 
 
FGF-2, or basic fibroblast growth factor, was initially described in 1977 as cartilage derived 
growth factor (CDGF) and was able to stimulate DNA synthesis and cell division of bovine 
chondrocytes (Klagsbrun et al., 1977).   It was later found to be identical to the ubiquitous 
growth factor, FGF-2 (Lobb et al., 1986).  In chondrocytes, the role of FGF-2 as an important 
cell growth regulator in the growth plate is well established (Kilkenny and Hill, 1996); however, 
reports on the action of FGF-2 in adult cartilage are somewhat contradictory.  Many studies 
have implied anabolic effects of FGF-2 suggesting a role in cartilage regeneration and repair.  
For example, a study using an adeno-associated virus to transfect FGF-2 into rabbit knee 
synovial tissue indicated potential for FGF-2 to promote repair as assessed  macroscopically 
and by histological scoring (Hiraide et al., 2005).  Other studies using FGF-2 in scaffold models 
of cartilage regeneration showed that controlled and sustained release of FGF-2 was able to 
stimulate repair of knee cartilage defects in rabbits (Deng et al., 2007).  FGF-2 was also shown 
to stimulate proteoglycan synthesis and cell differentiation in bovine articular cartilage (Sah et 
al., 1994).  Our group has shown that FGF-2 is chondroprotective in an in vivo model of murine 
OA through the suppression of ADAMTS5 (Chia et al., 2009), and in addition is able to 
suppress IL-1 induced aggrecan breakdown in human tissue (Sawaji, Hynes et al. 2008).  In 
contrast, FGF-2 also causes induction of matrix metalloproteinases including MMP-13, MMP-1 
and MMP-3 (Vincent et al., 2004) and is described as anti-anabolic in human ankle 
chondrocytes (Im, Muddasani et al. 2007). 
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The interaction between FGFs and HS is thought to be important in regulating presentation of 
FGFs to FGF receptors (FGFRs) and their subsequent oligomerisation and activation. In the 
case of FGF-2, HS is essential to FGF-2 cell signalling, as demonstrated by the fact that 
addition of heparin or HSPG was shown to restore growth in FGF-responsive HSPG-deficient 
cells (Yayon, Klagsbrun et al. 1991). Some studies suggest that heparin/HS interacts with both 
FGF-2 and FGFR (Guimond et al., 1993),  whereas others suggest that heparin/HS induces 
FGF-2 dimerisation and increases the affinity of the complex for FGFRs (Nugent and Edelman, 
1992). In either case heparin/HS is believed to facilitate FGFR dimerisation and subsequent 
activation. Evidence from epithelial cells suggest that perlecan may play a role in protecting 
FGF-2 from degradation by extracellular proteinases (Saksela et al., 1988). Conversely, 
evidence from both perlecan knockout and FGFR3 gain-of-function mice have suggested that 
perlecan may act as a negative regulator of FGFR3 signalling, possibly through sequestering 
and inactivating FGF, via its HS chains (Arikawa-Hirasawa, Watanabe et al. 1999).   
 
It is likely that the specific localisation of FGF-2 to the PCM, bound to perlecan, is important for 
regulation of growth factor signalling. Work in our group has suggested that perlecan may be 
important in holding FGF-2 back from the cell surface, and only upon mechanical loading 
allowing the growth factor to interact with its receptor (Vincent et al., 2007).  Therefore, 
perlecan may act as a reservoir for growth factors and only upon mechanical stimulation allows 
activation of signalling pathways.  This may explain why cells that are surrounded by perlecan 
and produce FGF do not proliferate out of control (Whitelock et al., 2008).  HS fragments are 
thought to be more bioactive than the native HS chains from which they are derived (Kato, 
Wang et al. 1998).  Indeed the bioactivity of FGFs may be modulated by their release from the 
ECM as a complex with a fragment of HS (Reiland et al., 2006).  Patel et al. (2007) showed that 
release of FGF-10, bound to HS, from perlecan was mediated by heparanase which 
colocalised with perlecan in the basement membrane of mouse submandibular gland.  Release 
of FGF-10 by heparanase modulated the bioactivity of FGF-10 causing MAPK phosphorylation 
(Patel, Knox et al. 2007).  It is possible that mechanical loading of cartilage releases FGF-2 
bound to HS either through direct cleavage or through activation of heparanase; however this 
is yet to be investigated.   
 
FGF-18 has been shown to have significant anabolic effects on chondrocytes in a variety of 
cartilaginous tissues.  Evidence from the FGF-18 -/- mouse suggests that it plays an important 
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role in chondrogenesis; regulating chondrocyte proliferation, the onset of hypertrophic 
chondrocyte differentiation, vascular development and vascular invasion of the hypertrophic 
chondrocyte zone at the growth plate (Liu, Lavine et al. 2007).  Ellsworth et al. (2002) showed 
that FGF-18 could stimulate cell proliferation, ECM production, and PG synthesis in primary 
porcine and human adult articular chondrocytes (Ellsworth, Berry et al. 2002).  Intra-articular 
administration of FGF-18 in a rat meniscal tear model of OA caused dose-dependent increase 
in de novo cartilage formation and a parallel reduction in cartilage degeneration scores in the 
tibial plateau of osteoarthritic rats (Moore et al., 2005). 
 
It has been suggested that FGF-18 binds the HS chains of perlecan which act as co-receptors 
for FGF-18 signalling (Melrose, Hayes et al. 2008).  However it is unclear whether the 
mechanism involved is similar to that identified for FGF-2.  Interestingly, in a study on the 
effects of FGF-18 in the growth plate, Hassel et al. (2007) have suggested that FGF-18 binds 
to the perlecan core protein, possibly to domain III.  The addition of perlecan to growth plate 
chondrocyte cultures was able to significantly reverse the proliferative effects of FGF-18.  It is 
possible that in this context, perlecan acts to protect FGF-18 within the matrix, and modulates 
its ability to effect growth plate chondrocyte proliferation (Smith et al., 2007). 
 
 
TGF-β superfamily proteins 
Bone morphogenic proteins (BMPs) are members of the TGF-β superfamily and were originally 
identified as inducers of bone and cartilage formation in ectopic sites in vivo (Reddi, 1992).  At 
least 20 members have been described with BMP-2, -4, -6 and -7 the most important in bone 
and cartilage formation.  BMPs are considered to be among the most potent anabolic factors in 
articular cartilage.  Knockout mice have shown the importance of BMPs in cartilage 
development as well as suggesting a role in maintaining articular cartilage.  For example, a 
joint-specific deletion of BMP receptor 1a,  thereby blocking the effects of BMPs, showed 
degeneration of the cartilage, after initially normal joint and cartilage development (Rountree, 
Schoor et al. 2004).  Both BMP-2 and BMP-7 stimulate synthesis of aggrecan and type II 
collagen by human articular chondrocytes in vitro (Luyten, Yu et al. 1992; Flechtenmacher, 
Huch et al. 1996) and knock down of BMP-7 using antisense oligonucleotides reduces 
aggrecan gene expression and leads to proteoglycan depletion (Soder, Hakimiyan et al. 2005).  
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Furthermore, BMPs have been shown to inhibit IL-1 induced MMP-13 induction in human 
articular chondrocytes (Im, Pacione et al. 2003).   
 
Although localisation of BMPs to the matrix has not been demonstrated, in vitro experiments 
have shown that rhBMP-2 is able to bind to HS chains attached to domain I of perlecan and in 
combination with type II collagen fibrils, promote chondrogenesis (Yang et al., 2006).  
Interestingly, another study has implicated perlecan in binding the BMP antagonist Noggin, 
which is able to bind BMPs and modulate their activity (Paine-Saunders et al., 2002).  
 
Transforming growth factor (TGF-β) is another member of the TGF-β superfamily of proteins 
and regulates cell growth and differentiation in connective tissues.  In mammals, there are 
three isotypes of TGF-β, called β1, β2 and β3. All isoforms show a high degree of homology 
(84–92%).  TGF-β has been shown to increase synthesis of matrix molecules including type II 
collagen and aggrecan by rabbit articular chondrocytes (Redini, Galera et al. 1988; Pujol, 
Galera et al. 1991).  It has been shown to inhibit IL-1 induction of metalloproteinases and 
reduction in proteoglycan synthesis (Chandrasekhar and Harvey 1988) possibly through the 
downregulation of IL-1 receptor expression (Redini et al., 1993).  
 
TGF-βs are synthesised as proproteins, with the associated pro-peptide having an unusually 
high affinity for the TGF-β molecule. Therefore, even following cleavage from the mature TGF-
β dimer in the Golgi, the pro-peptide assembles into a non-covalent complex composed of 
homodimers of the pro-peptide (termed the latency associated peptide, LAP) and the active 
TGF-β molecule. The high-affinity association of LAP to TGF-β inhibit the interaction of TGF-β 
with its receptors. The complex TGF-β/ LAP binds to a latency TGF-β binding protein (LTBP), 
via disulphide linkages, to form the large latent complex (LLC) (Miyazono, Olofsson et al. 1991; 
Annes, Munger et al. 2003; Jenkins 2008).  The LTBP and its bound latent TGF-β are found 
primarily as components of the matrix, covalently crosslinked to molecules such as fibronectin 
and fibrillin via the N-terminal region of the LTBP (Saharinen, Taipale et al. 1996; Dallas, 
Keene et al. 2000; Fontana, Chen et al. 2005).  In order for TGF-β to exert biological effects, it 
must be activated.  This refers to liberation of TGF-β from the latent complex (Annes et al., 
2003).   
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A number of TGF-β activators have been described.  Proteases including plasmin, thrombin, 
elastase, MMP-2, MMP-9 and MMP-13 directly activate TGF-β in vitro (Taipale, Lohi et al. 
1995; Yu and Stamenkovic 2000; Karsdal, Larsen et al. 2002).  There are three proposed 
mechanisms by which proteases might facilitate activation; cleavage of the LTBP, liberating the 
still latent LAP bound TGF-β, which would have to be processed further for activation; 
convertion of proLLC to a mature form (LLCm), rendering the latent complex activation 
competent; cleavage of LAP, releasing active TGF-β from its latent complex.  However, in vivo 
studies on mice encoding null mutations in genes encoding activating proteases do not 
demonstrate any phenotype consistent with TGF-β deficiency (Annes et al., 2003).  This may 
indicate that the action of proteases demonstrated in vitro may not represent a physiological 
mechanism in vivo. Alternatively, it is likely that proteases activate TGF-β either indirectly via 
effects on other activating molecules or directly in co-ordination with molecules that increase 
local concentrations of TGF-β, which facilitate functional interactions between TGF-β and the 
protease (Jenkins, 2008).   
 
One such activating molecule is the matricellular protein thrombo-spondin-1 (TSP-1) which is 
able to interact directly with LAP.  Evidence supporting the role of TSP-1 as an in vivo activator 
of TGF-β comes from TSP-1 null animals which demonstrate a similar phenotype to TGF-β null 
animals (Murphy-Ullrich and Poczatek, 2000).  The role of integrins is thought to be essential in 
TGF-β activation.  The integrin αvβ6 has been shown to activate TGF-β via directly binding to 
LAP (Munger, Huang et al. 1999).  Mice encoding a mutation in the integrin binding RGD 
sequence of LAP have been shown to completely phenocopy TGF-β1 null mice, suggesting 
that most or all in vivo activation of TGF-β1 requires interactions with integrins (Yang et al., 
2007).  The integrin αvβ8 has been shown to activate latent TGF-β1.  The mechanism of 
activation is thought to involve additional proteolytic action by MT1-MMP.  It is suggested that 
the integrin concentrates latent TGF-β on the cell surface, where it is subsequently activated by 
MT1-MMP (Mu, Cambier et al. 2002).    
 
TGF-β has been shown to bind the PCM protein biglycan through its core protein.  The role of 
biglycan in TGF-β activation is unclear. It has been suggested that biglycan may be 
responsible for the sequestration of high quantities of TGF-β near the cell to promote binding to 
their respective cell-surface receptors.  However, it was shown that binding to biglycan reduced 
binding of TGF-β to TGF-βRI and betaglycan, a cell-surface proteoglycan receptor, in mink 
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lung epithelial cells, while binding to type II receptors was unaffected (Hildebrand et al., 1994).  
Experiments on decorin-null mice showed that addition of exogenous biglycan decreased 
binding of labelled TGF-β to both type I and type II receptors in myofibroblasts (Droguett, 
Cabello-Verrugio et al. 2006).  Therefore, it may be possible that biglycan acts to protect TGF-β 
from activation, through cleavage of LTBP or LAP, and subsequent binding to its cell-surface 
receptors.  
 
Another PCM protein, fibronectin, is also thought to be important in the localisation and 
presentation of TGF-β through its interaction with the TGF-β binding protein LTBP-1. LTBP-1 
regulates TGF-β at multiple levels.  Firstly, it associates with TGF- β inside the cell and 
facilitates secretion of the latent complex (Miyazono et al., 1991).  It then targets TGF- β to the 
matrix for storage, through binding to fibronectin (Taipale et al., 1994). Following proteolytic 
cleavage of LTBP-1, it may act as a vehicle to facilitate binding of TGF-β to its cell surface 
receptors (Dallas, Rosser et al. 2002). Indeed there is evidence that LTBP-1 plays a role in 
activation of the TGF-β complex (Annes, Chen et al. 2004). Colocalisation of fibronectin and 
LTBP-1 was demonstrated in human fibroblasts and this association was shown to be 
abolished through treatment with plasmin (Taipale, Saharinen et al. 1996).  Dallas et al. (2005) 
showed colocalisation of LTBP-1 and fibronectin in osteoblast and fibroblast cultures. The 
same study showed that in the absence of fibronectin, LTBP-1 failed to assemble in embryonic 
fibroblasts indicating the importance of pericellular fibronectin in regulating TGF-β signalling 
(Dallas, Sivakumar et al. 2005).   
 
LTBP-1 has also been shown to colocalise with the PCM protein fibrillin in osteoblasts, an 
interaction that may play a role in regulating TGF-β activation.  A disruption in this interaction, 
through mutations in the fibrillin-1 gene, is thought to result in Marfan syndrome; a disease 
affecting the connective tissues that leads to skeletal abnormalities (Dallas et al., 2000).  
 
Other regulatory molecules 
Vascular endothelial growth factor (VEGF) is a known mediator of angiogenesis and is critically 
involved in the terminal stages of endochondral ossification, mediating the in-growth of blood 
vessels which leads to the differentiation of hypertrophic chondrocytes, apoptosis and matrix 
calcification (Gerber, Vu et al. 1999).  The role of VEGF in articular cartilage is slightly less 
clear.  It has been identified at both the protein and mRNA levels in both normal and 
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osteoarthritic cartilage (Pfander et al., 2001).  It has been suggested through in vitro studies 
that VEGF may induce expression and production of proteinases that degrade extracellular 
matrix.  Stimulation of both normal and OA chondrocytes with isoforms of VEGF caused an 
increase in production of MMP-1 and MMP-3 in OA, but not normal chondrocytes (Enomoto, 
Inoki et al. 2003).  Another study on a human chondrocytic cell line showed an increase in 
MMP-1, -3, -13 and a decrease in TIMP-1 and-2 (Pufe et al., 2004).   
 
Perlecan is thought to bind VEGF through its HS chains (Iozzo, 2005).  In endothelial cells, 
perlecan is able to bind larger isoforms of VEGF, but not shorter isoforms; thereby allowing 
these shorter isoforms to diffuse through the PCM and induce cellular responses (Robinson 
and Stringer 2001).  The localisation of VEGF to the PCM in articular cartilage has not been 
confirmed, although staining of condylar articular fibrocartilage of sheep temporomandibular 
joints suggested pericellular staining around maturing chondrocytes (Yee et al., 2003).   
 
Perlecan has also been shown to bind connective tissue growth factor (CCN2).  Although 
originally described as a growth factor, CCN2 has more recently been re-identified as a 
matricellular protein implicated in cartilage development (Nishida, Kubota et al. 2002; Ivkovic, 
Yoon et al. 2003; Maeda, Nishida et al. 2009).  It has been suggested to increase expression of 
matrix proteins as well as increasing enzymes involved in matrix degradation (Nishida, Kubota 
et al. 2002; Blaney Davidson, Vitters et al. 2006).  Colocalisation of CCN2 and perlecan has 
been shown in a chondrosarcoma cell line although whether CNN2 binds to HS chains on 
perlecan or the protein core remains unclear, as does the mechanism by which perlecan 
regulates CCN2 activity (Nishida et al., 2003).    
 
Insulin-like growth factor (IGF-1) is one of the main anabolic growth factors for articular 
cartilage. It enhances proliferation of chondrocytes and controls proteoglycan synthesis and 
degradation (Schmid 1995; Coutts, Sah et al. 1997; Hickey, Frenkel et al. 2003).  IGFs are 
usually found associated with one of the six known high-affinity binding proteins (IGFBP-1 to 6) 
which are thought to regulate the interaction between IGF-1 and IGF1R (Dupont and 
Holzenberger, 2003). IGF analogs without affinity for the binding proteins are more potent than 
the natural peptide, implying an inhibitory role for IGFBPs (Morales 1997).  Chondrocyte 
response to IGF-1 declines with age and this is thought to be mediated in part by an increase 
in expression of IGF binding proteins which are upregulated in both OA chondrocytes 
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(Matsumoto, Tsukazaki et al. 1994; Tardif, Reboul et al. 1996) and in normal chondrocytes 
stimulated with IL-1 (Matsumoto et al., 1994) and may block binding of IGF-1 to cell surface 
receptors.   
 
In addition to LTBP-1,  fibronectin has also been implicated in binding IGF-1, although this is 
thought to be via an interaction of fibronectin and the IGF binding protein-3 (Gui and Murphy, 
2001).  Binding of IGFBP-3 to fibronectin occurs via the heparin-binding C-terminal fragment.  
The fibronectin-IGFBP-3 complex may play a role in sequestration of IGF-1 within the PCM, 
contributing to the regulation of IGF activity.   
 
1.8.2.2 Sequestration of proteins involved in matrix turnover  
In addition to growth factors, PCM proteins have also been implicated in binding other 
regulatory molecules including both enzymes and inhibitors involved in matrix turnover.  Plaas 
et al. (2007) have shown the colocalisation of ADAMTS-5 with pericellular HA in human 
chondrocytes from both normal and OA tissue. The consequence of this interaction is not fully 
understood.  The formation of such proteinase–HA complexes in human cartilage may be 
protective against aggrecanase-mediated tissue destruction.  On the other hand, it is possible 
that persistent or excessive accumulation of such complexes may increase release of an active 
form of the enzyme through cleavage of HA (Plaas et al., 2007).  Indeed, it has been shown 
that enzymatic cleavage of HA, producing HA fragments, occurs in aging tissues (Bayliss and 
Dudhia, 2002). 
 
Although not specific to cartilage Hashimoto et al. (2004) have demonstrated an interaction 
between the C-terminal domain of fibronectin and the C-terminal domain of ADAMTS-4.  The 
same study showed colocalisation of fibronectin with ADAMTS-4 around 293T cells stably 
expressing the enzyme.  In addition, incubation with either intact fibronectin or fibronectin 
fragments was able to inhibit aggrecanase activity of ADAMTS-4.  Fibronectin does not bind 
the catalytic domain of the enzyme.  However, binding of the C-terminal domain to aggrecan 
GAG chains is required for aggrecan degradation by ADAMTS-4 and fibronectin may therefore 
act to hinder the proteinases binding to aggrecan (Hashimoto, Shimoda et al. 2004).    
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Heparan sulphate proteoglycans have been implicated in binding MMPs.  Yu et al. (2000) 
demonstrated that MMP-7 (matrilysin) colocalised with heparan sulphate on rat epithelial cells 
and staining was diminished following treatment with heparitinase. MMP-2, -9 and -13 were 
also shown to bind heparin; however with a lower affinity than MMP-7 (Yu and Woessner 
2000).  Also, a study on oral epithelial dysplasia demonstrated similar expression patterns for 
MMP-1, MMP-2, MMP-7 and perlecan (Tilakaratne et al., 2009).   
 
TIMP-3 has been shown to be localised to the extracellular matrix in a large number of cultured 
cell types including fibroblasts (Kishnani, Staskus et al. 1995).  Another study by Yu et al. 
(2000) showed the colocalisation of TIMP-3 to heparan sulphate in the endometrium subjacent 
to the lumen of the uterus in rats (Yu, Yu et al. 2000). In addition, Knox et al. (2006) quoted an 
unpublished study by Saunders et al. demonstrating that TIMP-3 could bind perlecan and like 
perlecan, was localised pericellularly (Knox and Whitelock, 2006).  
 
1.8.3 A biomechanical role for the PCM. 
The structure of articular cartilage provides a mechanism by which physiological compressive 
and shearing forces are absorbed, redistributed and transmitted to the subchondral bone.  
During normal joint activity, chondrocytes are exposed to a complex mechanical environment 
and this micromechanical environment of chondrocytes, in conjunction with biochemical factors 
(e.g., growth factors, cytokines), plays an important role in cartilage homeostasis. The PCM 
has been suggested to have a biomechanical role; a role which incorporates both its functions 
in cell-matrix interactions and the sequestration of regulatory molecules.   
 
Poole et al. (1988) first described the PCM as providing a protective environment for the 
chondrocyte while studying chondrons isolated from canine cartilage.  It was suggested that 
during loading, deformation of the chondron could cause ‘an adaptive water loss from 
pericellular matrix proteoglycans’ providing protection for the chondrocyte (Poole et al., 1988b).  
It has also been shown that the Young’s modulus of elasticity of the PCM is approximately  one 
order of magnitude less than that of the ECM.  Young’s modulus was measured using a 
micropipette technique coupled with theoretical formulations of a biphasic finite element model 
as described in (Guilak et al., 2005).  During compression, large inhomogeneities in the levels 
of stress-strain occur in the ECM.  It is thought that the PCM provides a uniform cellular 
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environment by reducing the stress magnitudes at the cellular level (Guilak, Jones et al. 1999; 
Alexopoulos, Setton et al. 2005; Guilak, Alexopoulos et al. 2006).   
 
The ability of the PCM to control chondrocyte deformation and amplify compressive strains has 
suggested that the PCM serves as a mechanical transducer.  The interactions between type VI 
collagen and integrins and HA and CD44 at the cell surface are thought to mediate such 
signals (Knudson and Loeser, 2002).  Our group has demonstrated that loading of articular 
cartilage leads to the induction of cellular responses mediated by pericellular FGF-2; by 
manipulating the pericellular concentration of FGF-2 in vitro, it was possible to determine the 
dependence of pericellular FGF-2 concentration on the strength of ERK activation in 
chondrocytes.  It is hypothesised that loading of the cartilage results in presentation of FGF-2 
on HS chains of perlecan to cell surface receptors.  This loading response was inhibited in the 
presence of an FGFR inhibitor (Vincent et al., 2007).   
 
The permeability of the PCM is significantly lower than the surrounding TM suggesting that the 
PCM may have a significant influence on diffusion to and from the chondrocyte.  It is likely that 
this reflects the ability of the PCM to sequester regulatory molecules and retain molecules for 
modification, such as aggrecan (Sandy et al., 1989).  
 
1.9 The PCM in osteoarthritis 
With regards to the PCM in OA, structural and histochemical studies indicate that the chondron 
is remodelled during OA (Poole et al., 1991b). Most commonly this is seen as a swelling and 
distension of the PCM which may represent the increase in expression of molecules such as 
type VI collagen and perlecan during OA (Soder, Hambach et al. 2002; Tesche and Miosge 
2004).  These changes may reflect an attempt by the chondrocyte to repair the degrading 
matrix.   
 
1.9.1 Type VI collagen in OA 
Changes in expression of type VI collagen have widely been associated with OA.  Arican et al. 
reported that pericellular staining for type VI collagen in articular canine cartilage was 
increased after induction of experimental OA (Arican et al., 1996).   Increased type VI collagen 
immunostaining in the middle and deep layers was detected in human tissues with moderate 
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OA (Hambach, Neureiter et al. 1998; Pullig, Weseloh et al. 1999). Hambach et al. (1998) 
reported an increase in type VI collagen within the interterritorial matrix suggesting  diffusion of 
type VI collagen degradation products in OA tissue (Hambach et al., 1998). Consistant with 
this, there are reports to suggest an increase in degradation of type VI collagen in OA 
(Ronziere et al., 1990).  Despite these reports it is unclear how type VI collagen is degraded 
within cartilage as it appears resistant to classical collagen-degrading enzymes (Bruns, 1984).  
Indeed type VI collagen is not degraded by IL-1 induced MMPs (Kielty et al., 1993). It has also 
been suggested that type VI collagen fibrils may be transformed to banded isoforms, in 
diseased cartilage, that are functionally impaired (Soder et al., 2002). These changes in the 
composition or structure of type VI collagen during OA are likely to have significant functional 
effects within the PCM.  Chondrocytes may thus lose the protective ‘basket’ of the PCM which 
protects against compressive forces and cell-matrix interactions may be disrupted, influencing 
the synthetic activity of the chondrocytes (Collins and Mc, 1960).  
 
Mice lacking type VI collagen exhibit accelerated development of OA possibly due to 
alterations in the mechanical properties, particularly a decrease in the Young’s modulus, which 
may lead to increased strain at the cellular level and affect chondrocyte metabolism 
(Alexopoulos et al., 2009).  
 
1.9.2 Perlecan in OA 
Tesche et al (2004) have shown an increase in both protein and mRNA levels of perlecan in 
human osteoarthritic knee joints.  Upregulation of perlecan was especially demonstrated in the 
deep zones of cartilage, adjacent to OA defects. Whether perlecan produced during late stages 
of the disease is able to support growth factor binding and signalling unclear (Tesche and 
Miosge, 2004).  It has been suggested that an increase in perlecan, especially in the areas 
next to the main tissue defects may represent an effort by the tissue to compensate for the 
rapid loss of other matrix components such as aggrecan (Poole et al., 1993).   
 
1.9.3 Changes to other PCM molecules in OA 
Expression of the PCM protein fibronectin also increases during OA, as does the presence of 
fibronectin fragments (Rees et al., 1987) leading to increased binding and expression of 
IGFBP-3 and IL-1 as discussed; both of which contribute to degradation of cartilage matrix.  
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Increased in cleavage of HA has been described in aging tissues.  This may contribute to 
aggrecanolysis through the release of ADAMTS-5 (Bayliss and Dudhia, 2002; Plaas et al., 
2007).  Expression of pericellular type IX collagen is decreased in OA and may reflect early 
structural changes associated with cartilage degradation (Poole et al., 1991a) as may the 
presence of degraded type II collagen within the PCM which is markedly increased during OA 
(Dodge and Poole, 1989).  
 
1.9.4 Mechanical changes in the PCM in OA 
During OA, the Young’s modulus of the PCM is decreased by up to 50% in osteoarthritis 
leading to increased compressive strains and cell deformation (Guilak et al., 2006).  In addition, 
permeability of the PCM in osteoarthritis is increased.  These changes are likely to contribute to 
both anabolic and catabolic events that occur during OA.  An increase in cell-matrix 
interactions is likely to be involved in the reparative processes in early OA.  An increase in the 
fluidity of the PCM may be involved in increasing the transport of degradative enzymes from 
the PCM to surrounding matrix leading to destruction of the cartilage.   
 
It is the purpose of my work firstly to gain an understanding of the structure and organisation of 
the PCM using a variety of histological techniques.  Following this, my aim was to identify other 
regulatory molecules, in addition to FGF-2, present within the PCM of articular cartilage using a 
proteomic approach. 
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2.1 Reagents 
2.1.1 General laboratory reagents.  
Unless otherwise specified, all general analytical-grade chemical reagents were obtained from 
BDH Laboratory Supplies (Poole, UK) or Sigma Chemical Co. (MO, USA)/ Sigma-Aldrich 
Chemie Gmbh (Steinhem, Germany). Phosphate buffered saline (PBS) was obtained as a 10X 
sterile solution (43mM Na2HPO4, 14mM KH2CO3, 14mM KCL and 1.37M NaCl at pH 7.3) 
(VWR, Lutterworth, UK).  A 1X PBS solution was generated by diluting the 10X stock with 
ddH2O. 
 
2.1.2 Table of antibodies  
A number of primary and secondary antibodies used for Western blotting or 
immunofluorescence in my studies are listed in Table 2.1 below. 
 
Antibody Against Use Type  Source  Dilution. 
Perlecan Western blot 
Immunofluorescence 
Rat 
monoclonal 
Chemicon 
(MAB1948) 
1:500 
1:1000 
Perlecan Immunofluorescence 
Immunohistochemistry 
Mouse 
monoclonal 
The Antibody shop 
(CSI 001-76) 
1:1000 
1:1500 
Type  
VI collagen 
Immunofluorescence 
Immunogold 
Immunohistochemistry 
Rabbit 
polyclonal 
Abcam (ab6588) 1:1000 
1:500 
1:800 
Beta 1 integrin Immunofluorescence Mouse 
monoclonal 
Biohit 1:100 
Hyaluronic acid 
binding protein 
Immunofluorescence Biotinylated Seikagaku (H00763) 1:20 
Aggrecan BR1 
 
 
 
Immunofluorescence Rabbit 
Polyclonal 
Donated by Dr T. 
Hardingham 
1:100 
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Aggrecan 2B6 Immunofluorescence Rabbit 
polyclonal 
Donated by Prof. B 
Caterson, Cardiff. 
1:1000 
Type II collagen Immunofluorescence Mouse 
monoclonal 
Donated by Dr V. 
Duance.  
 
1:50 
Biglycan Immunofluorescence Rabbit 
polyclonal 
Donated by Prof. D 
Heinegard, Lund.  
1:1000 
Decorin 
 
 
Immunofluorescence Rabbit 
polyclonal 
Donated by Prof. D 
Heinegard, Lund. 
1:1000 
Link protein Immunofluorescence Mouse Developmental Studies 
Hybridoma Bank 
(9/30/8-A-4) 
1:100 
Basic FGF-2 Western blotting 
Immunofluorescence 
Mouse 
monoclonal 
Upstate (05-118) 1:1000 
CCN2 Western blotting 
Immunoflurescence 
Goat 
polyclonal 
Santa Cruz (sc-14939) 1:1000 
V5 
 
Western blotting Mouse 
monoclonal 
Invitrogen (R960-25) 1:5000 
Phospho SMAD 2  
 
Western blotting Rabbit 
polyclonal 
Upstate (AB3849) 1:500 
Sox-9 Western blotting Rabbit 
polyclonal 
Chemicon (AB5535) 1:1000 
Phospho-ERK  
 
 
Western blot Rabbit 
polyclonal 
Cell signalling 
Technology (9101s) 
 
1:1000 
Total ERK 
 
 
Western blotting Rabbit 
polyclonal 
Santa-Cruz (sc-154) 1:1000 
Rat IgG HRP 
 
 
Western blotting 
(Secondary) 
 
 
Rabbit anti 
rat 
DAKO (P0450) 1:2000 
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Rabbit IgG HRP Western blotting 
(Secondary) 
Swine anti 
rabbit 
DAKO (P0217) 1:2000 
Mouse IgG HRP Western blotting 
(Secondary) 
Rabbit anti 
mouse 
DAKO (P0218) 1:2000 
Goat IgG HRP Western blotting 
(Secondary) 
Rabbit anti 
goat 
DAKO (P0160) 1:2000 
Goat IgG Immunofluorescence 
(Blocking) 
Goat R and D (AB-108-C) 1:1000 
Rabbit IgG Immunofluorescence 
(control) 
Rabbit R and D (AB-105-C) 1:1000 
Rat IgG  Immunofluorescence 
(control) 
Rat R and D (6-001-A) 1:1000 
Mouse IgG1 Immunofluorescence 
(control) 
Mouse Sigma (M7894) 1:1000 
Alexa 488-
conjugated rabbit 
IgG 
Immunofluorescence 
(Secondary) 
Goat anti 
rabbit 
Invitrogen (A-11008) 1:2000 
Alexa 488-
conjugated   
Mouse IgG 
Immunofluorescence 
(Secondary) 
Rabbit anti 
mouse 
Invitrogen (A-11059) 1:2000 
Alexa 488-
conjugated Goat 
IgG 
Immunofluorescence 
(Secondary) 
Rabbit anti 
goat 
Invitrogen (A-11078) 1:2000 
Alexa 647-
conjugated rat IgG 
Immunofluorescence 
(Secondary) 
Goat anti rat Invitrogen (A-21247) 1:2000 
Alexa 647-
conjugated mouse 
IgG 
 
Immunofluorescence 
(Secondary) 
Rabbit anti 
mouse 
Invitrogen (A-21239) 1:2000 
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Streptavidin, Alexa 
Fluor 488 
conjugate 
Immunofluorescence 
(Secondary) 
Streptavidin Invitrogen (S11223) 1:2000 
Gold-labelled 
rabbit IgG (10 nm) 
Immunogold  
(Secondary) 
Goat anti 
rabbit 
British Biocell Int.  1:25 
Table 2.1 Primary, secondary, blocking and control antibodies. 
 
2.1.3 Table of recombinant growth factors and cytokines 
A number of factors used to stimulate cells are listed in Table 2.2 below 
 
Growth factor/cytokine Species Source 
Interleukin-1  Human Prof. J Saklatvala 
Fibroblast growth factor-2 Human Peprotec EC Ltd. London, UK 
Transforming growth factor-
β1  
Human Peprotec EC Ltd. London, UK 
Transforming growth factor-
β3 
Human Insight Biotechnology, UK. 
Activin Human R and D Systems. 
Minneapolis, USA. 
CCN2 Human Donated by Prof. David 
Abraham (UCL, London) 
 
Table 2.2 Cytokines and growth factors. 
 
2.2 Tissue and Cell culture 
2.2.1 Tissue culture reagents:  Tissue explants or isolated chondrocytes were cultured in 
Dulbecco’s modified Eagle’s medium (DMEM).  DMEM was obtained as a 1X sterile and 
endotoxin-free solution from Biowhittaker (Verviers, Belgium).  DMEM was always 
supplemented with 25mM HEPES buffer, 100U/ml penicillin and 100μg/ml streptomycin, all 
purchased from Biowhittaker. DMEM was often supplemented with 10% (v/v) foetal calf serum 
(FCS). FCS was also purchased from Biowhittaker. FCS was aliquoted and stored at -20°C 
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until required. All tissue culture plastics were purchased from Beckton-Dickinson (Oxford, UK).  
Other cell types were specifically cultured as described below. 
 
2.2.2 Cartilage explants:  Porcine articular cartilage was dissected aseptically from the 
metacarpophalangeal joints of 3-6 month old pigs obtained fresh from a local abattoir within 24 
hours of slaughter (Vincent et al., 2002). Human articular cartilage was obtained from the knee 
joint of individuals undergoing surgery at the RNOH, Stanmore, for the removal of bone 
tumours.  5 different human samples were obtained from individuals of ages ranging from 8-76 
years old.  Osteoarthritic cartilage and some normal cartilage was obtained from individuals 
undergoing surgery at Charing Cross Hospital, Hammersmith, London.  Explants used for 
immunohistochemistry were either washed in serum-free DMEM and snap frozen using liquid 
nitrogen or fixed using 4% glutaraldehyde for a minimum of 4 hours at 4ºC and then snap 
frozen using liquid nitrogen.  Some explants were stimulated with TGF- , purified CCN2 or 
heparin prior to tissue fixing.  Explants used for electron microscopy were washed in serum-
free DMEM and fixed using 4% glutaraldehyde for a minimum of 4 hours at 4ºC.   
 
2.2.3 Isolation of primary porcine chondrocytes: Freshly dissected cartilage explants were 
incubated with collagenase (1mg/ml/g) for 5-6 hours at 37°C.  The digest was strained then 
centrifuged at 1500 RPM for 5 minutes.  Pellets were washed twice in DMEM medium and then 
resuspended in DMEM containing 10% foetal calf serum (FCS).  Cells were plated in 6 well 
plates or 24 well plates at a density of approximately 3.5-5 million cells or 1 million cells per 
well respectively.  Chondrocytes were serum starved for 5 hours, or overnight, prior to 
stimulation (Vincent et al., 2002).   
 
2.2.4 Human skin dermal fibroblasts: Normal human dermal fibroblasts (NHDF) were 
obtained from American Type Culture Collection (ATCC) and cultured in DMEM with 10 % (v/v) 
FCS (Biowest). Cells were cultured in a humidified atmosphere with 5 % CO2 at 37ºC. All cell 
culture was carried out in a class ΙΙ laminar flow cabinet. For passaging, cells were washed 
twice with sterile PBS, trypsin was added and cells incubated at 37ºC for approximately 5 
minutes. Once cells had detached they were pelleted in a sterile tube containing an equal 
volume of DMEM (5 minutes, 600 g). Cells were passaged for general maintenance every 
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week at ratios of either 1:5 or 1:10 depending on demand. Cells were plated in 6 well plates at 
a density of 1.8 x 105 cells per well and serum starved for 24 h prior to stimulation. 
 
2.2.5 HEK 293-EBNA cells: Human embryonic kidney 293 (HEK 293) cells were obtained from 
Invitrogen (Groningen, Netherlands) and cultured in 15cm2 dishes in DMEM containing 10 % 
(v/v) FCS.  Cells were passaged by trypsin digestion as previously described (section 2.2.4) 
Cells were passaged at ratios of 1:2 or 1:4 depending on demand. 
 
2.2.6  Murine mesenchymal stem cells:  Murine MSCs were a kind donation from a member 
of our laboratory (Dr R Vaghjiani), derived as previously described (Vaghjiani et al., 2009).  
Briefly, murine MSCs were isolated from the bone marrow of 5-week old male BALB/b mice 
(Harlan, UK Ltd, UK).  Marrow was flushed from the tibiae and femora, and red blood cells 
were removed using RBC lysis buffer (Sigma, UK).  Cells were seeded in DMEM, 
supplemented with glutamine, 100U/ml penicillin and 100μg/ml streptomycin and 10% FBS 
(Biosera, UK).  Nonadherent cells were removed after 24 hours and the media was changed 
once a week.  After 3-4 weeks, colonies were detected and isolated (with cloning rings).  
Colonies were passaged and cultured at a density of 1x105 cells/well of a 6 well plate. Cells 
were maintained in DMEM plus Glutamax containing 10% adult bovine serum (ABS) and 
passaged as described in section 2.3.5.  Cells at a density of 2 x 105 were plated as a 20µl 
drop at the centre of a 24-well tissue culture plate and allowed to adhere for 1 h at 37°C prior 
to flooding with 1 ml of DMEM (containing 1% FCS and 1% insulin/transferin/selenium + linoleic 
acid (ITS+1) with TGF-β3, CCN2 or TGF-β3 and CCN2 in combination for indicated time points 
before harvesting.  In the case of signalling experiments, cells were seeded as described and 
rested overnight in DMEM plus Glutamax containing 10% ABS.  Cells were then serum starved 
for 5 hours or overnight and then stimulated in 500 l DMEM with TGF- 3 or CCN2 alone, or in 
combination for 1 hour before harvesting. 
 
2.2.7 Porcine chondrons 
Mechanical isolation: Porcine cartilage was dissected as described above and allowed to rest 
overnight at 37 oC.  Dissected cartilage was cut into 1-2 mm2 pieces and suspended in 20 ml of 
PBS.  The suspension was then put on ice and homogenised using a polytron for 3-4 minutes.  
The flocculent supernatant was removed and filtered through a 70 µm nylon cell strainer.  
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Homogenisation was repeated twice on the remaining cartilage and the supernatant was 
collected and filtered.  Filtered supernatants were pooled and centrifuged at 1500 RPM for 15 
minutes (Lee et al., 1997)  The resulting pellet was resuspended in 5 ml PBS.  200 µl was 
used for confocal microscopy. 
 
Enzymatic isolation: Porcine MCP cartilage was dissected as described above and allowed to 
rest overnight at 37 oC.  Chondrons were obtained using 0.3% collagenase and 0.2% dispase 
in Ca 2+- and Mg2+-free phosphate-buffered saline (PBS) at 37 oC with constant agitation for 4 
hours. The resulting chondron suspension was filtered through a 70 µm nylon cell strainer and 
centrifuged at 1500 RPM for 15 minutes.  The resulting pellet was resuspended in 5 ml PBS.  
200 µl was used for confocal microscopy. The suspension was then centrifuged at 1500 rpm 
for 5 minutes to obtain the chondron pellet (Lee et al., 1997).  
 
2.3 Extraction of chondron pellets 
2.3.1 Extraction using a dissociative lysis buffer 
Chondron pellets were obtained as described in the preceding section.  The pellets were 
extracted for 15 minutes at room temperature using 1 ml RIPA lysis buffer (Table 2.3), 
containing protease inhibitors, per chondron pellet.  Following centrifugation at 13,000 RPM for 
5 minutes, the supernatant was retained and the pellets were either extracted further or 
resuspended in 1ml of PBS and sonicated prior to gel electrophoresis.  
 
2.3.2 Extraction using trypsin/proteinase K 
Chondron pellets, following extraction with lysis buffer, were exposed to further digestion using 
trypsin extraction buffer containing 1 % SDS or 50 µg/ml of proteinase K (Ambion, USA).  
Pellets were incubated in 1 ml of trypsin/SDS/proteinase K, for increasing time points. After 
each point the suspension was centrifuged for 5 minutes at 13000 RPM, supernatants 
collected and fresh trypsin/SDS/proteinase K solution was added.  After the last time point, the 
pellets were resuspended in 1 ml of PBS and sonicated prior to gel electrophoresis.  
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2.3.3 Extraction using guanidine hydrochloride 
Chondrons pellets, following extraction with lysis buffer, were extracted for time periods 
indicated using 4M guanidine hydrochloride (GnHCl) with constant agitation at 4 oC.  Following 
centrifugation at 13,000 rpm for 10 minutes, the supernatant was retained and the pellets were 
either resuspended in 1 ml of PBS and sonicated prior to gel electrophoresis or extracted 
further. 
2.3.4 Further extraction methods 
Following GnHCl extraction, the chondron pellets were washed twice in PBS and then digested 
further either using 0.1M Tris HCl pH 8.5, supplemented with 100 mM DTT, for 4 hours at room 
temperature or MMP13, pepsin or hyaluronidase (100 µg/ml in PBS) for 24 hours at 25 oC, 4 oC 
or 37 oC respectively.  Following centrifugation at 13000 RPM for 5 minutes, the supernatants 
were retained and the pellets resuspended in 1 ml PBS and sonicated prior to gel 
electrophoresis.  
 
Extraction buffers Ingredients: 
RIPA buffer 100mM Trizma base pH 7.4, 300mM NaCl, 
20mM NaF, 2mM EDTA, 0.2mM beta-
glycerophosphate, 2% (w/v) Na vanadate, 2% 
(w/v) Na deoxycholate, 0.5% SDS, and 1% 
(v/v) NP-40. 
Protease Inhibitors  1 mM phenylmethlsulfonyl fluoride (PMSF), 
10μM E64, 2 μg/ml pepstatin A, 10 μg/ml 
aprotinin, 1 μM microcystin. 
 Trypsin extraction buffer 5 µg/ml trypsin (Promega, UK)  in 25mM 
ammonium hydrogen carbonate containing 
20% MeOH 
MMP13 extraction buffer 10 nM  MMP13 (provided by Dr R. Visse at 
the Kennedy Institute of Rheumatology) in 
TNC buffer/0.05 % Brij-35, pH 7.5), 
Pepsin extraction buffer 0.5 or 10 mg/ml pepsin in 0.5M acetic acid 
Table 2.3 Extraction buffers 
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2.4 Preparation of cell lysates 
Cell lysates were generated for gel electrophoresis and western blotting (see later, sections 2.5 
and 2.6).  Isolated chondrocytes and murine mesenchymal cells were lysed with a dissociative 
buffer (RIPA). RIPA buffer was also supplemented with a cocktail of protease inhibitors with 
broad specificity for the inhibition of serine, cysteine, aspartic proteases and aminopeptidases. 
100μl of the inhibitor cocktail was mixed with 10ml of RIPA buffer according to the 
manufacturer’s instructions provided by the company.   For cell lysis 150 μl (chondrocytes) or 
100 μl, (MSCs) of RIPA buffer containing protease inhibitors was added to each well.  After 
10min at 4°C the cell lysates were collected and spun at 13000 RPM for 10min to remove 
cellular debris. For cell lysates, 75μl of supernatant was removed and mixed with 25μl 4X SDS 
sample buffer.  Finally the samples were sonicated for 5 min and boiled for 10 min prior to 
electrophoresis.  In the case of phospho-SMAD2 experiments, MSC lysates were precipitated 
using an SDS-cleanup kit (GE-Healthcare, Buckinghamshire, UK), according to the 
manufacturer’s instructions. 
 
Buffer: Ingredients: 
4 x sample buffer 0.4M Tris/HCl pH 6.8, 40% (v/v) glycerol, 0.4% 
(w/v) SDS, 2% (v/v) beta-mercaptoethanol 
and 0.02% (w/v) bromophenol blue 
 
Table 2.4 Cell lysis solutions 
 
2.5 Gel electrophoresis 
Proteins were separated by gel electrophoresis using two systems as indicated for individual 
experiments.  For laboratory prepared gels 10 or 12% acrylamide gels were made.  
Alternatively proteins were separated using the NuPAGE Bis-Tris discontinuous pre-cast 
polyacrylamide mini-gel system (1.5mm thickness) purchased from Novex, San Diego, CA. 
These gels were composed of a 4% acrylamide stacking gel and a 4-12% acrylamide gradient 
separating gel. 50μl of the cell/tissue lysate (described above) were loaded into the wells of the 
stacking gel. Often, pre-stained molecular weight markers (SeeBlue pre-stained molecular 
weight markers, Novex, San Diego, CA) were run alongside the samples to allow size 
determination of proteins. The gels were then run at 100V for approximately 2h, in tris glycine 
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running buffer or NuPAGE MOPS-SDS running buffer (Invitrogen, UK), in the XCell SureLock 
Mini-Cell electrophoresis apparatus (Novex, San Diego, CA). After separation of the proteins 
the gels were either silver stained, stained with colloidal Coomassie Brilliant Blue G-250, or 
western blotted.  
 
Buffer: Ingredients: 
Separating solution 380 mM Tris-HCl pH 8.8, 0.1% (w/v) SDS, 
either 10% or 12% (w/v) acrylamide.   
Stacking solution 
 
125 mM Tris-HCl pH 6.8, 0.1% (w/v) SDS, 5% 
(w/v) acrylamide 
Tris glycine running buffer 25 mM Tris-base, 192 mM glycine, 0.1% (w/v) 
SDS. 
Table 2.5 Gel electrophoresis solutions 
   
2.6 Western blotting 
Proteins were separated by gel electrophoresis as described above (see section 2.5). Next, 
proteins were transferred onto PVDF membranes (Millipore, Bedford, MA). The PVDF 
membranes were pre-hydrated using 100% methanol for 5min followed by ddH2O wash. 
Transfer of proteins was carried out at 100V for 90min in a Trans-blot chamber (Biorad, 
Hercules, CA) filled with western-blotting transfer buffer.  Transfer buffer was kept at 4°C by a 
water-circulating cooling pump. Next, membranes were blocked for 30-60 minutes with a 
solution of 1 x PBS containing 5% (w/v) Marvel (low fat dried milk) and 0.1% tween-20. 
Membranes were incubated with primary antibody for 1 hour at room temperature or overnight 
at 4ºC.  Primary antibodies were made up in a 5% (w/v) Marvel (low fat dried milk) in 1 x PBS, 
0.1% tween-20 solution.  The membrane was washed three times in 1 x PBS-tween then 
incubated with secondary horseradish peroxidase-conjugated antibody (1:2000) in 5% (w/v) 
Marvel/PBS-tween for 1 hour at room temperature.  In the case of the phospho-SMAD2 
antibody, PBS was substituted with TBS and Marvel was substituted with BSA in primary 
antibody solutions.  Finally, the blots were washed again 3 times for 10min with 1 X PBS 
tween, or 1 x TBS tween-20, and signal was developed by enhanced chemiluminescence 
(ECL), (Amersham, Little Chalfont, UK). Protein bands were visualized on blue-sensitive film 
(Fujifilm Super RX, Fujifilm, Bedford, UK). 
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Buffer Ingredients: 
Transfer buffer  25mM Trizma base, 190mM glycine, and 
20% (v/v) methanol 
10 x Tris-buffered saline 100 mM Tris pH 7.4, 1.5M NaCl. 
Table 2.6 Western blotting buffers 
 
2.7 Silver staining 
Silver staining was used in order to visualize proteins in gels following extraction of chondrons 
or purification of CCN2 by chromatography. The silver staining method was compatible with 
mass spectrometric identification of proteins. All reagents used were of ultra-pure analytical 
range. Similarly, H2O was double distilled (ddH2O), free from protein and microbial products. 
Initially gels were fixed in a 50% methanol (v/v) / 5% acetic acid (v/v) solution for 20min. They 
were then washed in a 50% (v/v) methanol solution for another 20min and finally in ddH2O for 
2h. Next, the gels were incubated in the sensitizer solution (0.02% (w/v) sodium thiosulphate) 
for 1min, washed twice for 1min with ddH2O and then incubated at 4°C for 20min with the silver 
reagent (0.1% (w/v) pre-cooled silver nitrate solution). Gels were washed twice with ddH2O for 
1min and then incubated with the developing solution (2% (w/v) sodium carbonate and 0.04% 
(v/v) formaldehyde (35%)). Formaldehyde was added in the developing solution immediately 
before the solution was incubated with the gels. The developing solution was changed twice 
within the first 2min of incubation in order to reduce background staining. The developing 
reaction was stopped with 5% (v/v) acetic acid when protein bands were clearly visable. 
Finally, the gels were washed with ddH2O and stored at 4°C in ddH2O until used. 
 
2.8 Protein identification by mass spectrometry 
Protein bands from gel electrophoresis were identified by mass spectrometry at various stages 
of my PhD studies. The mass spectrometry identification and in-gel digestion was performed by 
Dr. Robin Wait in the Kennedy Institute’s Proteomics Unit.  
 
2.8.1 In-gel digestion: In-gel digestion of silver-stained protein bands with trypsin was 
performed according to published methods (Jeno et al. 1995; Wilm et al. 1996; Shevchenko et 
al. 1996) and modified (Wait et al. 2001) for use with a robotic digestion system (Investigator 
ProGest, Genomic Solutions).  
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2.8.2 Electrospray Mass Spectrometry:  Tandem mass spectra were recorded using a Q-Tof 
spectrometer (Waters, Manchester, UK) interfaced to a Waters CapLC capillary 
chromatograph. Samples were dissolved in 0.1% formic acid and injected onto a 300 m x 5 
mm Pepmap C18 column (LC Packings, Amsterdam, NL) and eluted with an acetonitrile/0.1% 
formic acid gradient. The capillary voltage was set to 3,500 V. A survey scan over the m/z 
range 400-1300 was used to identify protonated peptides with charge states of 2, 3 or 4, which 
were automatically selected for data-dependent MS/MS analysis, and fragmented by collision 
with argon. The resulting product ion spectra were transformed onto a singly charged m/z axis 
using a maximum entropy method (MaxEnt3, Waters) and proteins were identified by 
correlation of uninterpreted spectra to entries in SwissProt/TrEMBL, using ProteinLynx Global 
Server (Version 1.1, Waters).  The database was created by merging the FASTA format files of 
SwissProt, TrEMBL and their associated splice variants (1,768,175 entries at the time of 
searching). No taxonomic or protein mass and pI constraints were applied. One missed 
cleavage per peptide was allowed, and the initial mass tolerance window was set to 100 ppm. 
For further confirmation of the identifications the spectra were also searched against the NCBI 
nr database (4,496,228 sequences as of January 2007) using Mascot 
(www.matrixscience.com).  For an identification to be considered valid we required that two or 
more peptides independently matched the same protein sequence, that the peptide score was 
significant (typically greater than 55 (P<0.05)), and that manual interpretation confirmed 
agreement between spectrum and peptide sequence. In addition Mascot searches of all 
spectra were performed against a randomised version of the NCBI database using the same 
parameters as in the main search. 
 
 
2.9 Confocal Microscopy 
2.9.1 Chondrons: Following isolation, chondrons from one porcine MCP joint (approximately 
1g of tissue) were resuspended in 5 ml of PBS and a small volume was coated onto Lab Tek II 
chamber slides (VWR International).  Chondrons were air dried, fixed in methanol for 10 
minutes and pre-treated with chondroitinase ABC (10 mu/ml) (Seikagaku, Japan) for 90-120 
minutes at 37 ºC.  The chondrons were blocked in 10 % goat serum/PBS and incubated with 
primary antibody for 1 hour at room temperature or overnight at 4ºC.  Chondrons were washed 
three times with PBS, then incubated (in the dark) with secondary FITC labeled antibodies for 1 
hour at room temperature.  Chondrons were washed further and mounted using 50 % glycerol.  
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Fluorescence signals were detected by Ultraview confocal microscopy (Perkin-Elmer, x60 oil 
immersion lens). 
 
2.9.2. Human and porcine tissue:  Following snap freezing, all tissue sections were 
processed by Mr David Essex at the Histology Department, Charing Cross Hospital, London.  
Cartilage explants were mounted in OCT and 7 µm frozen cryostat sections were cut onto 
Surgipath snowcoat Xtra slides, air dried for 1 hour and then left for a further hour at 60ºC to 
ensure tissue adherence.  Tissue sections were fixed in methanol for 10 minutes and pre-
treated with chondroitinase ABC (10 mu/ml) (Seikagaku, Japan) for 90-120 minutes at 37 ºC.  
The sections were blocked with 10 % goat serum/PBS for 60 minutes at room temperature, 
and then incubated with primary antibody for 1 hour at room temperature or overnight at 4ºC.  
Sections were washed three times with PBS, then incubated (in the dark) with secondary FITC 
labelled antibodies for 1 hour at room temperature.  Sections were further washed and 
mounted using 50 % glycerol.  Fluorescence signals were detected as above.  For human 
samples, confocal microscopy was carried on at least 3 different patient samples per 
experiment, except in the case of young tissue which was performed on just one sample.  In 
the case of porcine tissue, microscopy was carried out on explants from at least 3 different 
animals per experiment.  Results shown are representative of the staining obtained.   
 
2.9.3 Chondrocytes: Cells were isolated as described above, plated onto Lab Tek II chamber 
slides and rested for 48 hours at 37 ºC.  Cells were then incubated in the presence of TGF-β, 
with or without heparin, or purified CCN2 for a further 48 hours.  Cells were fixed in methanol 
for 10 minutes and washed with PBS.  The cells were then blocked in 10% BSA and incubated 
with primary antibody for 1 hour at room temperature or overnight at 4ºC.  Chondrocytes were 
washed three times with PBS, then incubated (in the dark) with secondary FITC labeled 
antibodies for 1 hour at room temperature.  Cells were washed further and mounted using 50 
% glycerol.  Fluorescence signals were detected as above.   
 
2.10 Electron Microscopy 
Human cartilage explants were fixed in 4 % glutaraldehyde in PBS as described above and 
washed twice in PBS for a minimum of 10 minutes.  Explants, if larger than 4 mm2, were cut 
into smaller pieces.  The tissue was then fixed in 1 % aqueous osmium tetroxide (Agar 
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Scientific) for 30-60 minutes, washed twice quickly in water and then dehydrated in an acetone 
series (50 %, 70 %, 80 %, 90 % and 100 % acetone for 10 minutes each).  Tissue explants 
were then incubated in a 1:1 solution of dried acetone and araldite (Agar Scientific), rotating, 
overnight at room temperature.  The acetone/araldite solution was discarded and the explants 
incubated in 100 % araldite, rotating, for 1 hour at room temperature.  After 1 hour, the araldite 
solution was changed and left for a further 30 minutes.  The tissue was incubated for a further 
30 minutes at 50ºC.   Superficial layers of approximately 1mm thickness were cut from the 
explants, noting the orientation, and pre-embedded flat on droplets of fresh araldite on 
polythene sheets.  The araldite was allowed to partially polymerise at 50ºC for 15-30 minutes.  
BEEM capsules were filled with araldite, inverted over each tissue explant, and left at 60ºC for 
1-2 days.  Ultra-thin sections (50–100 nm) were cut with a Reichert Ultracut E microtome 
and picked up on uncoated copper grids.  The grids were stained with 2 % (w/v) uranyl acetate 
and Reynolds lead citrate for 30 minutes and 15 minutes respectively.   The sections were 
examined using a JEOL 1200 EX electron microscope operated at 100KV and 
"working" images recorded onto a 1kx1k CCD camera (Tetiz Fastscan).  For viewing large 
areas at high magnification, for example when viewing gold particles and large cellular regions, 
it was essential to record onto EM film (Kodak SO163) at 5000, 10000 and 12000x 
magnification.  A tilt/ rotation specimen holder (EM-BSR) was used to facilitate the orientation 
and imaging of the cartilage explants.   The electron micrographs were scanned with a Nikon 
Coolscan 8000ED 4000 dpi scanner. 
 
2.11 Immunogold electron microscopy 
Human cartilage explants were fixed and embedded as described in the preceding section.  
Thin sections (0.5-1 µm) were cut with a Reichert Ultracut E microtome and picked up on glass 
slides.  The sections were then immersed in saturated sodium ethoxide solution (prepared by 
dissolving sodium ethoxide pellets in ethanol) for 7 minutes to remove the araldite.  The 
sections were then hydrated using 100 % ethanol, 50 % ethanol and distilled water, for 5 
minutes each.  Following rehydration, the sections were immersed in 5 % hydrogen peroxide 
for 10 minutes, in order to re-oxidise the osmium, and then washed twice in PBS. The sections 
were blocked in PBS containing 5% BSA for 1 hour at room temperature and then incubated 
with primary antibody (1:100) for 2 hours at room temperature. The sections were washed 3 
times in PBS and once in PBS at a pH of 8.2 then incubated with 10nm gold-labelled 
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secondary antibody (1:25) in 5% BSA in PBS (pH 8.2).  The sections were washed a further 3 
times in PBS and then the gold label was enhanced using a gold enhancement kit 
(Nanoprobes, NY) for 5-10 minutes.  Successful staining was detected by light microscopy.  
The sections were dehydrated in an acetone series and then incubated in a 1:1 solution of 
dried acetone and araldite (Agar Scientific), overnight at room temperature.  The 
acetone/araldite solution was discarded and the explants incubated in 100 % araldite, for 1 
hour at room temperature.  After 1 hour, the araldite solution was changed and left for a further 
30 minutes.  The tissue was then incubated for a further 30 minutes at 50ºC.  BEEM capsules 
were filled with araldite, inverted over each tissue explant, and left at 60ºC for 1-2 days.  The 
embedded sections were removed from the attached slides using liquid nitrogen.  Ultrathin 
sections were cut and examined as described in the preceding section.   
 
2.12 Molecular biology. 
2.12.1 Transformation of competent cells: Typically, 1µg of DNA was added to 50 µl of 
thawed competent E. coli cells (‘One Shot TOP 10 competent cells’, Invitrogen).  The mixture 
was then incubated on ice for 30 min.  Tubes were placed at 42°C (water bath) for 45 seconds, 
then transferred back onto ice for 2 min.  The bacteria were allowed to recover for 1 hour at 37 
°C in 400 μl Lysogeny broth (LB) without antibiotic. Bacteria were then plated onto LB-agar 
plates containing the appropriate antibiotic for selection of transformants.  Plates were 
incubated at 37 °C overnight and colonies were picked the following day.   
 
2.12.2 Small scale preparation of plasmid DNA (Miniprep): DNA mini preps were prepared 
using the QIAprep® spin miniprep kit from Qiagen. Single colonies picked from an LB-agar 
plate were cultured overnight at 37°C with agitation, in 4 ml of LB containing the appropriate 
selection antibiotic. The bacteria were pelleted from 1.5 ml of each culture by centrifugation at 
13000 RPM for 1 minute. The supernatant was discarded, the bacteria were lysed and DNA 
purified according to the manufacturer’s instructions.  DNA was eluted in 40 μl of the elution 
buffer provided.  DNA absorbancies were measured at 260 nm (A260) to calculate its 
concentration and purity was assessed using A260/A280 ratio. 
 
2.12.3 Large scale preparation of plasmid DNA (Maxiprep): 100 ml of LB containing the 
appropriate selection antibiotic was inoculated with 1ml from a 4 ml culture of bacteria.  This 
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was left to incubate at 37oC overnight with gentle agitation. Bacteria were then pelleted by 
centrifugation at 13000 RPM for 15 minutes. The supernatant was discarded and the DNA from 
the pellet was purified using the UltraMobius 1000 endotoxin-free plasmid kit from Novagen. 
The pellet of DNA obtained was washed with 70% ethanol, before being resuspended in 100 to 
500 μl of DNAse-free water depending on its size. DNA concentration and purity were 
measured as described previously for the miniprep.  
 
2.12.4 Transient transfection of HeLa cells:  A human CCN2 construct was kindly provided 
by Professor Roger Mason at The Hammersmith Hospital. The cDNA which contained a His 
Tag for purification and a V5 epitope for immunological identification, at the C terminus, was 
inserted into a pcDNA 3.1 expression vector (Wahab et al., 2001b) (Figure 4.1).   HeLa cells 
were seeded into 6 well plates at a density of 2.5 X 105/ well and left to grow overnight. The 
cells were transfected with 0, 10, 100, or 1000 ng of CCN2 plasmid DNA.  The empty CMV 
vector was also added so that equal amounts of DNA were transfected in each case. Each 
plasmid was complexed with superfect according to the manufacturer’s instructions and then 
added to the cells for 4 hours after which time the transfection mix was removed and the cells 
were washed twice with sterile 1x PBS and fresh DMEM alone or DMEM supplemented with 10 
% (v/v) FCS. Conditioned medium was collected at 24 or 48 hours after transfection and run on 
SDS PAGE (4-12%).  To obtain larger volumes of conditioned medium for purification 
purposes, transient transfections were carried out on HeLa cells in T150 flasks.  Cells were 
grown to approximately 70% confluency and transfected with 15µg CCN2 plasmid DNA using 
superfect as described above.  Following transfection, cells were washed twice with sterile 1x 
PBS and fresh DMEM (30ml) was added to the cells and conditioned for 24 hours.  
 
2.12.5 Subcloning into pCEP4 vector:  pCEP4 is an episomal mammalian expression vector 
that uses the cytomegalovirus (CMV) immediate early enhancer/promoter for high level 
transcription of inserted recombinant genes. It also carries an Epstein-Barr Virus replication 
origin (oriP) and EBNA-1 gene, to permit extrachromosomal replication.  It was decided to 
subclone the CCN2 construct from the original pcDNA 3.1 vector into a pCEP4 expression 
vector (Figure 4.12).  The CCN2 fragment was cut out of the pcDNA 3.1 vector by PmeI and 
KpnI digestion.  This was subcloned into the pCEP4 expression vector (Invitrogen, UK), which 
had previously been linearized by PvuII and KpnI digestion and dephosphorylated 
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(dephosphorylation with 2 U of Calf Alkaline Phosphatase (CIP) for 1 hour at 37 °C, followed 
by 15 min at 70 °C to inactivate the enzyme).  Ligations were performed in a final volume of 20 
μl in the presence of 1 μl T4 DNA Ligase, 2 μl 10 x ligation buffer, and using the two different 
vectors at ratios of 1:1, 1:1.5 and 1:3.  Ligations were then used to transform competent E. coli 
cells as described.  Transformed bacteria were selected on LB-agar plates containing 100 
μg/ml ampicillin.  Plasmid DNA from several colonies selected at random was prepared as 
described, and restriction digests performed to identify positive clones.  DNA ‘maxiprep’ stocks 
for pCEP4-CCN2 were then prepared as described.  
 
2.12.6 Stable transfection of HEK 293-EBNA cells:  HEK 293-EBNA cells, a human 
embryonic kidney cell line, were chosen as an alternative to HeLa cells.  They are commonly 
used for generating recombinant proteins as they are straightforward to both grow and 
transfect.  They contain a vector inserted into the chromosome that allows expression of the 
EBNA-1 gene.  They also contain a neomycin resistance gene and therefore cells were 
maintained in the presence of the antibiotic G418 to enable selection of EBNA-1 positive cells.  
The presence of the EBNA-1 gene within the HEK 293 cells promotes a higher level of 
episomal expression of the pCEP4 plasmid which contains the oriP site.  HEK 293-EBNA cells 
were seeded into 6 well plates at a density of 1.5 X 105/ well and left to grow overnight. The 
cells were transfected with 1 µg of CCN2 pCEP4 plasmid DNA using Lipofectamine 2000 
(Invitrogen, UK) according to the manufacturer’s instructions.  After 4 hours, the cells were 
washed twice with PBS then replaced with fresh DMEM, containing 10% (v/v) FCS. The 
medium was conditioned and collected after 24 hours and assayed for the presence of CCN2.  
Transfected cells were then positively selected using increasing concentrations of the antibiotic 
hygromycin B (PAA Laboratories Ltd, UK) (100, 400 and 800µg/ml) for approximately 10-14 
days.  Medium was replaced every 2-3 days and the positively selected cells were 
resuspended and allowed to re-adhere.  Positively selected cells were either frozen down for 
future use or grown to confluency in 15cm2 dishes in DMEM containing 10% FCS, 250 µg/ml of 
the antibiotic G418 and 100 µg/ml hygromycin B. Once confluent, cells were washed twice with 
1x PBS, and 40 ml of serum free medium, containing 250 µg/ml G418 (PAA Laboratories Ltd, 
UK), was conditioned for 24 hours and then replaced with fresh medium. The resulting 
conditioned medium was stored at -20 °C until needed for purification of CCN2 by 
chromatography.  
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2.12.7 RNA extraction for RTPCR:  Media was removed from either NHDFs or murine MSC 
and total RNA was extracted and purified with RNeasy mini-columns (Omega Bio-tek) 
according the manufacturer’s instructions.  RNA was eluted in 40 μl of H2O and its 
concentration and purity was determined by measuring the absorbance at 260 nm and at 280 
nm.  
2.12.8 Reverse Transcription:  cDNA was generated from the RNA sample using a reverse 
transcription kit from Invitrogen, San Diego, CA.  Reverse transcription was performed in a final 
volume of 40 l.  The RNA template was denatured at 65 C for 6 minutes and rested on ice for 
5 minutes before addition of the other reagents.  Reactions were performed in a T3 
thermocycler (Whatman biometra, Goettingen, Germany) using the following protocol: 25 C for 
10 minutes, then 42 C for 50 minutes, followed by heating to 70 C for 15 minutes. 
 
 
Buffer Containing: 
Reverse transcription reaction mixture 22 l of RNA template (0.2 g of total RNA), 
2 l of dNTP mix (10 mM each), 2 l of random 
hexamer primers (100 ng/ml), 8 l of 5x First-
Strand buffer, 4 l of DTT (0.1 M), 1 l of 
RNAguard and 1 l of SuperScript™ ІІ 
Table 2.7 Reverse transcription reaction mixture buffer. 
 
2.12.9 Quantitative real time PCR: All cDNA was processed using the Taqman  realtime 
PCR system (Applied Biosystems Inc.) using pre-validated primer/probe mixes obtained from 
the same company.  Realtime PCR was performed in a final volume of 12 l per reaction.  All 
samples were in duplicate.  The thermocycling conditions were as follows: hold at 50 C for 
2min for optimal activity of UNGerase enzyme, then denaturation at 95 C for 10min followed by 
40 cycles of denaturation at 95 C for 2min followed by an annealing/ extension step at 60 C for 
30s.  All thermocycling was carried out in a Rotor-Gene  6000 real-time rotary analyzer 
(Corbett Life Science, Corbett Research UK Ltd) and all data capture and primary analysis was 
carried out using Rotor-Gene 6000 software version 1.7 (Corbett Life Science, Corbett 
Research, UK Ltd, Cambridgeshire, UK)  The expression levels of the genes of interest were 
normalized to those of GAPDH. 
 Chapter 2                                                              Materials and Methods 
 
76 
 
Buffer Containing: 
RTPCR reaction mixture 5 l appropriately diluted cDNA template, 
0.4 l 20x primer/probe FAM/MGB dye mix 
(Gene expression assay), 0.6 l nuclease free 
H20 (Promega) and 6 l Taqman  2x 
Universal PCR mix (Applied Biosystems Inc.). 
Table 2.8 RTPCR reaction mixture buffer 
 
 
Gene 
 
 
ABI catalogue 
number 
Amplicon size 
(bp) 
GenBank number 
GAPDH (murine) Mm99999915_g1 107 NM_008084.2 
Sox-9 (murine) Mm00448840_m1 101 NM_011448.4 
GAPDH (human) Hs99999905_m1 122 NM_002046.3 
CCN2  Hs01026927_g1 70 NM_001901.2 
Collagen Type I 
 
Hs00164099_m1 68 NM_000089.3 
Fibronectin Hs01549940_m1 66 NM_212474.1 
Table 2.9 Taqman Gene Expression Assay  primers/probe mixes (Applied Biosystems) used 
in Taqman  Real-time RT-PCR. 
 
2.12.10 Statistical Analysis:  All statistical analysis was performed using Prism 4 for Windows 
XP (Graphpad Software Inc., USA).  Significance was calculated using a one way ANOVA test 
followed by Bonferroni’s multiple comparison test. ns= p value of >0.05 (not significant), *= p ≤ 
0.05 (significant), **= p ≤ (very significant), ***= p ≤ 0.001 (extremely significant).  
 
2.13. Purification of CCN2 from conditioned medium  
In all cases, the AKTA system (Pharmacia, Uppsala, Sweden) was used for purification. 
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2.13.1 Heparin-agarose chromatography: Conditioned medium (5ml) from transfected HeLa 
cells was filtered through a 0.45 M filter and loaded onto a 1ml heparin-agarose column (GE 
Healthcare Ltd, Buckinghamshire, UK) previously equilibrated in 1x PBS.  The material was 
pumped through the column at 1ml/min.  The column run-through was collected and proteins 
were eluted from the column in 1 ml fractions on a 5ml step-wise NaCl gradient ranging from 0-
1M NaCl.  Fractions were western blotted for the presence of CCN2.   
 
2.13.2 Nickel affinity chromatography:  Initially conditioned medium (100-500ml) from 
transfected HeLa cells was filtered and loaded onto either a 1 or 5ml nickel affinity column (GE 
Healthcare Ltd, Buckinghamshire, UK) previously equilibrated in 20mM sodium pyrophosphate, 
0.5M sodium chloride, 20mM imidazole, pH 7.4 and pumped through the column at 1 or 
2ml/min.  The column run-through was collected and proteins were eluted in 1 or 2.5ml 
fractions on a 5ml or 15ml linear gradient ranging from 20mM imidazole to 500mM imidazole.  
Fractions were western blotted for the presence of CCN2.   
 
In later experiments, conditioned medium (200ml) from transfected HEK 293 cells was 
supplemented with 20mM imidazole before being filtered and loaded onto a 5ml nickel affinity 
column (GE Healthcare Ltd, Buckinghamshire, UK) previously equilibrated in 20mM sodium 
pyrophosphate, 0.5M sodium chloride, 20mM imidazole, pH 7.4.  The column run-through was 
collected and proteins were eluted in 2.5ml fractions on a 15ml linear gradient ranging from 
20mM imidazole to 500mM imidazole.  Fractions (2.5ml) were western blotted for the presence 
of CCN2.   
 
2.13.3 Dialysis and ultrafiltration: The positively identified fractions were subjected to dialysis 
in order to equilibrate fractions into physiological buffer (1X PBS) for 8-12 hours at 4 C before 
use in cell culture. For dialysis, positive fractions were placed in 10KDa molecular weight cut-
off SpectraPor Float-A-Lyzers purchased from Fisher scientific (Hampton, NH). 10kD cut-off 
ultrafiltration spin-columns (Vivaspin, Sartorius, Goettingen, Germany) were used to 
concentrate dialysed fractions to 10x concentrates. The retained fractions were then aliquoted 
and stored at -200C until used.   
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2.14 Metabolic labeling of cultured chondrocytes. 
Metabolic labeling of porcine chondrocytes was carried out in order to study the production of 
newly synthesized proteins upon stimulation of cells.  Monolayer chondrocytes (1 x 106/well of 
a 24 well plate), cultured for 48 hours in 10% FCS containing medium, were washed with 
serum-free medium for 2 hours and then stimulated with different factors (e.g FGF-2, CCN2) 
for a further 12 hours.  Next, chondrocytes were washed with methionine/cysteine free medium 
(serum-free) (Biowhittaker, Verviers, Belgium) and incubated with the same medium which was 
supplemented with 35S labelled methionine/cysteine (35S[met/cys], Amersham, Little Chalfont, 
UK) (15µCi/well for 6 hours).  The radiolabelled medium was then removed, centrifuged at 
13000 RPM for 5min to clarify, mixed with 4X SDS sample buffer and boiled for 10min.  
Samples were subjected to gel electrophoresis and gels were fixed and silver-stained as 
described previously.  Silver-stained gels were then dried.  35S[met/cys] labeled, newly 
synthesized proteins were visualized by autoradiography on blue-sensitive film (Fujifilm Super 
RX, Fujifilm, Bedford, UK).   
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3.1 Introduction 
Previous work from our group has suggested that the PCM plays an important role in 
chondrocyte homeostasis by sequestering the growth factor FGF-2.  Controlled release of the 
growth factor occurs when the tissue is damaged by cutting (Vincent et al., 2002) or loading 
(Vincent et al., 2004).  This project aimed to determine the other structural components of the 
PCM and to identify other regulatory molecules held within the matrix. 
 
3.2 A histological approach to studying the pericellular matrix. 
I first determined the structure and organisation of some of the major components of the PCM 
using two histological techniques: electron microscopy and confocal microscopy.  
 
3.2.1 The pericellular matrix by electron microscopy. 
The pericellular matrix is described as the zone of matrix surrounding individual chondrocytes 
throughout the tissue.  Relatively few studies have looked at the exact structure of the PCM, 
with the majority of the work in this area published by Poole and co-workers.  My aim was to 
define the PCM in more detail and I worked in collaboration with Dr. Pradeep Luther at South 
Kensington, to study articular cartilage using transmission electron microscopy.   
 
Human articular cartilage was obtained from the knee joints of individuals undergoing surgery 
at the RNOH, Stanmore, or Charing Cross Hospital, Hammersmith.  Ultra-thin sections (50–100 
nm) were examined in a JEOL 1200 EX electron microscope and images recorded onto EM 
film at 5000, 10000 and 12000 x magnification.  Figure 1A shows a chondrocyte surrounded by 
a distinct zone of matrix that can be clearly distinguished from the further removed extracellular 
matrix.  This apparently lucent zone around the chondrocyte, which separates it from the 
denser territorial matrix (TM), is the PCM.  This can be seen more clearly at higher 
magnification (Figure 1B).  The TM can be defined by the presence of thick striated type II 
collagen fibres, whereas the PCM is clearly devoid of these fibrils.  Cell processes can be seen 
extending into the PCM from the chondrocyte and are presumably responsible for the essential 
interactions between the cell and the matrix.  
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Figure 1. The pericellular matrix by electron microscopy.  Normal human knee cartilage was fixed in 4% 
glutaraldehyde for 4 h and then post-fixed in osmium tetroxide for 30-60 min.  After dehydration in an acetone series, 
the tissue was embedded in araldite and then processed for electron microscopy. Scale (A) Bar=1µm  (B) 
Bar=500nm 12000x.  The extracellular matrix is defined by the presence of  type II collagen fibrils (black arrows) with 
the distinct zone of pericellular matrix surrounding the chondrocyte (demarked by white arrow)
A B
 
 
 
Little else can be clearly identified within the PCM, apart from the presence of thin filamentous 
material which is possibly type VI collagen.  The use of conventional transmission electron 
microscopy in this way gives a clear image of the PCM as a distinct zone within the matrix, 
although one is unable to identify specific components.  
 
3.2.2 Localisation of perlecan and type VI collagen within the PCM. 
A number of cartilage polymers have been identified mainly by immunohistochemistry, as 
components of the PCM.  PCM molecules previously described include type VI collagen (Poole 
et al., 1988a), perlecan (Melrose et al., 2006), hyaluronan (Mason, 1981), type IX collagen 
(Wotton et al., 1991), biglycan (Miosge et al., 1994), and a range of less abundant 
glycoproteins including link protein (Ratcliffe A, 1996) and fibronectin (Glant et al., 1985).  As 
mentioned, thin filamentous material identified within the PCM by electron microscopy may 
represent type VI collagen.   Type VI collagen is described as being a ‘minor’ collagen within 
articular cartilage and is unique among the collagens for its monomer and microfibrillar 
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arrangement.  Poole et al. (1988) showed type VI collagen to be concentrated within the PCM 
of isolated chondrons and it is in fact regarded as a key molecular marker for chondrons 
(Poole, 1997; Poole et al., 1992; Poole et al., 1988a).  Type VI collagen has been shown to 
interact with a number of components within the matrix in vitro, including perlecan.  Perlecan is 
a proteoglycan that in adult articular cartilage is predominantly substituted with heparan 
sulphate (HS) (Vincent et al., 2007).  It has been shown by immunohistochemistry to be 
localised pericellularly in foetal, postnatal and mature articular cartilage (Melrose et al., 2006).  
Interaction between these two molecules is thought to occur through binding of the α2 chain of 
type VI collagen to HS chains of perlecan.  (Tillet et al., 1994).   Although both are described as 
major components of the PCM and have been shown to interact, the two have not been shown 
to colocalise by microscopy.  Therefore, I decided to firstly confirm the presence and 
localisation of these molecules within the PCM.  Adult human cartilage explants were snap-
frozen and 7 µm sections were cut.  The tissue sections were fixed, treated with chondroitinase 
and then incubated with the appropriate primary antibodies.  Chondroitinase removes the 
chondroitin sulphate (CS) chains of the highly abundant CS-proteoglycan aggrecan, thereby 
assisting antigen retrieval.  Following incubation with secondary FITC labelled antibodies, 
fluorescence signals were detected by Ultraview confocal microscopy (Perkin-Elmer, x60 oil 
immersion lens).  Figure 2A shows the localisation of both perlecan (in red) and type VI 
collagen (in green) within the tissue.  Both proteins appeared to be exclusively localised within 
the matrix surrounding the cell, with little or no staining in the further removed TM.  When the 
two images were merged, there appeared to be some, although not complete, colocalisation of 
the two components.  This confirmed both the localisation and interaction of perlecan and type 
VI collagen within the PCM.  Figure 2B shows cartilage sections incubated with non-immune 
control antibodies and corresponding secondary FITC labeled antibodies.  There was no 
detectable staining indicating the specificity of staining for the target molecules.   
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Perlecan  Type VI collagen                             PI Merged
Figure 2.  Localisation of perlecan and type VI collagen in human articular cartilage. Frozen sections (7 
µm) of human articular cartilage were pre-treated with chondroitinase (10 mu/ml for 90-120 min).  Sections 
were stained with primary antibodies to perlecan (1:1000) and type VI collagen (1:1000) (A) or non-immune 
control antibodies (rat and rabbit) (B) Sections were washed and incubated with secondary FITC-labelled 
antibodies (1:2000) and propidium iodide (PI) (1:1000) .Fluorescence signals were detected by UltraVIew 
confocal microscopy.  Bar = 20µm.
A
B Rat NI                             Rabbit NI                                       PI
 
 
3.2.3 Heparan sulphated (HS) proteoglycans within the PCM. 
In addition to perlecan, there are a number of other HS proteoglycans described within articular 
cartilage.  The HS proteoglycans are a family of proteins which are substituted with heparan 
sulphate glycosaminoglycan chains.  They are broadly divided into those that are membrane 
bound including syndecan-2 (fibroglycan), syndecan-4 (amphiglycan), CD44 and glypican, and 
those that reside in the matrix, e.g. perlecan.  HS is a known regulator of cell function through 
the ability to sequester heparin-binding growth factors, e.g. FGF-2, and through its critical role 
in growth factor signalling (Aviezer et al., 1994; Delehedde et al., 2002).  Although we had 
shown colocalisation of FGF-2 with perlecan in the PCM (Vincent et al., 2007), it was important 
to determine the expression of other HS proteoglycans within the tissue and assess their role in 
growth factor sequestration.  I decided to investigate the abundance of perlecan compared to 
other HS proteoglycans within articular cartilage. Cartilage sections were treated with the 
enzyme heparitinase, an enzyme which degrades HS, and then stained both with an antibody 
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recognising the heparan sulphate stub, generated by heparitinase treatment, and an antibody 
to perlecan (Figure 3).  Staining of cartilage prior to heparitinase treatment (control) showed 
perlecan to be typically pericellular, with no staining in the TM.  There was no matrix staining 
detected by the HS stub antibody although there did appear to be some localisation within the 
chondrocyte itself.  This was likely to be non-specific.  Post heparitinase treatment revealed 
typical pericellular perlecan staining and in contrast to the control, the HS stub antibody was 
also localised pericellularly, with no staining in the TM.  When the images were merged, there 
was largely complete colocalisation of perlecan and the antibody to the HS stub.  Based on 
these observations, it was reasonable to conclude that perlecan was the most abundant 
heparan sulphated proteoglycan in articular cartilage.   
 
Figure 3.  Localisation of HSPGs in articular cartilage. Frozen sections (7 µm) of human articular cartilage 
were pre-treated with hyaluronidase (0.01%, 1 h) with or without heparitinase (10 mu/ml for 1 h). Sections 
were stained with the HS stub antibody 3G10 (1:1000) and perlecan (1:1000) (Sections were washed and 
incubated with secondary FITC labelled antibodies (1:2000). Fluorescence signals were detected by 
UltraVIew confocal microscopy. Bar = 20µm. 
Perlecan  HS stub Merged
Control
Heparitinase 
treated
 
 
3.2.4 Immunogold labelling approach to looking at PCM components.  
I have shown that perlecan and type VI collagen partly colocalise within the PCM of articular 
cartilage.  Although informative, confocal microscopy does not allow one to determine the exact 
organisation of molecules within the PCM, or their localisation in relation to one another. For 
example, it is difficult to determine whether perlecan and type VI collagen are localised 
exclusively within the same zone of the PCM, or whether one molecule lies in closer proximity 
to the chondrocyte, or the further removed TM, than the other.   In an attempt to gain further 
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understanding of the ultrastructural organisation and interaction between these two molecules, 
I decided to use immunolabelling, at the level of electron microscopy. 
 
There is a small number of published methods for studying cartilage using immunogold 
labelling, each involving different fixative, cutting, embedding and staining techniques.  The 
difficulties that arise when using electron microscopy and immunolabelling are reflected by the 
relative shortage of these studies in the literature.  The primary problem is the balance between 
tissue preservation and quality of immunostaining.  I attempted a number of published methods 
involving immunolabelling both pre and post-embedding of the tissue.  
 
As described in section 3.1, human articular cartilage was fixed and embedded in araldite.  At 
the stage of cutting sections for electron microscopy, instead of ultrathin sections (50-100 nm), 
thin sections (0.5-1 µm) were cut and picked up on glass slides.  In order for immunolabelling 
to be successful, the osmium tetroxide (used to fix the tissue) and the araldite had to be 
removed.  This was done with solutions of 5 % hydrogen peroxide and saturated sodium 
ethoxide.  The sections were then incubated with a primary antibody to type VI collagen 
(1:100).  The sections were then washed and incubated with a secondary antibody conjugated 
to gold particles 10 nm in size.  In order to increase the chance of visualising the gold particles 
by electron microscopy, a gold-enhancement kit was used which works by catalytically 
depositing gold ions around the initial gold particle used for immunostaining. This also allowed 
light microscopy to be used, prior to electron microscopy, to determine if the immunolabelling 
was successful.  The sections were then dehydrated in acetone, re-embedded in araldite and 
ultrathin sections were cut as described above.  It should be noted that cutting ultrathin 
sections from sections of only 1 µm is technically very difficult.  Cut sections were picked up on 
copper grids and visualised by electron microscopy, as described previously.  
 
Figure 4A shows human articular cartilage immunolabelled for type VI collagen.  It appeared 
that the gold particles were localised specifically within the zone of matrix directly surrounding 
the chondrocyte – previously identified as the PCM.  There was little or no staining within the 
further removed TM, confirming the theory that type VI is present exclusively within the PCM.  
This can be seen more clearly at higher magnification (Figure 4B). There also did not appear to 
be any staining within the chondrocyte itself implying that the staining seen was specific.  
However, as discussed, there were problems in preserving the tissue.  This is seen by 
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comparing the images in Figure 4 to Figure 1.  The difference in clarity of the of type II collagen 
fibres in the extracellular matrix is apparent, as is the structure of the chondrocyte itself.  
Further evidence for a disruption of the integrity of the tissue can be seen in Figure 4C and D.  
Again, it was difficult to identify type II collagen within the TM or cellular components.  Also, the 
chondrocyte appeared shrunken, possibly having lost its interaction with the surrounding PCM.  
It is even possible that the PCM has been lost from the tissue section altogether. As a 
consequence, the immunostaining for type VI collagen appears reduced in comparison to the 
strong staining seen in Figure 4A and B.  One additional interesting observation is the striking 
staining of type VI collagen on the extended cell processes (Figure 4D arrow) demonstrating a 
direct interaction of type VI collagen with the cell surface.  Type VI collagen has been shown to 
interact with a number of cell surface molecules including integrins α3β1, α10 β1, α2β1, and in 
chondrocytes specifically the α1β1 integrin and the membrane-bound proteoglycan NG2 (Burg 
et al., 1997; Doane et al., 1998; Leitinger and Hohenester, 2007; Loeser, 1997; Midwood and 
Salter, 2001).  Type VI collagen has also been identified as a ligand for the Discoidin Domain 
Receptor 1 (DDR1); a member of the receptor tyrosine kinase (RTK) family known to be 
involved in regulating cell adhesion and extracellular matrix remodelling (Vogel et al., 2006).   
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Figure 4. Localisation of Type VI collagen by immunogold electron microscopy.  Normal human knee cartilage was 
fixed in 4% glutaraldehyde and embedded as described for Figure 1.  Thin sections (0.5-1 µm) were cut and picked up 
on glass slides.  A combination of sodium exothide and hydrogen peroxide was used to remove both araldite and 
osmium from the sections prior to immunostaining.  The sections were then incubated with an antibody to type VI 
collagen (1:1000).  Sections were washed and incubated with a 10 nm gold-conjugated secondary antibody.  The gold 
label was then enhanced with a gold-enhancement kit.  Successful staining was visualised by light microscopy.  Stained 
sections were then dehydrated in an acetone series and re-embedded in araldite and then processed for transmission 
electron microscopy. A and C: Bar = 1µm, B and D: Bar= 500nm. 
 
It is evident that the method used was not ideal due to difficulties in maintaining integrity of the 
tissue, during extensive processing.  Also it was technically difficult to cut sections from already 
thin sections.  It does prove however that immunostaining is possible.  In order for the tissue to 
be successfully preserved, it must be fixed in glutaraldehyde.  The main problem with this for 
immunostaining is that a number of important antibodies, including those to perlecan, do not 
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react with antigen in fixed paraffin-embedded tissue.  In an attempt to overcome these 
problems, the tissue was fixed in gluteraldehyde, then snap-frozen using liquid nitrogen.  
Sections (7 µm) were then cut and the tissue was immunostained with conventional peroxidase 
staining with antibodies to both type VI collagen and perlecan.  Both type VI collagen and 
perlecan could be detected within the PCM of the tissue, as expected (Figure 5A and B).  Thus, 
it appeared that these antibodies worked efficiently after both fixation and subsequent freezing 
of the tissue.  Fixed and frozen sections were then stained using immunogold labelling and 
ultrathin sections were cut as described above.  However, although it appeared by light 
microscopy that, prior to cutting, sections had been stained successfully, upon visualisation 
using electron microscopy, the integrity of the tissue was again severely disrupted (data not 
shown).  This prevented successful identification and localisation of labelled molecules.  From 
the images shown in Figure 4, it is clear that immunogold labelling could serve as a valuable 
tool in the localisation of PCM proteins.  However, the difficulties experienced in attempting this 
technique and the potential time frame necessary to develop an efficient method, led to the 
decision to suspend further immunogold labelling.    
 
 
A                Type VI collagen                           B                         Perlecan
Figure 5.  Immunolocalisation of type VI collagen and perlecan on frozen, post fixed, human articular 
cartilage.  Articular cartilage from adult human was fixed in 4 % glutaraldehyde for a minimum of 4 hours. The tissue 
was then snap-frozen and sectioned (6 µm).  Sections were treated with hyaluronidase (0.01 % for 1h), then stained 
with antibodies to type VI  collagen (1:800) (A) or perlecan (1:1500) (B).  Antigens were VIsualised with the 
peroxidase based ABC kit (see methods).  
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3.2.5 Some components of the pericellular matrix are not exclusive to the PCM.  
Although some matrix components are exclusively localised within the PCM, including type VI 
collagen and perlecan (as shown above), other components are thought to be present in both 
the PCM and the extracellular matrix (territorial and interterritorial matrices) .  One of these 
components is hyaluronan.  Hyaluronan is a non-sulphated glycosaminoglycan consisting of 
repeating disaccharides composed of D-glucuronic acid and D-N-acetylglucosamine.  It 
interacts with aggrecan monomers at their G1 domain, an interaction which is stabilised by link 
protein.  It is thought to be bound to the cell surface receptor, CD44, and to be present within 
the PCM (Mason, 1981; Plaas et al., 2007).  Detection of hyaluronan (HA) by antibodies within 
the tissue is not possible due to the simplicity of the repeating sugar chains which do not 
provide suitable epitopes.  Thus, HA is detected through use of a biotinylated hyaluronan-
binding protein (HABP).  The biotinylated protein is subsequently detected using a streptavidin 
Alexa Fluor secondary antibody which recognises the biotin protein.  HABP binds to the free 
HA, but not to HA already bound by other ligands, so caution must be taken in its interpretation.  
Figure 6 shows human cartilage immunostained with an antibody to perlecan and the HABP.  
Staining for perlecan was typical, with strong staining pericellularly.  In the case of the HABP, 
there was a concentrated band of staining, seemingly within the PCM, and more diffuse 
staining in the outer TM.  When the two images were merged, there was some co-localisation 
with perlecan within the PCM.  HABP seemed to sit slightly closer to the cell than the perlecan, 
possibly reaching up to the cell surface.  This staining was consistent with the evidence that HA 
binds to both CD44 at the cell surface and aggrecan within the TM (Hascall and Heinegard, 
1974; Knudson, 1993).  
Figure 6.  Localisation of hyaluronan to pericellular matrix and further removed extracellular matrix. Frozen 
sections (7 µm) of human articular cartilage were treated and incubated with a primary antibody to perlecan (1:1000) 
and a biotinylated hyaluronan binding protein (HABP)  (1:20) as in figure 2.  Sections were washed and incubated 
with secondary FITC-labelled antibodies and propidium iodide.  Fluorescence signals were detected by UltraVIew
confocal microscopy.  
Perlecan HABP                                       PI Merged
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3.2.6 Exclusion of matrix components from the PCM. 
It is clear from electron microscopy that there are distinct structural differences between the 
PCM and the surrounding ECM.  The most obvious difference appears to be a lack of type II 
collagen within the PCM:  type II collagen is absent from the PCM, but is localised throughout 
the TM (Soder et al., 2002).  This is confirmed in Figure 7A which shows the localisation of type 
VI collagen and type II collagen in human articular cartilage by confocal microscopy.  There 
was no co-localisation between the two proteins, as seen by the lack of yellow staining when 
the images were merged.  The boundary at which type VI collagen and type II collagen meet 
marks the clear distinction between the PCM and the TM.  Figure 7B shows staining with the 
appropriate non-immune control antibodies and corresponding secondary FITC labelled 
antibodies.  There was little or no staining detected implying specificity of staining for both type 
II and type VI collagen.   
 
In addition to type II collagen, the other major matrix component of cartilage is the proteoglycan 
aggrecan.  Aggrecan has a fundamental role in articular cartilage by providing the tissue with a 
swelling pressure necessary to resist compressive loads.  The protein core of aggrecan is 
substituted with negatively charged glycosaminoglycans (GAGS) which are responsible for the 
hydrophilic properties of the ECM (Knudson and Knudson, 2001).  Aggrecan is also often 
described in the literature as being present within the PCM, bound to hyaluronan (Hardingham 
and Muir, 1972).  Figure 8 shows the distribution of aggrecan and type VI collagen in adult 
human articular cartilage.  The aggrecan antibody (2B6) recognises the terminal unsaturated 4-
sulfated disaccharide remaining after digestion of chondroitin sulfate chains with chondroitinase 
(Bayliss et al., 1999).  Staining for type VI collagen (green) was typically pericellular.  However, 
aggrecan staining was completely excluded from the PCM and only present within the TM 
(Figure 8A).  Not only was the aggrecan excluded from the PCM, but there also appeared to be 
a gap between the aggrecan and type VI collagen staining; possibly indicating that the 
aggrecan does not quite reach the PCM/TM boundary.  Figure 8B shows a similar pattern of 
localisation when using an antibody that recognises the core protein of aggrecan (BR-1).    
 
The small glycoprotein link protein is also described in the literature as being present within the 
PCM (Ratcliffe A, 1996), although the evidence for this is not strong.  Link protein stabilises the 
interaction of hyaluronan and aggrecan within cartilage (Hardingham, 1979).  Even though 
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hyaluronan was present within the PCM, I next investigated whether link protein would also be 
excluded from the PCM.  Figure 9A shows the localisation of type VI collagen (red) and link 
protein (green).  Link protein was localised both diffusely throughout the TM and also in a thin 
concentrated band.  This band of staining was similar to the localisation of type VI collagen and 
when the images were merged, yellow staining indicated co-localisation.  The distribution of 
link protein and perlecan can be seen in Figure 9B.  Perlecan showed typically pericellular 
staining.  Link protein again was distributed diffusely within the TM, with an additional 
concentrated band of staining directly surrounding the perlecan.  When the two images were 
merged, there was slight co-localisation at the outer edge of the perlecan; however this was 
less obvious than the co-localisation seen with type VI collagen.  This may imply that type VI 
collagen forms the ‘outer basket’ of the PCM and perlecan lies within this, closer to the cell 
surface.  Figures 9A and B indicated that link protein may be localised to the outer edge of the 
PCM, or possibly just outside the PCM, in the TM, close to the region where aggrecan staining 
becomes apparent.    
Type VI collagen                               Type II collagen                                     Merged
Figure 7.   Type II collagen is excluded from the PCM in human adult articular cartilage. Frozen sections (7 µm) 
were treated and incubated with primary antibodies to type II collagen (1:50) and type VI collagen (A) or non-immune 
control antibodies (rabbit and mouse)  (B).  Sections were washed and incubated with secondary FITC labelled
antibodies (1:2000). Fluorescence signals were detected by UltraVIew confocal microscopy.  
A
B Rabbit NI                                             Mouse NI
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Aggrecan (2B6)                   Type VI collagen                               PI Merged
Type VI collagen                                      Aggrecan (BR1)                                          Merged
A
B
 
 
Figure 8.  Aggrecan is excluded from the pericellular matrix in human adult articular cartilage. Frozen sections 
(7 µm) were treated and incubated with primary antibodies to aggrecan (2B6) and type VI collagen (A) or aggrecan 
(BR-1) and type VI collagen (B).  Sections were washed and incubated with secondary FITC labelled antibodies 
(1:2000) and propidium iodide (PI) (1:2000).  Fluorescence signals were detected by UltraVIew confocal microscopy.  
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Figure 9.  Localisation of link protein in adult human articular cartilage. Frozen sections (7 µm) were treated as 
described preVIously and incubated with primary antibodies to type VI collagen (1:1000) and link protein (1:100) (A), 
or perlecan (1:1000) and link protein (1:100) (B).  Sections were washed and incubated with secondary FITC labelled
antibodies Fluorescence signals were detected by UltraVIew confocal microscopy.  
Type VI collagen                                  Link protein                                         Merged
Perlecan                                             Link protein                                         Merged
 
 
3.2.7 Changes in the localisation of PCM components with age.  
That aggrecan is excluded from the PCM contradicts the widely held view that it is present 
throughout the PCM and TM.  A review of the literature shows that the majority of these studies 
were done on young animal cartilage, isolated chondrocytes or chondrons, and cell lines 
(Knudson et al., 1996; Poole et al., 1980; Poole et al., 1991a), but I am unaware of any reports 
of the localisation of aggrecan in adult articular cartilage.  I next investigated whether the tissue 
distribution of aggrecan changed with age/skeletal maturity of the tissue.   
 
Human articular cartilage was obtained from an 8 year old donor, undergoing surgery for a 
bone tumour, and snap-frozen.  The tissue was processed as described previously and 
immunostained with antibodies to the CS stub of aggrecan (2B6), following cleavage with 
chondroitinase, and type VI collagen.  Figure 10A shows the localisation of aggrecan and type 
VI collagen within young human articular cartilage.  Staining for type VI collagen was consistent 
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with previous images and showed pericellular localisation.  The localisation of aggrecan 
however, was noticeably different compared with staining seen in Figure 8.  Staining for 
aggrecan was not only considerably more intense throughout the TM, but also present within 
the PCM, as indicated by the yellow staining when the images were merged.  Staining could be 
seen to reach up to the cell surface and possibly within the cell itself.  These preliminary results 
on young tissue certainly indicate an age-dependent difference in the localisation of aggrecan.   
 
As discussed, the interaction of hyaluronan and aggrecan is stabilised by link protein.  The 
localisation of link protein in adult human cartilage has been discussed in section 3.2.6 and it 
appeared to be localised at the outer edge, or possibly just outside the PCM.  Following the 
localisation of aggrecan in young cartilage, an obvious next step was to look at link protein.  
Figure 10B shows the localisation of link protein with type VI collagen in young human articular 
cartilage.  Again, type VI collagen staining was consistent with previous images and appeared 
pericellular.  In contrast to the localisation of link protein in adult cartilage, staining for link 
protein appeared as a concentrated band, closer to the cell than type VI collagen.  There was 
little co-localisation between the two proteins indicated by the lack of yellow staining when the 
images were merged.  It was difficult to determine from this image whether the band of link 
protein near to the chondrocyte was localised within the PCM, on the cell surface, or in fact 
intracellularly.  Localisation of link protein in young cartilage may reflect localisation of 
aggrecan in young and adult cartilage and localisation of link protein may in fact determine 
aggrecan binding within the matrix.  In mature tissue, link protein binding within the PCM may 
be inhibited by other proteins binding to HA in the PCM.  
 
It is possible that the differences seen between young and adult cartilage are due to the 
synthetic nature of young, pre-skeletally mature, cartilage.  In other words, where there is 
increased synthesis of aggrecan, there is more transitting through the PCM from cell to the TM.   
Also, the efficiency of aggrecanases, involved in cleavage of proteoglycan aggregates, is also 
shown to be increased in adult cartilage (Roughley et al., 2003).  This may lead to an increase 
in degradation of pericellular aggrecan leading to the decrease in detection seen in the PCM of 
adult tissue.  
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Figure 10.  Localisation of aggrecan in young human cartilage.  7 µm frozen sections were cut from human 
articular cartilage from an 8 year old donor.  Sections were treated as described previously and incubated with 
primary antibodies to aggrecan (2B6) (1:1000) and type VI collagen (1:1000) (A), or link protein (1:100) and type 
VI collagen (1:1000) (B).   Sections were washed, incubated with secondary antibodies and propidium iodide (PI), 
and VIsualised as described previously.  
Aggrecan (2B6)                    Type VI collagen                               PI Merged
Type VI collagen                         Link protein                                 PI Merged
A
B
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Chapter 3                           Structural and regulatory molecules of the PCM of articular cartilage 
 
96 
 
3.3 Discussion  
The first section of this chapter was concerned with investigating the structural organisation of 
the PCM.  I have used both confocal and electron microscopy to gain a further understanding 
of the components of the PCM and how they interact.  
 
Electron microscopic data presented has defined the PCM as a clearly distinct zone; 
structurally different to the surrounding ECM, or TM.  The presence of thin filamentous material 
within the PCM may represent type VI collagen; previously described ultrastructurally as having 
a beaded appearance (Engel et al., 1985).  The presence of type VI collagen within the PCM 
was confirmed using confocal microscopy and was shown to partly colocalise with perlecan, 
which itself was shown to be the most abundant HS proteoglycan within articular cartilage.  It 
was difficult to determine the exact organisation of these two molecules in relation to one 
another.  In some areas of the PCM, type VI collagen appeared to sit outside the perlecan, 
whereas in other areas, perlecan appeared further from the cell.  Immunogold labelling was 
used in an attempt to confirm the exact localisation of components within the PCM.  
Unfortunately, poor tissue preservation severely limited the ability to localise type VI collagen 
and perlecan.  However, the images presented suggest that type VI collagen resides 
throughout the PCM, reaching from the boundary separating the PCM and TM, up to the cell 
surface. The exact function of type VI collagen within the PCM is not known.   However, an 
interaction with both the cell, via integrins and NG2 at the cell surface, and a number of matrix 
components including perlecan, biglycan, decorin, fibromodulin, hyaluronan and fibronectin, 
may represent roles for type VI collagen in communicating signals between the chondrocyte 
and the further removed TM (Bidanset et al., 1992; Kielty et al., 1992; Tillet et al., 1994; Wiberg 
et al., 2002).  It may also imply a role in anchoring the chondrocytes to the matrix.  
 
Confocal microscopy has shown that type VI collagen does not colocalise with type II collagen 
in articular cartilage confirming reports that type II is excluded from the PCM.  This has also 
been shown by Soder et al. (2002); however, the same study showed a slight overlap between 
type VI collagen and type II collagen staining by immunogold labelling.  Direct binding of type 
VI collagen to type II collagen has only been shown through in vitro studies (Bidanset et al., 
1992).  In fact a link between type VI collagen and either aggrecan or type II collagen in the TM 
is thought to be mediated through the binding of type VI collagen to members of the small 
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leucine-rich repeat (LRR) family of proteoglycans including biglycan, decorin, chondroadherin 
and matrillin (Wiberg et al., 2003).  It should be noted that attempts were made to localise both 
decorin and biglycan within the PCM.  However, detection was limited due to inconsistencies in 
antibody staining.  The point at which types II and VI collagen meet within the matrix , as 
demonstrated by both electron and confocal microscopy in this chapter, is likely to mark the 
clear distinction between the PCM and further removed TM.  Recent studies by Alexopoulous 
et al. (2009) have shown that although Col6a1-/- mice (generated by targeted disruption of the 
Col6a1 gene, which is responsible for the production of the α1(VI)-chain) retain a structurally 
intact PCM, the PCM exhibits significantly reduced mechanical properties, indicated by a 
decrease in the Young’s modulus of isolated chondrons, compared to wild-type controls.  Also, 
with age, these mice showed accelerated development of OA implying a major role for type VI 
collagen in maintaining the mechanical properties of the PCM, which when altered may lead to 
joint degeneration (Alexopoulos et al., 2009).   
 
In addition to type VI collagen and perlecan, hyaluronan was also shown to be present within 
the PCM, although not exclusively.  The use of HABP to determine the localisation of 
hyaluronan is somewhat limited as it only binds free HA, and not HA already bound by 
endogenous ligands.  Hyaluronan is described as binding to CD44 at the cell surface.  
Although HABP appeared to be localised close to the cell surface, it was difficult to determine 
whether endogenous binding to CD44 prevented localisation of HABP directly at the surface of 
the chondrocyte.  It may be interesting to investigate localisation of HABP and CD44 together 
to determine if this was the case.  Given the literature, it could be assumed that the presence of 
hyaluronan within the PCM would represent the structural basis for the aggregation of 
aggrecan within the PCM.  However, interestingly, aggrecan was shown to be excluded from 
the PCM in adult cartilage.  Additionally, link protein, which stabilises the interaction of 
aggrecan and hyaluronan, was shown to be localised to the outer edge of the PCM, 
colocalising with type VI collagen but sitting outside perlecan.  In contrast, confocal microscopy 
on young articular cartilage showed localisation of both aggrecan and link protein within the 
PCM.  As discussed, this observation may simply represent the synthetic nature of young 
tissue, or represent an increase in the activity of aggrecanases within mature cartilage.  It could 
also be hypothesised that aggrecan is excluded from the PCM of mature cartilage by the 
presence of other HA binding ligands which block link protein and aggrecan binding.  There are 
a number of other molecules within the matrix identified as hyaluronan-binding proteins 
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including tumour necrosis factor-stimulated gene 6 (TSG-6) (Lee et al., 1992) and the soluble 
form of CD44.  It is possible that in mature cartilage, these hyaluronan-binding proteins 
compete with link protein to bind HA and thereby direct link protein binding to the TM.  
Detection of HABP within the PCM may suggest free HA in the PCM, although it is possible 
that HABP was able to compete with other endogenous ligands within the tissue.  Preliminary 
work was done to localise TSG-6 within articular cartilage; however, problems in the 
consistency of antibody staining prevented any definitive answers as to whether TSG-6 was 
localised to the PCM of mature cartilage.  Given the data presented on the localisation of 
aggrecan and link protein in young cartilage, it is likely that hyaluronan would be also localised 
to the PCM in young cartilage.  In fact it has been reported that hyaluronan plays a role in the 
assembly of an aggrecan rich PCM, in embryonic chondrocytes (Knudson, 1993).  The 
differences in composition of the PCM with age may indicate a role for the PCM in the 
development of cartilage matrix and may be interesting to investigate further.   
 
A summary of the matrix proteins that I was able to identify and localise can be found in the 
table below.    
 
 
Protein 
 
Described localisation 
 
Identified localisation 
Perlecan PCM (Melrose et al., 2006) PCM 
Type VI collagen PCM (Poole et al., 1988a) PCM 
Type II collagen TM (Soder et al., 2002) TM 
Hyaluronan PCM (Plaas et al., 2007) PCM/TM 
Aggrecan PCM/TM (Poole et al., 1980) TM (adult) 
PCM/TM (young) 
Link protein PCM (Poole et al., 1980; Ratcliffe A, 
1996) 
PCM/TM (adult) 
PCM (young) 
Biglycan PCM (Miosge et al., 1994) Not identified due to 
inconsistencies 
Decorin 
 
 
TM (Miosge et al., 1994) Not identified due to 
inconsistencies 
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TSG-6 Unknown Not identified due to 
inconsistencies. 
Table 3.1 Localisation of proteins by confocal microscopy.  
 
A number of functions of the PCM have been proposed including; i) chondrocyte protection, ii) 
amplification of mechanical signals, iii) increasing transport of solutes from cell to TM and vice-
versa, and iv) sequestering growth factors/regulatory molecules.  Studies performed on 
chondrons, which comprise the chondrocyte together with its PCM, have shown that upon 
loading through microcompression, chondrons become compacted and deformed, but recover 
completely when unloaded (Broom and Myers, 1980).  Mechanical compression and 
deformation of the chondron are thought to cause an adaptive water loss from the pericellular 
matrix, which would dampen the compressive load and so provide hydraulic protection for the 
chondrocyte (Poole et al., 1984).  Young’s modulus, which is a determinant of elasticity, is 
approximately 1 order of magnitude less than that of the cartilage TM.  In fact Young’s modulus 
of the PCM is decreased by a further 50% in OA leading to an increase in compressive strains 
on the cell.  In addition, the permeability of the PCM was shown to be 1–2 orders of magnitude 
lower than that of the TM implying the PCM is important in controlling transport of molecules 
between the matrix and the cell.  It is likely that molecules such as aggrecan and growth factors 
become modified or retained within the PCM (Ruoslahti and Yamaguchi, 1991; Sandy et al., 
1989).  An increase in permeability of the PCM is seen in OA which may contribute to the 
changes seen in chondrocyte metabolism during aging or OA (Guilak et al., 2006).  The 
mechanical properties of the PCM and the fact that there are direct interactions between PCM 
proteins and chondrocytes have implicated a role for the PCM in mechanotransduction (Greco 
et al., 1992).   Indeed, previous work in our laboratory has demonstrated a role for perlecan, 
within the PCM, in the transduction of mechanical stress; both by sequestering FGF-2 in the 
matrix and controlling its bioavailability following the amplification of mechanical load.  The 
notion that the PCM serves as a repository for other regulatory molecules is addressed in the 
next section.    
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3.4 The role of the PCM in sequestering regulatory molecules.  
In studying the cellular responses of chondrocytes in articular cartilage to mechanical loading, 
we found that ERK activation was mediated by FGF-2 (Vincent et al., 2004).  FGF-2 could be 
released from the tissue by treatment with heparitinase (Vincent et al., 2002), suggesting that it 
was bound to a heparan sulphated proteoglycan.  Perlecan and FGF-2 colocalised in adult 
articular cartilage (Figure 11) and indeed, also bound to one another in vitro, assessed by 
surface plasmon resonance (Vincent et al., 2007).  The ability of FGF-2 to bind perlecan and 
the induction of cellular responses upon tissue loading led to the hypothesis that together FGF-
2 and perlecan form a mechano-sensory unit (Vincent and Saklatvala, 2006).  In rested tissue, 
FGF-2 is held back from the cell surface; however on loading the growth factor is made 
available to cell surface receptors leading to cell activation.  It was possible that perlecan not 
only sequesters the growth factor, but also plays a role in making the growth factor available to 
cell surface receptors and in facilitating cell signaling through its HS chains which is known to 
be a co-factor for FGFR tyrosine kinase activation.  Based on these observations, it was 
reasonable to hypothesise that the PCM may play a role in sequestering other regulatory 
molecules, in addition to FGF-2.  It was hoped that identification of such molecules may help to 
elucidate further a regulatory role of the PCM in articular cartilage.   
 
Figure 11.  Localisation of perlecan and FGF-2 in human articular cartilage. Frozen sections (7 µm) of human 
articular cartilage were pre-treated with chondroitinase (10 mU/ml for 90-120 min).  Sections were stained with 
primary antibodies to perlecan (1:1000) and FGF-2 (1:1000).  Sections were washed and incubated with secondary 
FITC-labelled antibodies (1:2000) .  Fluorescence signals were detected by UltraVIew confocal microscopy.  (From  
(Vincent, McLean et al. 2007).  Bar = 20µm. 
Perlecan  FGF-2                                                           Merged
 
 
 
 
 Chapter 3                           Structural and regulatory molecules of the PCM of articular cartilage 
 
101 
 
3.5 Purification of the PCM and identification of PCM proteins by mass spectrometry.   
In order to clarify further the molecular composition of the PCM and identify other potential 
regulatory molecules within the PCM, I attempted to purify the PCM from cartilage.  A 
proteomic approach was then taken to try and identify novel molecules within this purified 
material.  Mass spectrometry analysis was performed in collaboration with Dr Robin Wait at 
The Kennedy Institute of Rheumatology.   
 
3.5.1 Isolation of chondrons 
As discussed in section 1.7, the development of methods for isolating chondrons from cartilage 
has led to the ability to study the PCM in more detail.  Two methods for isolating chondrons 
have been published: mechanical (Alexopoulos et al., 2003; Lee et al., 1997) and enzymatic 
(Lee et al., 1997).  Mechanical isolation involves homogenisation of the cartilage to obtain a 
flocculent homogenate which contains intact chondrons. Enzymatic isolation involves digestion 
of cartilage with a combination of the enzymes dispase and collagenase for 3-4 hours.  This is 
similar to methods employed for isolation of chondrocytes for cell culture work which use 
collagenase digestion alone for approximately 6 hours.   
 
It was necessary to determine which method was more appropriate; so chondrons were 
isolated from porcine articular cartilage using the published methods.  Chondron preparations 
were fixed onto chamber slides using methanol and then immunolabelled for known PCM 
proteins including perlecan, type VI collagen and FGF-2.  Figure 12 shows immunolabelling of 
mechanically isolated chondrons.  Staining for both perlecan and type VI collagen was diffuse, 
and it was difficult to identify any specific structures within the chondron preparation.  In 
contrast, when chondrons were isolated enzymatically and immunolabelled for perlecan and 
type VI collagen (Figure 13A), chondrocytes could be identified, surrounded by a distinct zone 
of perlecan and type VI collagen.  Perlecan appeared to localise just within the ring of type VI 
collagen, closer to the cell surface, and when these images were merged, there was some 
overlap of localisation as indicated by yellow staining.  To determine whether enzymatic 
isolation led to small proteins within the PCM being lost, chondrons were immunolabelled for 
FGF-2.  Figure 13B showed similar localisation of perlecan directly around the chondrocyte.  
Although FGF-2 staining was fairly weak, it colocalised with perlecan. 
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This experiment was highly informative: it proved that it was possible to generate an intact 
chondron preparation;  it also indicated, as others have suggested, that type VI collagen forms 
the outer ‘nest’ of the PCM, with other structural proteins lying within it (Poole et al., 1987); and 
it confirmed our human data, that FGF-2 colocalises with perlecan.  Mechanical isolation of 
chondrons appeared to cause loss of the structural integrity of the PCM compared to enzymatic 
isolation and so enzymatic isolation was used in further experiments. 
Figure 12 Immunolocalisation of PCM proteins in mechanically isolated chondrons.  Chondrons were 
isolated from porcine articular articular cartilage by homogenisation of explants.  After homogenisation, the 
flocculent supernatant was removed and filtered.  The remaining tissue was homogenised a further 2 times, 
supernatants were collected, pooled and centrifuged.  Following isolation, chondrons were resuspended in PBS 
and a small volume was allowed to adhere to Lab Tek II chamber slides.  The chondrons were fixed in methanol, 
treated for 1-2h with chondroitinase (10mu/ml) and then incubated with primary antibodies to perlecan (1:1000) 
and type VI collagen (1:1000). The chondrons were washed and incubated with secondary FITC labelled
antibodies and propidium iodide (PI).  Fluorescence signals were detected using UltraVIew confocal microscopy. 
Perlecan  Type VI collagen Merged
 
 
Figure 13.  Immunolocalisation of PCM proteins in enzymatically isolated chondrons.  Chondrons were isolated 
from porcine articular cartilage with a combination of dispase (0.2%) and collagenase (0.3%) for 4h at 37°C.  Following 
isolation, chondrons were resuspended in PBS and a small volume was allowed to adhere to Lab Tek II chamber slides.  
The chondrons were fixed in methanol, treated for 1-2h with chondroitinase (10mu/ml) and then incubated with primary 
antibodies to perlecan (1:1000) and type VI collagen (1:1000) (A), or perlecan (1:1000) and FGF-2 (1:1000) (B).  The 
chondrons were washed and incubated with secondary FITC labelled antibodies and propidium iodide (PI).  Fluorescence 
signals were detected using Ultraview confocal microscopy. 
B Perlecan                                FGF-2 PI Merged
A Perlecan  Type vi collagen PI Merged
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3.5.2 Purification of the PCM from isolated chondrons:  methods of extraction. 
Chondrons contain both the chondrocyte and their surrounding PCM.  In order to investigate 
the PCM by mass spectrometry, removal of chondrocytes from the chondron preparation was 
necessary to reduce contamination by intracellular proteins.  Chondron pellets, following 
enzymatic isolation, were incubated with a dissociative lysis buffer (RIPA, see methods) for 15 
minutes in an attempt to remove intracellular proteins from the preparation.  The remaining 
pellet, enriched for PCM proteins, was then solubilised to allow analysis by SDS PAGE and 
mass spectrometry.  A number of different dissociative and/or enzymatic treatments were used 
in an attempt to solubilise the pellet; including trypsin in combination with sodium dodecyl 
sulphate (SDS), proteinase K, guanidine hydrochloride, hyaluronidase, matrix 
metalloproteinase 13 (MMP-13) and pepsin.  Examples of the results following some of these 
methods are shown in Figures 14, 15 and 16.   
 
From confocal microscopy it appeared that the chondron was rich in type VI collagen, and 
there is some evidence for degradation of type VI collagen by a number of serine proteases 
(Kielty et al., 1993).  The first method of extraction for enrichment of PCM proteins from the 
chondron pellet, therefore, involved the use of a combination of trypsin and SDS.  SDS is 
commonly used to denature proteins by disrupting non-covalent bonds; it was considered that 
a combination of trypsin and SDS might be more effective than either alone. In parallel, isolated 
chondrons were subjected to digestion by proteinase K.  Proteinase K is a serine protease that 
exhibits very broad cleavage specificity.  The results are shown in figure 14. In brief, neither 
method was effective in extracting PCM proteins from the insoluble chondron pellet.  This was 
demonstrated by the fact that few proteins were released into the supernatants following 
enzymatic treatment (lanes 3-9 and 11-17) and that the majority of the proteins identified 
following SDS PAGE had been retained in the pellets following extraction (lanes 10 and 18).  
Those proteins that did resolve were analysed by mass spectrometry and identified as type VI 
collagen, chondroadherin, biglycan, Ig-h3, SPARC and annexin.  In addition, type II collagen 
was identified in the pellet following proteinases K treatment.  This may indicate contamination 
of type II collagen following incomplete removal upon enzymatic digestion of chondrons. 
Identified peptide sequences and peptide mass spectra of type VI collagen and annexin are 
shown in Figure 14 (B-E).  It should be noted that the full sequence of porcine type VI collagen 
is not available and was therefore matched to a murine orthologue.  The mass spectrometry 
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and identification procedures were performed by Dr. Robin Wait, of the Kennedy Institute’s 
proteomics unit.  Of these proteins, both type VI collagen and biglycan (Miosge et al., 1994) 
have previously been described as pericellular, and there are some reports of annexin being 
present within the PCM (Mollenhauer et al., 1999).  Perlecan was also retained within the 
insoluble pellet as assessed by western blot (Figure 14F). Some perlecan was released early 
following treatment with SDS/trypsin although the electrophoretic mobility suggested that this 
was a higher molecular weight species compared to that which was retained in the pellet. 
Although it was clear that these methods of extraction were unsuccessful at solubilising the 
pellet, it appeared that there was some enrichment of PCM proteins within the pellet. The 
presence of other proteins including annexin, chondroadherin, SPARC and Ig-h3 within the 
pellets indicated that these proteins may also be localised to the PCM. 
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Figure 14.  Extraction of chondrons using a combination of trypsin and SDS or proteinase K. Chondrons were 
isolated from porcine articular cartilage using a combination of dispase and collagenase.  The resulting chondron 
pellet was extracted in 1 ml of RIPA lysis buffer for 15 min at room temperature.  Following centrifugation, the 
supernatants were retained and the resulting pellet was exposed to further digestion with 1 ml trypsin (5 µg/ml n 
25mM ammonium hydrogen carbonate containing 20% MeOH) containing either 1% SDS or 50µg/ml proteinase K, at 
37°C, for increasing time points. After each time point the suspension was centrifuged, supernatants retained and 
fresh trypsin/SDS or trypsin/proteinase K added.  After the last time point, the chondron pellets were resuspended in 
1 ml of PBS and sonicated.  Supernatants and pellets were run on 4-12% Bis Tris gels.  Gels were silver stained (A) 
and protein bands cut out and analysed by mass spectrometry.  Murine type VI collagen (alpha chain) amino acid 
sequence. Peptide sequence identified by tandem mass spectrometry is highlighted in red (B) Tandem mass 
spectrum of the type VI collagen peptide TAEYDVAFGER (C).  The full porcine annexin A2 amino acid sequence.  
Peptide sequence identified by mass spectrometry is highlighted in red (D) Tandem mass spectrum of annexin A2 
peptide TPAQYDASELK (E).  Alternatively, gels were immunoblotted with an anti-perlecan antibody (1:1000) (F). 
 
 
 Chapter 3                           Structural and regulatory molecules of the PCM of articular cartilage 
 
107 
 
It has previously been shown that GnHCl can be used to extract and purify both type VI 
collagen and perlecan from articular cartilage (Govindraj et al., 2002; McDevitt et al., 1988).  
Therefore, it was decided to use GnHCl to try to extract and solubilise proteins from isolated 
chondrons.  Figure 15 shows extraction of chondrons following incubation with 4M GnHCl for 
various times.  A number of proteins were identified by mass spectrometry as indicated.  The 
identification of intracellular proteins, such as pyruvate kinase, in the supernatant following 
GnHCl extraction, may represent inadequate removal of intracellular proteins following RIPA 
lysis.  Although there was a significant release of proteins into the supernatant, as indicated by 
the number of protein bands, not all of these proteins could be identified.  This may have been 
due to the abundance of cytoskeletal proteins including actin, vimentin and vinculin, which 
prevented identification of less abundant molecules.  Other proteins identified in the 
supernatants included type VI collagen, annexin and chondroadherin.  Despite the release of a 
significant number of proteins into the supernatants, there was still a large proportion of 
proteins retained in the pellet (lane 6).  The significant presence of type VI collagen in the pellet 
again indicated a resistance to degradation and it raised the possibility that type VI collagen 
may be protecting other PCM proteins from degradation.   
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Figure 15.   Extraction of chondrons using guanidine hydrochloride. Chondrons were isolated from porcine articular cartilage 
using a combination of dispase and collagenase.  The resulting chondron pellet was extracted in 1 ml of RIPA lysis buffer for 15 
min at room temperature.  Following centrifugation, the supernatant was retained and the resulting pellet was exposed to further
extraction with 1 ml 4M GnHCl at 4°C, for increasing times. After each time point the suspension was centrifuged, supernatants 
retained and fresh GnHCl added.  After the last time point, the chondron pellets were resuspended in 1 ml of PBS and sonicated.  
Supernatants and pellets were run on 4-12% Bis Tris gels and gels silver stained.  Protein bands were cut out and analysed by 
mass spectrometry.  
 
3.5.3 Purification of the PCM from isolated chondrons:   methods of extraction targeting 
type VI collagen. 
It was hypothesised that if type VI collagen was protecting the PCM from degradation, targeting 
this protein specifically might ‘loosen’ the PCM and allow further extraction of PCM proteins 
from the pellet.  Type VI collagen interacts with hyaluronan and can be destabilized by 
treatment with hyaluronidase (Kielty et al., 1992). It has also been shown to be degraded by 
the aspartyl protease pepsin ((Ronziere et al., 1990).  Although MMPs -1, -2, -3, and -9 are 
unable to degrade intact type VI collagen (Kielty et al., 1993), it was hypothesised that MMP-13 
might be effective as it is most active at cleaving type II collagen in cartilage. Therefore, I used 
a combination of a longer GnHCl extraction, for initial denaturation of proteins, followed by 
incubation with hyaluronidase, MMP-13 or pepsin (Figure 16).  Following extraction with MMP-
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13 and pepsin, there appeared to be little or no protein released into the supernatant.  There 
did appear to be a significant release of type VI collagen into the supernatant following 
hyaluronidase treatment; however few other proteins were identified by mass spectrometry.  
The reason for this is not clear, but may have been due to the sheer abundance of type VI 
collagen. Type VI collagen was also identified in abundance in all pellets following treatment.   
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Figure 16.   Extraction of chondron pellets using hyaluronidase, MMP-13 and pepsin. Chondrons were isolated 
from porcine articular cartilage using a combination of dispase and collagenase.  The resulting chondron pellet was 
extracted in 1 ml of RIPA lysis buffer for 15 min at room temperature.  Following centrifugation, pellets were exposed to 
further digestion by 4M GnHCl for 72h at 4°C.  Following centrifugation, the supernatant was retained and pellets 
exposed to further digestion with MMP13 (10 nM in TNC buffer/0.05 % Brij-35, pH 7.5), pepsin (0.5mg/ml in 0.5M 
acetic acid), or hyaluronidase (100 µg/ml in PBS) for 24h at 25°C, 4°C or 37°C respectively. Pellets were resuspended 
in 1ml PBS and sonicated. Supernatants and pellets were run on: 4-12% Bis Tris gels, silver stained and analysed by 
mass spectrometry.  
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3.5.4 Identification of regulatory molecules in extracted chondrons by western blotting. 
The growth factor FGF-2 is able to bind perlecan within articular cartilage and was present 
within isolated chondron preparations (Figure 13).  The failure to detect it by mass 
spectrometry following extraction of the PCM may have been due to the low abundance of 
FGF-2 relative to other PCM molecules or to loss during extraction.  To identify FGF-2 
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specifically within chondron preparations, western blotting was used.  Chondrons were isolated 
as previously described and initially lysed with RIPA buffer to remove intracellular proteins.  As 
GnHCl had been shown to be partly successful in the extraction of PCM proteins from 
chondron pellets, as determined by the presence of Type VI collagen within supernatant 
fractions, chondrons were then extracted for 1 hour with GnHCl and both the supernatant and 
pellet were immunoblotted for FGF-2 (Figure 17).  FGF-2 was detected at approximately 
18KDa in the RIPA supernatant; possibly representing the release of intracellular FGF-2.  A 
more significant band was detected within the supernatant following GnHCl extraction, which is 
likely to represent the release of FGF-2 from the PCM.  Some protein was retained within the 
pellet.  There was significant retention of perlecan within the pellet following trypsin/SDS 
extraction (Figure 14 F), although one would expect that GnHCl would dissociate FGF-2 from 
perlecan as this is an, albeit strong, ionic interaction. 
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Figure 17.   Detection of FGF-2 in guanidine hydrochloride extracted chondrons. Chondrons were isolated from 
porcine articular cartilage using a combination of dispase and collagenase.  The resulting chondron pellet was 
extracted in 1 ml of RIPA lysis buffer for 15 min at room temperature.  Following centrifugation, pellets were exposed to 
further digestion by 4M GnHCl for 1h at 4°C.  Following centrifugation, the pellet was resuspended in 1ml PBS and 
sonicated. Supernatants and pellets were run on a 12% Tris Glycine gel and Western blotted with an antibody toFGF-
2.
16
 
 
A number of other growth factors are known to be heparin and/or perlecan-binding including 
FGF-18, PDGF, VEGF and CCN2 (Iozzo, 2005; Nishida et al., 2003), and it was hypothesised 
that some of these might also be bound within the PCM in articular cartilage.  I chose to study 
connective tissue growth factor (CCN2) which had previously been identified in a proteomic 
analysis of cartilage, by Monica Hermansson, within our laboratory.  It was found to be 
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synthesized by young porcine tissue in culture, with or without stimulation with IL-1.  It was also 
made by some human osteoarthritic samples but not, by normal adult human tissue 
(Hermansson et al., 2004) (Hermansson, 2002).  Figure 18 shows examples of 2D gels of 
secreted proteins from either porcine cartilage explants (A) or human osteoarthritic tissue (B).  
CCN2 was identified from both gels as a low-abundance 20-25KDa secreted protein.  CCN2 is 
synthesised as a 38KDa protein but lower molecular weight fragments are commonly observed 
(Ball et al., 1998; Steffen et al., 1998).  In order to determine whether CCN2 was present in 
chondrons, chondrons were extracted initially with RIPA buffer and then GnHCl (Figure 19).  A 
goat polyclonal antibody raised against a peptide within an internal region of CCN2 was used 
to detect the protein.  This antibody has been validated against purified CCN2 (see section 
4.2). Full length CCN2 could be clearly detected in the supernatant following GnHCl digestion 
of chondron pellets (GnHCl Sup).  There was a small release of CCN2 in the supernatant 
following the initial RIPA digestion of the pellets (RIPA Sup) which may indicate identification of 
intracellular CCN2.  There did not appear to be any CCN2 retained within the pellet following 
GnHCl digestion, implying that CCN2 present within the PCM is less tightly bound than FGF-2. 
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A B
Figure 18: Identification of secreted proteins from porcine and human osteoarthritic cartilage.  Porcine 
cartilage (2g) or human osteoarthritic cartilage (6g) was dissected and washed overnight in serum-free DMEM. 
The following day, the cartilage was pulsed with [35S]methionine/cysteine (200 µCi/ml) for 5 h. The explant 
medium was removed and treated with 3 mg of CPC/mg of GAG for 30 min at room temperature. The supernatant 
was removed and dialyzed into water at 4 °C and lyophilized. 60 µg of proteins were used for isoelectric focusing 
on a pH 3–10 gradient. Focused proteins were further separated by SDS-PAGE on a 12.5% gel. The gels were 
silver stained, dried and exposed to film for 1 week. The gels were rehydrated and protein sports excise and 
identified by mass spectrometry.  (Figure courtesy of  Dr M. Hermansson).
Porcine Human OA 
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Figure 19.  Detection of CCN2 in guanidine hydrochloride extracted chondrons. Chondrons were isolated from 
porcine articular cartilage using a combination of dispase and collagenase.  The resulting chondron pellet was 
extracted in 1 ml of RIPA lysis buffer for 15 min at room temperature.  Following centrifugation, pellets were exposed to 
further digestion by 4M GnHCl for 1h at 4°C.  Following centrifugation, the pellet was resuspended in 1ml PBS and 
sonicated. Supernatants and pellets were run on a 12% Tris Glycine gel and Western blotted with an antibody to 
CCN2.  
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3.6 Discussion 
A proteomic approach was taken to try and identify other structural and regulatory molecules 
within the PCM.  Isolation of chondrons, containing both the PCM and chondrocyte, from 
porcine articular cartilage proved successful as shown by confocal microscopy.   
 
Extraction of chondron pellets was attempted using numerous methods.  The overall trend 
observed in these experiments was considerable retention of proteins within the pellets 
following extraction, with the majority of peptides identified as type VI collagen.  Other proteins 
identified within either the supernatants or pellets following extraction included biglycan, 
annexin, chondroadherin, ig-h3 and SPARC.  Biglycan has previously been shown to bind type 
VI collagen and been localised to the PCM by confocal microscopy in chondrosarcoma cells 
(Wiberg et al., 2003).  Annexin has been localised to the PCM by light microscopy in human 
hypertrophic, normal adult and osteoarthritic cartilage (Mollenhauer et al., 1999).  Although not 
specifically localised to the PCM, chondroadherin has been identified as binding to the N-
terminus of type VI collagen.  Interestingly, Ig-h3 has been shown to interact with both biglycan 
and decorin, facilitating binding of these proteins to type VI collagen.  It is possible that these 
proteins were released into the supernatant, or present in the pellets still bound to type VI 
collagen.  SPARC has been identified as a secreted protein from both chondrocytes and 
cartilage explants (Chandrasekhar et al., 1994) and is thought to play a role in modulating the 
interactions between cells and matrix.  It regulates the production of the ECM by inducing 
MMPs (Tremble et al., 1993)  and plasminogen activator inhibitor-1 (Hasselaar et al., 1991) 
(PAI-1), and decreasing expression of fibronectin and thrombospondin-1 (Lane et al., 1992).  
The identification of SPARC, Ig-h3 and chondroadherin within chondron preparations may 
implicate them as novel PCM proteins.   
 
It is important to consider that the purity of the chondron preparations was not confirmed.  The 
presence of type VI collagen and the lack of type II collagen by mass spectrometry strongly 
implied isolation of the PCM without significant contamination of proteins from the further 
removed TM.  It should also be noted that positive identification of proteins within isolated 
chondrons does not rule out the possibility that they are also localised within other regions of 
the matrix.  It therefore may have been informative to perform mass spectrometric analysis on 
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retained supernatants following initial isolation of chondrons using dispase and collagenase, or 
to confirm localisation by confocal microscopy.   
The identification of a known low abundant PCM protein, FGF-2, by western blotting following 
extraction, indicated further that PCM proteins were being released from extracted chondrons. 
However, it is likely that the combination of i) the presence of highly abundant molecules, such 
as cytoskeletal proteins, within the supernatants, ii) resistance of type VI collagen to 
degradation, and iii) the sheer abundance of this protein within the pellets prevented 
identification of other less abundant and possibly significant pericellular proteins by mass 
spectrometry.   It was decided that this method of identifying regulatory molecules within the 
PCM was simply not specific enough to be useful.   
 
Western blotting was used to confirm the presence of another candidate regulatory molecule: 
connective tissue growth factor (CCN2).  CCN2 was previously identified as a secreted protein 
from both porcine and human cartilage and was known to be heparin binding.  Successful 
identification of CCN2 by western blotting of extracted chondron pellets suggested that this 
protein was bound to perlecan within the PCM of articular cartilage and may play a regulatory 
role.  It was therefore decided to investigate this further. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Chapter 3                           Structural and regulatory molecules of the PCM of articular cartilage 
 
115 
 
3.7 Investigating the localisation and expression of connective tissue growth factor 
(CCN2) in articular cartilage. 
CCN2 was first identified as a secreted factor from human umbilical vein endothelial (HUVE) 
cells that was able to compete with PDGF for binding to its receptor and demonstrated PDGF-
related biological activity.  A 38-kD cysteine-rich secreted protein was shown to have PDGF-
related activity and termed connective tissue growth factor (Bradham et al., 1991).  CCN2, also 
known as CTGF, is a member of the CCN family of matricellular proteins, which is so called 
due to the first three members identified- Cyr61, CTGF and NOV.  The family also includes 
ELM-1 and WISP-1, -2 and -3 (Moussad and Brigstock, 2000).  It consists of four structural 
modules containing conserved binding motifs. These are, IGF binding domain (module I), a von 
Willebrand factor type C repeat (module II), a thrombospondin type I domain (module III), and a 
C-terminal domain that contains a cysteine knot (module IV) (Lau and Lam, 1999; Moussad 
and Brigstock, 2000) (Figure 20).  The different modules of CCN2 appear to contribute to a 
number of different functions: module II is thought to mediate interactions with transforming 
growth factor-β (TGF-β) and bone morphogenic protein-4 (BMP4) (Abreu et al., 2002).  Module 
III has been implicated in enabling binding of CCN2 to extracellular matrix proteins, matrix 
metalloproteinases (MMPs) and integrins (Bornstein, 2001; Lau and Lam, 1999).  In certain cell 
types, the interaction of CCN2 with integrins promotes effects on cell survival, adhesion and 
migration (Babic et al., 1999).  In addition, module III is also involved in binding to the low-
density lipoprotein receptor-related protein (LRP).  CCN2 is reported to be internalized and 
degraded in the endosome through LRP.  Module IV is involved in binding both LRP and 
heparin, and is possibly involved in the binding of CCN2 to a heparan sulphated proteoglycan 
within cartilage.  It has been reported that CCN2 colocalises with perlecan in the PCM of the 
chondrosarcoma cell line HCS-2/8 (Nishida et al., 2003).  Module IV has also been implicated 
in the binding of CCN2 HS proteoglycans at the cell-surface which are thought to act as co-
receptors in the internalisation of CCN2 via LRP (Gao and Brigstock, 2003).  
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Figure 20.  Schematic of CCN2 structure.  CCN2 consists of four structural modules containing conserved 
binding motifs. These are, IGF binding domain (module I), a von Willebrand factor type C repeat (module II), a 
thrombospondin type I domain (module III), and a C-terminal domain that contains a cystine knot (module IV).  
 
3.7.1 Localisation of CCN2 within the PCM of normal and human osteoarthritic cartilage. 
Prior to investigating the role of CCN2 as a regulatory molecule, I first confirmed localisation of 
CCN2 within the PCM of human cartilage by confocal microscopy (Figure 21).  CCN2 is 
described as being upregulated in osteoarthritis (Omoto et al., 2004) and as mentioned was 
identified as a secreted protein from osteoarthritic tissue, in our laboratory.  Perlecan was 
detected pericellularly in both normal and OA tissue, although it was upregulated in OA tissue 
consistent with previous reports (Tesche and Miosge, 2004).  CCN2 was detected in both 
normal and OA tissue and colocalised with perlecan; however CCN2 staining was significantly 
stronger in OA cartilage (Figure 21, merged images) 
Normal
OA
Figure 21.  Localisation of  CCN2 in normal and OA human cartilage.  Frozen sections (7 µm) of  normal 
human articular  cartilage  and OA knee cartilage were pre-treated with chondroitinase (10 mu/ml for 90-120 min).  
Sections were stained with primary antibodies to perlecan (1:1000) and CCN2 (1:1000).  Sections were washed 
and incubated with secondary FITC-labelled antibodies (1:2000) and propidium iodide (PI) (1:1000).  Fluorescence 
signals were detected by UltraVIew confocal microscopy.  
Perlecan  CCN2 PI                                     Merged
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3.7.2 The role of heparin in the secretion of CCN2. 
Although CCN2 was confirmed to localise within the PCM, the original identification of CCN2 as 
a truncated secreted protein led to the decision to investigate its expression and secretion in 
more detail.  Previous studies looking at the release of CCN2 from mesangial cells showed that 
the addition of exogenous heparin into cultures significantly increased the amount of protein in 
the medium (Riser et al., 2000).  It was therefore decided to include heparin in explant and 
chondrocyte cultures.  Figure 22 shows the detection of CCN2, by Western blot, in the 
conditioned medium of both cartilage explants and chondrocytes following incubation with 
heparin for 24 hours.  CCN2 appeared as a number of bands between 36-38KDa in explants 
and chondrocytes incubated with varying concentrations of heparin.  These bands were absent 
from heparin alone (in the absence of cells) and from the controls which were incubated with 
medium alone (lanes 2 and 6), unless the medium was concentrated approximately 20 fold 
(data not shown).  In addition to bands at around 36KDa, lower molecular weight bands of 
approximately 20KDa, which were particularly prominent in explant cultures, were detected in 
the conditioned medium in the presence of heparin.  These may have represented processed 
forms of the protein that lack one or more of the four structural modules.  This is consistent with 
a 20KDa protein previously identified as CCN2 from porcine and human OA cartilage by 2D gel 
electrophoresis (Figure 18). 
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Figure 22.  Release of CCN2 into conditioned medium from cartilage explants and chondrocytes upon 
incubation with heparin.   Cartilage was dissected from one porcine MCP joint and rested overnight at 37°C.  
Approximately 0.125g of tissue was incubated with either 100, 500 or 1000µg/ml heparin in 500µl of medium, or 
medium alone for 24h. Chondrocytes were isolated from porcine articular cartilage using collagenase, seeded at 5 x 106
cells/well and rested overnight at 37°C.  Cells were incubated with either 50 or 250 µg/ml heparin in 1ml of medium, or 
medium alone for 24h.  Conditioned medium from both explants and chondrocytes was harvested, run on a 4-12 % Bis
Tris gel and immunoblotted with an antibody to CCN2 (1:500).  
0 10
0
50
0
25
0
10
00
0 5
0H
ep
ar
in
 a
lo
n
e
CCN2
 
 
 
The apparent increase in CCN2 in the presence of heparin could be explained by three 
possible mechanisms for control of CCN2 secretion: i) heparin is able to directly stimulate 
CCN2 mRNA or secretion of CCN2; ii) heparin is causing release of trapped HS-bound CCN2 
within the matrix; iii) heparin is interfering with the re-uptake or degradation of CCN2 by the 
chondrocyte. 
 
It was possible that heparin was directly affecting CCN2 at the mRNA level.  However, 
experiments using RT-PCR indicated that heparin did not cause any increase in the gene 
expression of CCN2 in porcine chondrocytes (Dr Y. Sawaji of the Kennedy Institute of 
Rheumatology, Imperial College London; personal communication).  To address the second 
possibility, porcine explants were subjected to repeated freeze-thawing in order to kill 
chondrocytes and therefore prevent active secretion of proteins.  Explants were then incubated 
in the presence of heparin to investigate the subsequent effect on CCN2 accumulation in the 
medium.  As seen previously, in live tissue (Figure 22) CCN2 accumulated (at both 36 and 
20KDa) in the medium in the presence of heparin (Figure 23).  Protein bands were detected at 
both 36KDa and 20KDa.  However, following freeze-thawing of the cartilage, incubation with 
heparin did not cause accumulation of full length CCN2 (Figure 23, F/T + heparin).  This means 
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that the accumulation of CCN2 in the presence of heparin depended upon synthesis and 
secretion of the protein.  Interestingly, there were bands at the lower molecular weights 
following freeze-thawing, which suggests that there is processed CCN2 bound within the 
matrix. 
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Figure 23  Release of CCN2 from cartilage explants upon incubation with heparin is not from a matrix 
bound pool. Cartilage was dissected from one porcine MCP joint and rested overnight at 37°C.  Approximately 
0.25g of tissue was incubated with either medium alone or heparin (100µg/ml) for 24h. Addtionally explants (0.25g) 
were subjected to repeated freeze-thawing (F/T) in 1ml medium.  The medium was harvested and then explants 
were incubated with heparin (100µg/ml) for 24h.  Conditioned medium from explants was harvested and run 
alongside conditioned medium harvested directly following freeze-thawing.  Samples were run on a 4-12 % Bis Tris
gel and immunoblotted with an antibody to CCN2 (1:500).  
CCN2
Treatment 
 
 
CCN2 has been shown to bind to LRP.  This interaction has been demonstrated in a number of 
cell types including; a bone marrow stromal cell line (Segarini et al., 2001), rat hepatic stellate 
cells (Gao and Brigstock, 2003), and a human chondrocytic cell line (HCS-2/8) (Kawata et al., 
2006).  LRP, is a member of the family of low density lipoprotein (LDL) receptors.  LRP is a 
600-KDa membrane protein that is able to bind at least 30 distinct ligands including; α2-
macroglobulin,  thrombospondin-1 and -2, apolipoprotein-E (apoE), receptor associated protein 
(RAP), a number of matrix metalloproteinases including MMP-2, MMP-13 and MMP-9 (Herz 
and Strickland, 2001), the tissue inhibitor metalloproteinase-3 (TIMP-3) (Troeberg et al., 2008) 
and CCN2, which is reported to bind LRP with a higher affinity than other reported ligands 
(Segarini et al., 2001).  LRP was originally considered as a scavenger receptor, mediating the 
clearance of specific molecules.  However, the number of distinct ligands that bind LRP 
suggest a function in physiological processes such as repair, remodelling and development  
(Gliemann, 1998).  A number of reports have shown that LRP acts as a signalling receptor and 
plays a role in cell processes including protease regulation, signal transduction, activation of 
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lysosomal enzymes and lipoprotein metabolism (Herz and Strickland, 2001).  The role of LRP 
as a receptor for CCN2 is not completely understood and it is unclear whether the interaction of 
LRP-CCN2 results in signalling or simply acts as a clearance mechanism.  The ability of CCN2 
to bind heparin may be important in LRP binding as a number of reports have implicated the 
involvement of heparan-sulphate proteoglycans in the binding of CCN2 to LRP at the cell 
surface (Gao and Brigstock, 2003).   
 
To investigate whether heparin was interfering with the uptake of CCN2, porcine chondrocytes 
were incubated in the presence of the receptor-associated protein (RAP).  RAP interacts with 
LRP with high affinity via its C-terminal heparin-binding sites (Warshawsky et al., 1993) and 
efficiently blocks the binding and uptake of all known LRP ligands.  I first confirmed that RAP 
caused accumulation of CCN2 and then compared this to incubation with heparin alone or in 
combination with RAP.  Incubation with RAP alone also caused accumulation of CCN2, 
although this was considerably less than that seen with heparin (Figure 24).  The combination 
of heparin and RAP caused massive accumulation of CCN2 in the medium, suggesting 
synergy.  This effect could be interpreted in a number of ways: 
i) Exogenous heparin may increase the ability of RAP to bind to LRP and prevent CCN2 
uptake.  In fact, it has previously been described that binding of RAP to LRP is 
heparin dependent (Gao and Brigstock, 2003).  However, this does not explain why 
heparin alone causes accumulation of CCN2. 
ii) Heparin may itself bind directly to LRP and function as an LRP ligand.  However, the 
synergistic response seen in combination treatment suggests that RAP and heparin 
are acting on different receptors. 
iii) HS proteoglycans have been directly implicated in LRP uptake of CCN2 at the cell 
surface. It is possible that exogenous heparin interferes with endogenous HS, 
inhibiting the ability of HS proteoglycans to act as co-receptors for CCN2 uptake by 
LRP.  
iv) Heparin may interfere with a mechanism of uptake that is independent of LRP.   
v) Heparin may protect CCN2 from proteolysis on the cell surface by specific proteases.  
Tam et al (2003) identified CCN2 as a substrate for the membrane type 1-MMP (MT1-
MMP) and has been shown to be processed by MMP-2 in mouse embryonic 
fibroblasts (Dean et al., 2007).  Heparin could protect CCN2 from MMPs directly, or 
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could enhance the inhibitory effects of endogenous tissue inhibitors of 
metalloproteinases (TIMPs).   
 
Data presented suggests that exogenous heparin works via a combination of mechanisms to 
cause accumulation of CCN2 in this system; both dependently and independently of LRP.  It is 
important to note that the use of exogenous heparin in cultures is somewhat artificial. 
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Figure 24  Release of CCN2 into conditioned medium is potentiated in the presence of both heparin and RAP. 
Chondrocytes were isolated from porcine articular cartilage using collagenase, seeded at 1 x 106
cells/well and rested overnight at 37°C.  Cells were incubated with either medium alone, heparin (100 µg/ml) or the 
receptor-associated protein (RAP) (500nM) alone, or in combination in 250µl of medium, for 24h.  Conditioned 
medium from both explants and chondrocytes was harvested, run on a 12 % Tris Glycine gel and immunoblotted with 
an antibody to CCN2 (1:500).  
Treatment 
CCN2
 
3.7.3 Induction of CCN2 in chondrocytes following stimulation with growth factors.  
CCN2 has been shown to be transcriptionally activated by a number of factors including TGF- 
β, BMP-2, glucocorticoids, high glucose and mechanical strain (Riser et al., 2000; Wahab et al., 
2001b).  The effect of pro-inflammatory cytokines on CCN2 induction is slightly less clear.  
There are reports of a decrease in expression of CCN2 mRNA following IL-1 stimulation in both 
human peritoneal mesothelial and airway smooth muscle cells (Sakamoto et al., 2005; Xie et 
al., 2005).  TNF-α has been reported to decrease CCN2 expression in fibroblasts (Beddy et al., 
2006) whereas in mesangial cells, in combination with TGF-β, appears to increase expression 
(Cooker et al., 2007).  In chondrocytes specifically, there are reports of induction by TGF-β and 
IL-1 (Takahashi et al., 2005), macrophage colony-stimulating factor (M-CSF) (Nakao et al., 
2005) and dexamethasone (Kubota et al., 2003). Following confirmation of the presence of 
CCN2 in porcine articular cartilage, the effect of a number cytokines on the level of protein was 
investigated.  Figure 25 shows a preliminary experiment performed by Dr Yasu Sawaji, within 
our group, investigating the effect on CCN2 protein induction in both chondrocyte lysates and 
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conditioned medium in the presence or absence of heparin.  CCN2 was detected in all lanes 
including the control samples; however, CCN2 expression appeared to be upregulated 
following stimulation with both IL-1 and TGF-β (Figure 25 A).  This upregulation was also 
demonstrated by an increase in CCN2 in the conditioned medium following stimulation with IL-
1, TGF-β and to a lesser extent, activin A (Figure 25 B).  CCN2 in the conditioned medium was 
only detected in the presence of heparin.  This effect was more striking on the secreted protein 
rather than in the cell layer, although a mild increase in CCN2 in the presence of heparin was 
apparent (Figure 25 A).  
 
Figure 25. Detection of CCN2 in conditioned medium and cell lysates of chondrocytes upon stimulation 
with growth factors. Chondrocytes were isolated from porcine articular cartilage using collagenase, seeded at 1 
x 106 cells/well and rested overnight at 37°C. Cells were incubated for 24h with medium alone, IL-1 (10ng/ml), b-
FGF (20ng/ml), actiVInA (20ng/ml) or TGF-β (20ng/ml) in the presence or absence of heparin (100µg/ml). Cell 
lysates (A) and conditioned medium (B) were harvested and run on 12% Tris Glycine gel and immunoblotted with 
an antibody to CCN2.  (Figure courtesy of  Dr Yasu Sawaji)
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3.7.4 Localisation of matrix bound CCN2 in porcine tissue. 
Porcine tissue was used to investigate the regulation of the matrix-bound fraction of secreted 
CCN2.  Porcine chondrocytes were isolated and cultured for 48 hours to allow for the 
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accumulation of PCM.  Cells were then stimulated for a further 48 hours with or without TGF-β, 
processed and immunostained with antibodies to perlecan and CCN2 (Figure 26).  Perlecan 
was seen to localise to the PCM in both stimulated and unstimulated cells although perlecan 
was seen to be increased in the presence of TGF-β as expected (T.Vincent, personal 
communication). CCN2 was detected very faintly in unstimulated cells, with significantly 
stronger detection in cells stimulated with TGF-β.  When both perlecan and CCN2 images were 
merged, there was significant colocalisation.   
 
Figure 27 shows immunolocalisation of CCN2 within porcine explants.  Explants were 
stimulated for 48 hours with TGF-β, processed and immunostained with antibodies to perlecan 
and CCN2.   As seen in chondrocytes, CCN2 staining was much more significant in explants 
following stimulation with TGF-β.  Perlecan showed typical pericellular staining and when the 
images were merged, CCN2 colocalised with perlecan within the PCM.  The weak staining in 
both unstimulated explants and chondrocytes is likely to imply low endogenous expression of 
CCN2, although these results also suggest that the level of perlecan expression may limit the 
amount of CCN2 bound. 
 
CCN2 accumulated within the medium of porcine articular cartilage explants following 
incubation with heparin.  It can be seen in Figure 27 that when explants were stimulated with 
TGF-β in the presence of heparin, immunostaining for pericellular CCN2 was significantly 
diminished.  The most likely explanation is heparin blocks the heparin binding sites on CCN2 
preventing it from binding HS within the PCM.  These results suggest that CCN2 is binding to 
the HS chains on perlecan rather than to another part of the molecule, such as the core 
protein.    
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Perlecan  CCN2                                      PI                                  Merged
Control 
TGF 
Figure 26. Immunolocalisation of CCN2 in stimulated isolated chondrocytes. Chondrocytes were isolated from 
porcine articular cartilage using collagenase, seeded at 2 x 106 cells/well in Lab Tek II chamber slides and rested for 48h 
at 37°C to allow accumulation of a PCM.  Cells were then stimulated for a further 48h with TGF-β3 (5ng/ml) or medium 
alone (control).  The chondrocytes were fixed in methanol, then incubated with primary antibodies to perlecan (1:1000) 
and CCN2 (1:1000). The cells were washed and incubated with secondary FITC labelled antibodies and propidium iodide 
(PI).  Fluorescence signals were detected using Ultraview confocal microscopy.  
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Perlecan  CCN2 PI                                    Merged
Control
TGF
TGF 
+ 
Heparin
Figure 27.  Immunolocalisation of CCN2 in porcine explants. Porcine articular cartilage was dissected aseptically from 
the metatarso-phalangeal joints of 3-6 month old pigs obtained fresh from a local abattoir within 24 hours.  Explants were 
cultured for 24h in serum free medium and then stiumlated for a further 48h with TGF-β3 (5ng/ml), with or without heparin 
(100 µg/ml) or medium alone (control). Explants were then snap frozen and 7 µm frozen sections were cut, fixed in 
methanol and treated for 1-2h at 37 °C with chondroitanase ABC.  Sections were then incubated with primary antibodies 
to perlecan (1:1000) and either CCN2 (1:1000).  The cells were washed and incubated with secondary FITC labelled
antibodies and propidium iodide (PI).  Fluorescence signals were detected using Ultraview confocal microscopy. 
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3.8 Discussion 
Evidence for expression of CCN2 in cartilage has previously come from immunohistochemical 
analysis of developing, normal and osteoarthritic tissue.  For instance, expression of CCN2 
was detected in the PCM surrounding hypertrophic chondrocytes during formation of the 
secondary ossification centre in mouse tibiae (Oka et al., 2007).  In normal human and 
osteoarthritic cartilage, CCN2 was shown within chondrocytes by immunohistochemistry, 
although staining was not described as pericellular (Omoto et al., 2004).  Only Nishida et al, 
2003 showed colocalisation of CCN2 with perlecan in a chondrosarcoma cell line using 
antibodies to both perlecan and the native heparan-sulphate chains (Nishida et al., 2003).   
 
I have shown the specific localisation of CCN2 to the PCM, colocalising with perlecan, in 
normal and osteoarthritic human cartilage by confocal microscopy.  Expression of CCN2 was 
increased in OA tissue.  This is consistent with a previous report by Omoto et al. (2004) that 
showed expression of CCN2 increased as the severity of OA increased.  Perlecan expression 
is also increased in human OA (Tesche and Miosge, 2004) and may reflect the increase seen 
in CCN2 within the PCM.  Interestingly, recombinant CCN2 has been shown to increase the 
mRNA expression of perlecan in HCS-2/8 cells (Nishida et al., 2003).  
 
CCN2 also localised pericellularly with perlecan, in both porcine chondrocytes and explants.  
Stimulation of explants and cells with TGF-β caused a significant increase in expression of 
CCN2.  The addition of heparin led to a decrease in staining of CCN2.  This was likely due to 
heparin blocking the heparin-binding sites of CCN2.  This would confirm the idea that the 
interaction between CCN2 and perlecan is through binding of CCN2 to HS chains on perlecan 
as indicated previously in HCS-2/8 cells by Nishida et al. (2003).  There was also an increase 
in the expression of perlecan in chondrocytes following TGF-β stimulation, consistent with 
previous results from our laboratory (T.Vincent, personal communication) and a study on 
human skin fibroblasts (Iozzo et al., 1997).  The increase in detection of CCN2 may again 
reflect an increase in the expression of perlecan, and therefore increased availability of HS 
within the tissue.  However, the obvious limitation of these experiments is in that fact that 
although confocal microscopy shows colocalisation, this does not confirm direct interaction or 
binding between these two molecules.  This could be further investigated using solid phase 
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binding assays which may also be able to deduce exactly where CCN2 binds to perlecan i.e. 
via the core protein, or its heparan sulphate chains.  
 
CCN2 was shown to accumulate in the medium of both porcine chondrocytes and cartilage 
explants in the presence of heparin. Heparin did not appear to increase expression of CCN2 at 
the gene level; however its effect was dependent on the active secretion of CCN2 from 
chondrocytes.  The potentiation of CCN2 release upon incubation with both heparin and the 
LRP ligand, RAP, suggested that heparin may be increasing the ability of RAP to bind LRP.  
The fact that heparin alone caused a release of CCN2 however, implied either a direct effect by 
heparin on LRP itself, or a possible interference with proposed HS proteoglycan co-receptor 
activity.  It was also difficult to rule out that heparin was not affecting a mechanism of uptake 
that was independent of LRP.   
 
The exact role of LRP as a receptor for CCN2 is not completely understood.  Initial 
observations in a human osteosarcoma cell line (MG-63), showed internalisation of CCN2 via 
LRP, followed by degradation of the protein.  It is unclear whether the interaction of LRP-CCN2 
results in signalling or simply acts as a clearance mechanism. (Segarini et al., 2001).  One 
report has suggested that CCN2 is able to induce tyrosine phosphorylation of the cytoplasmic 
domain of LRP in myofibroblasts and inhibition of LRP signalling reduced a CCN2-mediated 
effect of α-SMA expression (Yang et al., 2004).  In the chondrosarcoma cell line HCS-2/8, 
CCN2 was internalized by LRP-1 via endocytosis and then either transported to the nucleus, or 
degraded (Kawata et al., 2006).  Experiments in human mesangial cells showed that CCN2, 
following endocytosis, was transported to both the cytosol, where it was phosphorylated, or to 
the nucleus where it was thought to directly affect transcription (Wahab et al., 2001a).  Whether 
binding of CCN2 to LRP in porcine chondrocytes results in signalling remains unknown.  This 
may be addressed following the identification of a specific effect of CCN2 on chondrocytes.  
Blocking CCN2 uptake by LRP using RAP may determine whether the observed effect is LRP 
dependent.   
 
CCN2 is a heparin-binding protein and a number of reports have implicated the involvement of 
heparan-sulphate proteoglycans in the binding to LRP at the cell surface.  While Segarini et al 
(2001) showed that CCN2 was capable of binding to the surface of MG-63 cells depleted of 
GAGs, Gao et al (2003) showed that the interaction of CCN2-LRP was heparin dependant and 
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required for adhesive signalling in rat hepatic stellate cells.  It may be interesting to investigate 
the role of endogenous HS in chondrocytes, in the binding and uptake of CCN2 by LRP.  This 
could be addressed by using heparitinase to cleave HS or sodium chlorate to suppress HS 
expression.  Any accumulation of CCN2 seen following removal of HS may indicate a role in 
uptake and imply that exogenous heparin is acting through competitive binding.  
 
The work presented in this section raises a number of questions: Does CCN2 bind perlecan at 
the same site as FGF-2?  If so, does CCN2 compete for binding of perlecan with FGF-2? This 
could be addressed using confocal microscopy to determine whether FGF-2 bound to perlecan 
can be displaced with the addition of exogenous CCN2.  Also, what is the role of CCN2 within 
the matrix, bound to perlecan?  It was hypothesised that the interaction of FGF-2 with perlecan 
facilitates binding to cell surface receptors and subsequent induction of cellular responses by 
FGF-2 upon mechanical stimulation.  Is CCN2 released from perlecan upon mechanical 
stimulation? Does mechanical loading affect uptake of CCN2, or indeed play a role in inducing 
activity of CCN2 within cartilage?   
 
To clarify the role of this protein in cartilage, the use of recombinant protein is essential.  
Therefore it was decided to generate purified CCN2, and this will be the subject of the next 
chapter.
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4.1 Introduction 
CCN2 has been described to exhibit numerous effects on many different cell types.  A wide 
variety of methods have been used to investigate CCN2 function, although the majority of 
studies have looked at the role of CCN2 in vitro.  With regards to in vivo studies, the generation 
of CCN2 -/- mice has suggested a role for CCN2 in growth plate angiogenesis, skeletal 
development and chondrogenesis (Ivkovic et al., 2003).  Recently, the generation of transgenic 
mice overexpressing CCN2, under the control of the human osteocalcin promoter, has shown 
CCN2 to decrease bone formation and cause osteopenia (Smerdel-Ramoya et al., 2008b).  
Another study using transgenic mice that overexpress CCN2 under the control of mouse type 
XI collagen promoter, has confirmed the effect on bone formation and also implicated CCN2 in 
embryonic development of the testis (Nakanishi et al., 2001).  Overexpression of CCN2 in 
Xenopus embryos modulates Wnt signalling, indicating a role in embryonic development 
(Mercurio et al., 2004).  A number of studies have investigated the role of CCN2 using animal 
models of disease.   In a mouse fibrosis model, injection of recombinant CCN2 into the 
subcutaneous tissue of newborn mice, demonstrated that CCN2 was required for the 
development of persistent fibrosis (Mori et al., 1999).  Murine bone tumours treated with a 
CCN2-neutralizing antibody, indicated a role for CCN2 in osteolytic metastasis of breast cancer 
(Shimo et al., 2006).  Pancreatic tumour growth was decreased and tumour angiogenesis was 
attenuated following administration of a CCN2-specific antibody (Aikawa et al., 2006).  
Treatment of rabbit skin wounds with antisense oligonucleotides to CCN2 reduced hypertrophic 
scarring (Sisco et al., 2008).  Specific to a role in cartilage, a study using the monoiodoacetic 
acid (MIA)-induced experimental rat osteoarthritis (OA) model in which recombinant CCN2, 
incorporated in gelatin hydrogel, was injected into rat knee joints, showed repair of cartilage 
defects implicating CCN2 in the regeneration of articular cartilage (Nishida et al., 2004).   
 
The majority of published data on the role of CCN2 has been from in vitro studies.  
Overexpression of CCN2 either by transient or adenoviral transfection methods have been 
used in a number of cell types (Hishikawa et al., 2000; Hishikawa et al., 1999; Liu et al., 2008; 
Luo et al., 2004; Wahab et al., 2001b).  The generation of recombinant protein has been the 
predominant method for studying the role of CCN2.  There are a small number of companies 
who provide recombinant CCN2.  However, the biological activity of some of these is 
questionable.  Many groups have used recombinant CCN2 from FibroGen; a company 
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primarily involved in the development of therapeutics for fibrotic disease.  However, they have 
recently scaled back their operation and recombinant protein is no longer advertised on their 
website.  As a consequence, a number of studies have involved the generation of their own 
recombinant protein, prior to investigating CCN2 function.  There are a number of published 
methods for the generation of recombinant human CCN2 including; the use of transformed 
HeLa cells followed by purification with a combination of heparin and antibody affinity 
chromatography (Nakanishi et al., 2000); expression in a bacculoviral system followed by 
purification using heparin affinity chromatography (Frazier et al., 1996); expression in 
competent M15[pREP4] E. coli followed by nickel affinity chromatography (Tong and Brigstock, 
2006); expression in transformed human mesangial cells, followed by purification with either 
metal or heparin affinity chromatography (Wahab et al., 2001b).   
 
Due to lack of commercially available protein and in the absence of a conditional 
transgenic/knock out mouse, it was decided to generate recombinant protein to study the role 
of CCN2 further.  This shall be the focus of this chapter.   
 
 
4.2 Transient transfection of HeLa cells with CCN2  
CCN2 is highly conserved amongst mammalian species (human, pig, bovine and mouse). A 
human CCN2 construct was kindly provided by Prof. Roger Mason of the Hammersmith 
Hospital.  The cDNA was inserted into a pcDNA 3.1 expression vector and was constructed to 
contain a His Tag for purification and a V5 epitope at the C terminus for immunological 
identification.  A schematic of the vector containing the inserted cDNA is represented in Figure 
1. 
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Figure 1.  Graphical representation of  pcDNA 3.1 vector.  CCN2 construct (provided by Prof. R Mason) 
was inserted into a pcDNA 3.1 vector.  The vector was constructed to have a His tag for purification and a V5 
epitope at the C terminus for immunological identification.  It has human CCN2 cDNA from nucleotide 123-
1177 of M92934 (2075bp) = 1054bp cloned into vector at PCR product insert site.
 
 
Expression of the protein was initially attempted using transformed human mesangial cells 
(courtesy of Prof. R. Mason) as they had been used to express full-length CCN2 (Wahab et al., 
2001b).  Transfection of mesangial cells was attempted using calcium phosphate and 
Superfect methods.  Briefly, cells were transfected with 0-1000ng of CCN2 plasmid DNA and 
incubated for 24 or 48 hours.  Conditioned medium was harvested and immunoblotted using an 
antibody to the V5 domain of the construct; however, I was unable to detect CCN2 within the 
medium of transfected mesangial cells.  It was then decided to attempt to transfect HeLa cells, 
with Superfect, since they are a commonly used cell line for expressing proteins due to their 
high proliferation rate. Concentrations ranging from 0-1000 ng of CCN2 plasmid DNA were 
transiently transfected.  After 24 or 48 hours, conditioned medium was collected and western 
blotted with an antibody that recognised the V5 domain (Figure 2).  A number of bands 
corresponding to the correct size of CCN2 between 34-38KDa were detected following 
transfection with 1µg CCN2 plasmid DNA, after both 24 and 48 hours (lanes 3 and 8), as well 
as a strong band at approximately 120KDa.  The different molecular weight bands (34-38KDa) 
may represent glycosylated forms of the protein.  There was no protein detected in the 
conditioned medium at lower concentrations of DNA, or in the control or mock transfected cells.  
All following transfections used a DNA concentration of 1µg and conditioned medium was 
collected after 24 hours as there had been no significant increase in protein expression beyond 
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this time.  To confirm successful transfection, conditioned medium was also western blotted 
using an antibody to CCN2 (Figure 3).  As seen with the V5 antibody, bands of the correct size 
ranging from 35-38KDa were detected in the conditioned medium of cells transfected with 
CCN2 plasmid DNA, but were absent from both control and mock transfected cells.  As in the 
previous figure, a higher molecular band above 100KDa was detected by the antibody to 
CCN2.  However, the fact that this band was present in the conditioned medium of control, 
mock and CCN2 transfected cells implies it was non-specific.   
 
Following successful expression of the protein, different methods of purification were 
considered.  The most obvious methods were to either utilise the ability of CCN2 to bind 
heparin (as it is described as heparin binding), or to use the His Tag present at the C-terminus 
of the construct.  Although the expressed protein clearly contained the V5 epitope (as 
determined by western blotting), initial experiments using an antibody against the His Tag, 
which is downstream of the V5 domain, proved unsuccessful. Being unable to confirm that the 
His Tag was intact on the expressed protein, I first investigated the ability of the protein to bind 
to heparin. 
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Figure 2.  Transient transfection of Hela cells with CCN2.  Hela cells were plated at 250,000 cells/well and 
incubated overnight at 37°C.  Cells were transiently transfected with superfect with concentrations ranging from 0-
1000 ng of CCN2 plasmid DNA.  After 4h, cells were washed twice in 1x PBS and incubated for 24 or 48h in 3ml of 
medium containing foetal calf serum.  Conditioned medium was harvested and run on 12 % tris glycine gel and 
immunoblotted with an antibody to the V5 domain (1:5000).  
Transfection
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Figure 3.  Detection of CCN2 following transfection with an antibody to CCN2. Cells were transiently transfected
with superfect with either no DNA, a control vector or 1 µg of CCN2 DNA.  After 4h cells were washed twice in 1x PBS 
and incubated for 24 3ml of DMEM in the absence of serum.  Conditioned medium was harvested and run on 12 % tris
glycine gel and immunoblotted with an antibody to CCN2.
105
 
 
4.3 Binding of expressed CCN2 to heparin beads. 
CCN2 is described as a heparin binding protein.  The heparin binding domain of CCN2 lies in 
C-terminal 103 residues of the molecule (Brigstock et al., 1997).  In order to determine whether 
the expressed protein was heparin binding, conditioned medium from both mock transfected 
cells and cells transfected with 1 µg CCN2 plasmid DNA was incubated with heparin beads 
(Figure 4).  Beads and supernatants were Western blotted with an antibody to the V5 domain.  
As seen previously, no CCN2 was detected in the conditioned medium from mock transfected 
cells (lanes 1-3).  Positive bands detected between 35-38KDa in the conditioned medium of 
transfected cells were depleted from the supernatant following incubation with heparin beads 
(sup).  These bands were recovered when the beads were run on SDS PAGE (beads) and 
were concentrated.  There appeared to be full recovery on heparin beads as 4 times as much 
material had been loaded onto the beads compared to that in the starting material (S.M).  
There was some depletion of the band at 120KDa, although there was no recovery of this band 
from the beads.  It is not clear whether this is non-specific or an anomalous CCN2 species.  
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Figure 4.  Pull down of CCN2 from conditioned medium using heparin beads.  Conditioned medium (200 
µl) from HeLa cells transfected with either a control vector or 1 µg of CCN2 DNA was incubated with 40 µl 
heparin beads with agitiation overnight at 4 °C.  Samples were spun and supernatants were retained.  Beads 
were washed twice with 1x PBS, boiled for 10 mins in 4x sample buffer to elute protein.  Conditoned medium 
(S.M) (50µl), eluted protein (beads) (40µl) and supernatant post incubation with beads (sup) (50µl) were run on 
a 4-12% Bis Tris gel and immunoblotted with an antibody to V5.  
 
 
4.4 Identification of expressed protein by mass spectrometry. 
Although identified by western blotting, it was necessary to confirm identification of CCN2 by 
mass spectrometry.  The binding of CCN2 to heparin beads was utilised to partially purify the 
protein.  Conditioned medium (750 µl) from transfected cells was incubated with 50 µl heparin 
beads to concentrate the protein.  Beads were washed with PBS, run on SDS PAGE (4-12%) 
and silver stained (Figure 5).  Silver stained bands were cut out and analysed by mass 
spectrometry.  From the heparin beads, a number of proteins were detected between 
approximately 32-38KDa.  All of these bands were identified as CCN2 following analysis by 
mass spectrometry.  The different molecular bands may represent both glycosylated and 
processed forms of the protein.  In addition to CCN2, a number of other proteins were identified 
including the serum protein anti-thrombin III.  This could be attributed to the presence of serum 
within the media during the 24 hour transfection.  Serum was subsequently omitted from the 
culture medium in all transfections without apparent reduction in CCN2 expression.  
 
 Chapter 4                                          Expression and purification of CCN2 
 
136 
 
35
50
75
30
25
105
S
.M
CCN2
Anti thrombin III
Figure 5.  Identification of CCN2 in conditioned medium of transfected Hela cells following concentration with 
heparin beads.  Conditioned medium (750µl) from Hela cells transfected with 1µg CCN2 DNA was incubated with 50µl 
heparin beads at room temperature for 5h.  The sample was spun and supernatant was retained.  Beads were washed 
twice with 1xPBS and boiled for 10min in 4x sample buffer to elute protein.  Conditioned medium (S.M), eluted protein 
(beads) and supernatant post incubation with beads (S/N) was run on 4-12 % Bis Tris gel and silver stained.  Protein 
bands were cut out and analysed by mass spectrometry
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4. 5 Elution of CCN2 from heparin beads. 
In order to investigate the binding affinity of the expressed CCN2 protein to heparin, the protein 
was eluted from heparin beads using increasing concentrations of sodium chloride (Figure 6).  
Following incubation of conditioned medium from transfected cells with heparin beads, the 
beads were washed with 0.5M, 1M and 2M salt, with the supernatants being collected after 
each step.  Both supernatants and the resultant beads were Western blotted with an antibody 
to the V5 domain.  As seen previously, protein bands were detected between 34-38KDa in the 
conditioned medium.  These bands were largely depleted from the supernatant (sup post 
beads), but were present in the supernatant following the 0.5M NaCl wash (sup 0.5M NaCl).  
The absence in other supernatants or the heparin beads (Sup 1.0M NaCl, Sup 2.0M NaCl, 
beads) indicated that CCN2 could be completely removed from the beads at 0.5M NaCl.  This 
represents a relatively low binding affinity of CCN2 to heparin in comparison to other growth 
factors such as FGF-2. 
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Figure 6.  Elution of CCN2 from heparin beads using sodium chloride. Conditioned medium (750µl) 
from HeLa cells transfected with 1 µg of CCN2 DNS was incubated with 50 µl of heparin beads overnight 
at 4°C.  The sample was spun and supernatant was retained. Beads were washed twice in 1x PBS and 
incubated in 0.5M NaCl for 1h at room temperature. Beads were spun and resultant supernatant was 
retained.  Beads were then incubated for 1h in 1M NaCl, spun and supernatant was retained.  Finally 
beads were incubated for 1h in 2M NaCl, spun and supernatant was retained. Beads were then washed 
twice in 1xPBS and boiled for 10min in 4x sample buffer to elute protein.  Samples were run on 4-12% Bis 
Tris gel and immunoblotted with an antibody to V5.
 
4. 6 Purification of CCN2 using a heparin column. 
Following confirmation that the expressed CCN2 protein was able to bind heparin and was 
eluted at approximately 0.5M sodium chloride, further purification of the conditioned medium 
using a heparin column was investigated.  Conditioned medium (165ml) was filtered, to remove 
any cell debris, loaded onto a 1 ml heparin column and eluted using a stepwise gradient of 
increasing concentrations of NaCl (0-1M).  Fractions (1ml) were collected and western blotted 
using an antibody to CCN2.  As seen previously, bands around 35-38KDa were detected in the 
starting material pre- and post-filtration (Figure 7B) although there were perhaps modest losses 
upon filtration.  The column run-through was omitted from this experiment making it difficult to 
determine what percentage of starting material bound to the column.  CCN2 was detected 
mainly in fraction 4 with some spreading across fractions 3 and 5.  It was difficult to calculate 
the precise recovery on this column in view of the semiquantitative nature of western blotting 
and the weak staining of the starting material.  However, the results are consistent with a 165 
fold concentration that would be expected assuming full recovery of the loaded material.  
Fraction four was silver stained and mass spectrometry was used to identify 4 bands ranging 
from 35-38KDa in size as CCN2 (Figure 7C).  However, silver staining visualized a number of 
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bands other than CCN2 within fraction 4 indicating that the use of heparin column 
chromatography alone was not suitable for purification to homogeneity.   
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Figure 7.  Purification of CCN2 from conditioned medium using a heparin column.  Conditioned medium 
(165ml)  from Hela cells transfected with 1µg CCN2 DNA was applied to a 1ml heparin column previously 
equilibrated with 2x PBS.  Protein was eluted using a stepwise gradient of  NaCl.  Samples were collected in 1ml 
fractions.  Fractions  (50µl) were run on 4-12% Bis Tris gel and immunblotted with an antibody to CCN2  (A)or 
the gel was silver stained and protein bands cut out and analysed by mass spectrometry (B).
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4. 7 Elution of CCN2 from nickel agarose beads. 
Despite the fact that initial experiments using an antibody designed to recognise the His Tag 
were unable to prove it was present at the C-terminus of the expressed protein, the incomplete 
purification achieved with heparin column chromatography led to the decision to revisit 
purification using the His Tag.  The polyhistidine-tag is an amino acid motif that consists of at 
least six histidine (His) residues.  Metal ion affinity chromatography utilises the ability of 
histidine residues to chelate metal ions such as nickel.  Therefore, I decided to determine the 
ability of CCN2 to bind to nickel agarose beads.    Following incubation of conditioned medium 
from transfected HeLa cells with Ni-NTA agarose beads, the beads were washed with 
increasing concentrations of imidazole, which competes with the polyhistidine tag for binding to 
nickel.  Both supernatants and the resultant beads were western blotted with an antibody to the 
V5 domain (Figure 8).  Protein bands were detected between 34-38KDa in the starting material 
(S.M).  These bands were largely depleted from the supernatant following incubation with Ni –
NTA beads (sup post beads), and were released from the beads following washing with 50mM 
imidazole. Further protein was eluted with 100mM imidazole.  Some protein could be detected 
in the Ni-NTA agarose beads implying that there was incomplete elution of the protein even 
after a 500mM imidazole wash.  The precise recovery was difficult to determine, however it did 
appear that the there was less than the expected 15 fold concentration following elution which 
indicates imcomplete recovery of starting material.  
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Figure 8. Elution of CCN2 from nickel agarose beads using imidazole.  Conditioned medium (15ml) from HeLa 
cells transfected with 1µg CCN2 DNA was incubated overnight at 4°C with 150 µl nickel agarose beads (prewashed 
in 20mM Tris, 150mM NaCl).  Beads were spun and the supernatant retained.  Beads were then incubated for 1h at 
RT with  1ml of increasing concentrations of imidazole (50-500mM).  Beads were spun and supernatants retained 
between each wash step.  Finally beads were washed twice in PBS and boiled for 10min in 50 µl 4x sample buffer to 
elute proteins.  Samples (50µl)  were run on 12 % Tris Glycine gel and immunoblotted with antibody to the V5 
domain.   
Sup post wash
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4.8 Purification using nickel affinity chromatography. 
Following confirmation that the expressed CCN2 protein was able to bind nickel agarose, 
further purification of the conditioned medium using a nickel affinity column was investigated.  
In initial experiments, 100 ml of conditioned medium was filtered, to remove cell debris, and 
applied to a 1ml nickel affinity column and proteins eluted using a linear gradient of increasing 
concentrations of imidazole (20-500mM), containing 0.5M NaCl  to eliminate ion-exchange 
effects.  Fractions (1ml) were collected and immunoblotted with an antibody to the V5 domain 
and silver stained (Figure 9).  Faint bands corresponding to CCN2 were detected in the starting 
material pre- and post-filtration.  There did appear to be less protein detected following 
filtration; however, it is not clear whether this is a true observation or an artefact due to a 
problem during protein transfer.  The column run-through was omitted from this particular 
experiment making it difficult to determine what percentage of starting material bound to the 
column.   CCN2 was detected in fractions 2 and 3 following eultion as detected by both western 
blotting (Figure 9A) and silver staining (Figure 9B).  These results are consistent with the 100 
fold concentration that would have been expected assuming full recovery of the loaded 
material.   In contrast to heparin chromatography, silver staining showed there was no 
contamination with non-specific proteins with detection of what appeared to be 3-4 bands at the 
correct molecular weight.   
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Figure 9.  Purification of CCN2 from conditioned medium using a 1ml nickel affinity column.  Conditioned 
medium (100ml)  from HeLa cells transfected with 1µg CCN2 DNA was applied to a 1ml nickel affinity column 
previously equilibrated with binding buffer (20mM sodium pyrophosphate, 0.5M sodium chloride, 20mM 
imidazole). Protein was eluted using a linear gradient ranging from 20mM-500mM imidazole.  Samples were 
collected in 1ml fractions.  Starting material (50µl of 100ml) and fractions (50 µl of 1ml) were run on 4-12% Bis
Tris gel and immunblotted with an antibody to CCN2 (A)  or the gel was silver stained (B).  
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4.9 Identification of purified CCN2 by mass spectrometry 
Silver-stained bands from fractions 2 and 3 were manually excised and in-gel digested with 
trypsin. Electrospray tandem mass spectrometry identified all bands as CCN2.  The identified 
peptide sequences are highlighted in Fig. 10A and a CCN2 peptide mass spectrum is shown in 
Fig. 10B as an example. As mentioned, the mass spectrometry and identification procedures 
were performed by Dr. Robin Wait, of the Kennedy Institute’s proteomics unit.  
 
 
human CCN2 amino acid sequence
MSATGLSPVRCAFVLLLALCSRPASGQDCSGQCQCAAGKRRACPAGVSSL
LEGCGCCRLCAKHLGDLCTERAPCDPHKGLFCDFGSPANRKIGVCTAKDCA
PCVFGGTVYRSGESFQSSCKYQCTCLDGAVGCVPLCSMDVRLPSPDCPFP
RRVKLPGKCCEEWVCDEPKDHTVVGPALAAYRLEDTFGPDPTMMRANCLV
QTTEWSACS KTCGMGISTR VTNDNASCRL EKQSRLCMVRPCEADLEENI 
KKGKKCIRTP KISKPVKFEL SGCTSVKTYR AKFCGVCTDG RCCTPHRTTT 
LPVEFKCPDG EVMKKSMMFI KTCACHYNCP GDNDIFESLY YRKMYGDMA
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Figure 10. Identification of CCN2 by mass spectrometry. (A) The full human CCN2 amino acid sequence.
Peptide sequences identified by tandem mass spectrometry are highlighted in red. (B) Tandem mass spectrum of the
CCN2 peptide GLFCDFGSPANR.  
 
4.10 Quantification of purified CCN2 indicated inadequate expression.  
As proteins had been eluted from the column using buffers containing approximately 150mM 
imidazole and 0.5M sodium chloride, it was necessary to exchange positive fractions into a 
more physiological buffer.  Both dialysis against water and desalting columns were used for 
removal of salt within the fractions. In both cases, removal of salt led a significant loss in 
protein; as determined by silver staining (data not shown).  Following removal of salt from 
positive fractions, protein concentration within fractions 2 and 3 were calculated using the Beer-
Lambert Law (A =  * b * c; where  is the wavelength-dependent molar absorptivity 
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coefficient with units of M-1 cm-1, b is the path length, and c is the analyte concentration).  It 
should be noted that attempts were initially made to measure protein concentration by Bradford 
assay; however, readings were inconsistent and often below detection. Subsequently, 
absorbance readings (A280nm) were taken and shown to be low for all positive fractions.  
Corresponding protein concentrations were calculated to be less than 20ng/ml.  A decision to 
scale-up the purification was taken. It was hoped this would enable retention of a higher 
concentration of protein following both purification and removal of salt from positively identified 
fractions.   
 
4.11 Scale up of purification using nickel affinity chromatography.  
In further experiments, up to 500ml of conditioned medium from HeLa cells was applied to a 
5ml nickel affinity column (Figure 11).  As before, proteins were eluted using a linear gradient 
of increasing concentrations of imidazole (20-500mM).  Fractions (2.5ml) were collected and 
immunoblotted with an antibody to the V5 domain.  Figure 11 shows a representative western 
blot using 500ml of conditioned medium.  Purification of CCN2 was spread across fractions 2, 3 
and 4, with the majority of protein present within the third fraction.  Column losses appeared to 
be minimal according to the expected relative concentration of recovered: starting material (200 
fold).  Positive fractions were then subjected to de-salting to remove both the sodium chloride 
and imidazole within the fractions using a disposable de-salting column.  Absorbances were 
measured pre-, and post-desalting.   Protein concentrations were calculated to be less than 
50ng/ml.  Following removal of salt, silver staining indicated significant loss of material (data 
not shown).  The fact that such a low yield of protein was obtained from a relatively high 
volume of starting material indicated that the use of transient transfection of HeLa cells to 
generate conditioned medium may not have been the most suitable method for sufficient 
generation of recombinant protein.    It was therefore decided at this point to generate a stably 
expressing cell line. 
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Figure 11.  Purification of CCN2 from conditioned medium using a 5ml nickel affinity column.  
Conditioned medium (500ml)  from HeLa cells transfected with 1µg CCN2 DNA was applied to a 5ml nickel 
affinity column previously equilibrated with binding buffer (20mM sodium pyrophosphate, 0.5M sodium chloride, 
20mM imidazole). Protein was eluted using a linear gradient ranging from 20mM-500mM imidazole.  Samples 
were collected in 2.5ml fractions.  Starting material (50µl of 500ml) and fractions (50 µl of 2.5ml) were run on 4-
12% Bis Tris gel and immunblotted with an antibody to CCN2.
 
 
4.12 Stable expression of CCN2 in HEK 293 cells. 
It was clear that transient transfection of HeLa cells would not produce adequate amounts of 
CCN2 for our purpose.  As discussed in section 2.12.6, HEK 293-EBNA cells, a human 
embryonic kidney cell line, were chosen as an alternative to HeLa cells due to their ability to 
induce high levels of plasmid expression as a consequence of the EBNA-1 gene inserted into 
the chromosome.  Selection of EBNA-1 expressing cells was maintained using G418.  Before 
attempting transfection of HEK 293 cells, it was decided to subclone the CCN2 construct from 
the original pcDNA 3.1 vector into a pCEP4 expression vector (Figure 12).  pCEP4 is an 
episomal mammalian expression vector that uses the cytomegalovirus (CMV) immediate early 
enhancer/promoter for  high level transcription of inserted recombinant genes. It also carries an 
Epstein-Barr Virus replication origin (oriP) and EBNA-1 gene, to permit extrachromosomal 
replication.  The presence of the EBNA-1 gene within the HEK 293 cells promotes a higher 
level of episomal expression of the pCEP4 plasmid and therefore it was hoped that expression 
of CCN2 within this vector would increase protein yields.  The CCN2 fragment was cut out of 
the pcDNA 3.1 vector using restriction enzymes and subcloned into the linearised pCEP4 
expression vector. Ligated DNA was then used to transform competent E. coli cells from which 
plasmid DNA was finally purified.  HEK 293 cells were transfected with the purified CCN2-
pCEP4 vector using Lipofectamine 2000; a commonly used method of transfection in this cell 
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line.  Transfected cells were cultured for 24 hours and conditioned medium was immunoblotted 
for CCN2 (Figure 13).  CCN2 was detected only in the conditioned medium of cells transfected 
with the CCN2-pCEP4 vector and not with the empty vector.  The pCEP4 vector carries the 
hygromycin B resistance gene for stable selection in transfected cells.  The stably transfected 
cells were therefore selected for hygromycin B resistance using different concentrations of the 
antibiotic (100, 400 and 800 µg/ml).  Conditioned medium from cells surviving selection was 
immunoblotted for CCN2 to confirm continued expression of the protein (Figure 14). Following 
positive selection, further culture of stably transfected cells was done in the presence of 100 
µg/ml of hygromycin B as this was a sufficient concentration of antibiotic to maintain positive 
selection.   
 
CCN2
CCN2
Figure 12.  Graphical representation of  subcloning of CCN2 construct from pcDNA 3.1 vector into 
pCEP4 vector.  CCN2 construct (provided by Prof. R Mason) was excised. The CCN2 fragment was cut out 
of the pcDNA 3.1 vector using restriction enzymes and subcloned into the pCEP4 expression vector, which 
had previously been linearized and dephosphorylated. Ligations were then used to transform competent E. 
coli cells.  Transformed bacteria were selected on LB-agar plates containing 100 μg/ml ampicillin.  Plasmid 
DNA from several colonies selected at random was prepared and restriction digests performed to identify 
positive clones.  DNA ‘maxiprep’ stocks for pCEP4-CCN2 were then prepared.
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Figure 13.  Transfection of HEK 293 cells  with CCN2-pCEP4 vector.  HEK cells were plated at 150,000 
cells/well and incubated overnight at 37°C.  Cells were transfected with 1µg of CCN2 plasmid DNA or empty 
pCEP4 vector (control) using Lipofectamine 2000.  After 4h, cells were washed twice in 1x PBS and incubated for 
24h with 2ml of medium containing foetal calf serum.  Conditioned medium was harvested and run on 12 % tris
glycine gel and immunoblotted with an antibody to CCN2 (1:500).  
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Figure 14.  Confirmation of stable transfection of HEK 293 cells following selection with hygromycin B.  HEK 
293 cells were transfected as described above. Following successful transfection, cells were positively selected 
using hygromycin B  at different concentrations (100, 400 and 800 µg/ml) for approximately 10-14 days.  Medium 
was replaced every 2-3 days and postiviely selected cells were resuspended and allowed to readhere. After this 
selection period, to confirm positive selection, conditioned medium was harvested and run on 12 % tris glycine gel 
and immunoblotted with an antibody to CCN2 (1:500).  
CCN2
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4.13 Optimisation of conditioning following stable transfection. 
Prior to purification of CCN2 from conditioned medium of stably transfected cells, it was 
important to determine the conditions that would produce maximal release of protein.  It had 
previously been described that the presence of heparin within cultures could increase levels of 
CCN2 released into the culture medium.  Stably transfected cells were cultured to confluency 
and then incubated in the presence of heparin at different concentrations overnight 
(H(50)/H(100)) .  Figure 15 shows that the presence of heparin at either concentration did not 
appear to increase the levels of CCN2 detected in the medium by western blotting, using an 
antibody to both CCN2 and the V5 domain.  This experiment also compared the levels of 
CCN2 within conditioned medium from HeLa cells, used in original purification experiments.  It 
should be noted that HeLa cells were originally seeded at a slightly lower density, however it is 
clear that there is an overwhelming increase in the level of CCN2 expressed from HEK 293 
cells compared to HeLa cells.   
 
The next step was to determine the optimal conditioning period for maximal release of protein 
into the medium.  Cells were again grown to confluency and the medium was conditioned for 
incremental time periods.  It can be seen in figure 16 that there was an accumulation of CCN2 
in the medium as the conditioning time increased.  It did appear that conditioning for longer 
than 24 hours caused a more significant release of lower molecule weight forms of CCN2; that 
may represent processed forms of the protein.  Obviously a shorter conditioning time would 
lead to generation of a larger volume of material more quickly.  Therefore, 24 hours was 
chosen as the preferred conditioning period for the generation of material.  In an attempt to 
give an approximate concentration of CCN2 within the conditioned medium, a preparation of 
recombinant CCN2 (100ng), provided by Professor D Abraham, was loaded onto the gel.  The 
recombinant preparation was barely detectable compared to expected protein levels implying 
high microgram levels of CCN2 in the medium.  We cannot be sure however, that there was 
not degradation of his recombinant preparation. 
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Figure 15.  Comparison of relative amounts of CCN2 within conditioned medium and effect of heparin on 
release from stably transfected cells.  Positively selected HEK 293 cells were grown to confluency in DMEM 
containing 10% FCS, 250 µg/ml G418 and 100 µg/ml hygromycin B.  Cells were plated at 5 x 105 cells/well and 
rested overnight at 37°C.  Cells were then incubated in the presence of heparin at 50 or 100 µg/ml for 24h. 
Conditioned medium was harvested and run alongside the same volume of conditioned medium from transiently 
transfected HeLa cells on a 12 % tris glycine gel and immunoblotted with an antibody to CCN2 (1:500).  
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Figure 16.  Optimisation of conditioning period of medium from stably transfected HEK 293 cells.  Positively 
selected HEK 293 cells were grown to confluency in 15cm3 dishes in DMEM containing 10% FCS, 250 µg/ml G418 
and 100 µg/ml hygromycin B.  Medium was then replaced with 40ml of DMEM containing 250 µg/ml G418 and 
conditioned for different time periods.  Medium was harvested and 50 µl of 40ml was run alongside 100ng of a 
preparation of recombinant CCN2 (provided by Dr D Abraham).  Samples were run on a 12% Tris Glycine gel and 
immunoblotted with an antibody to CCN2.  
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4.14 Purification using nickel affinity chromatography following stable transfection. 
Conditioned medium was generated from stably transfected HEK 293 cells.  In contrast to 
previous purification experiments, conditioned medium was supplemented with 20mM 
imidazole to optimise binding of the His Tag and minimize binding of host non-specific proteins 
to the nickel column.  Conditioned medium (200ml) was filtered and applied to a 5 ml column 
and eluted using a linear gradient of imidazole (20-500mM).   From the chromatographic trace 
(Figure 17A) there appeared to be two significant peaks at fractions 3 and 4.  It should be 
noted that the increase in absorbance seen throughout elution of the column is likely due to 
imidazole itself absorbing at 280 nm.   Following elution, fractions were assayed using an 
antibody to CCN2 (Figure 17B).  To estimate losses following purification, both eluted fractions 
and starting material were loaded in equivalent amounts.  There was strong detection of CCN2 
within the starting material, pre- and post-filtration.  There was detection of a faint band in the 
run-through of the column; this may indicate that the capacity of the column was exceeded.  
However, detection of CCN2, primarily in fraction 3 showed a band of similar intensity to the 
starting material indicating that there were not any significant losses of protein following 
purification.   Again, alongside experimental samples, recombinant CCN2 (100ng) was loaded.  
As before, protein was barely detectable, possibly indicating significant degradation of the 
preparation.  Interestingly, there did not appear to be any protein detected within fraction 4, 
corresponding to the peak seen in the chromatographic trace.  It is possible that this peak may 
represent contamination with proteins that may bind to the nickel column non-specifically.  
However, upon silver staining (Figure 17C), there was no significant detection of proteins within 
this fraction.  Protein could be detected as a relatively strong band in fraction 3 with what 
appeared to be little or no contamination from other proteins.  It should be noted the 
concentration of protein loaded on to the silver stained gel in this experiment was fives time 
less compared with previous purification experiments using nickel affinity chromatography 
(Figure 9).  This indicated a significant increase in the concentration of protein purified.  From 
this point in my thesis, CCN2 generated as a result of the described purification is referred to 
as ‘purified CCN2’.   
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Figure 17.  Purification of CCN2 from conditioned medium from stably transfected HEK 293 cells using a 5ml 
nickel affinity column.  Conditioned medium (200ml)  from stably transfected HEK 293 cells was applied to a 5ml 
nickel affinity column previously equilibrated with binding buffer (20mM sodium pyrophosphate, 0.5M sodium chloride, 
20mM imidazole). Protein was eluted using a linear gradient ranging from 20mM-500mM imidazole.  Samples were 
collected in 2.5ml fractions.  Fractions (0.6 µl or 10 µl of 2.5ml) were run on 4-12% Bis Tris gel and immunblotted with 
an antibody to CCN2 (B) or the gel was silver stained (C) and protein bands cut out and analysed by mass spectrometry.   
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4.15 Purified CCN2 is retained upon dialysis and ultrafiltration. 
As indicated in section 4.10, the preparation of purified CCN2 following elution from the nickel 
affinity column contained approximately 150mM imidazole and 0.5M NaCl.  Therefore, it was 
necessary to remove these contaminating salts prior to use in any biological system.  As 
described, previous methods of de-salting included dialysis or use of a commercially obtained 
de-salting column.  Previous attempts at dialysis were performed against water. It was 
suggested that the dramatic change in salt concentration could be causing a precipitation of the 
protein and explain the demonstrable losses.  Therefore, it was decided to attempt dialysis 
against PBS (1x) as it is isotonic and non-toxic to cells.  Fraction 3, following nickel affinity 
chromatography was dialysed for 16 hours at 4°C against PBS (1x) across a 10kD membrane 
(Figure 18).  Following dialysis, the sample was loaded onto a gel, alongside the pre-dialysed 
material and proteins were visualized by both silver and coomassie staining.  Eluted fraction 3 
from the nickel column was successfully retained upon dialysis (# 3 dialysed) and could be 
concentrated using a 10KDa cut-off ultrafiltration spin-column (#3 dialysed + conc x10).  The 
success of these experiments was most likely a consequence of dialysing against PBS (1x) 
combined with higher concentrations of CCN2 which minimised losses upon dialysis. 
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Figure 18. Purified CCN2 is retained upon dialysis and concentration.  Positive fractions (7.5ml) from three 
separate purification experiments using nickel affinity chromatography were collected, pooled and dialysed overnight at 4 
°C against 1x PBS using a 10KDa cut-off SpectraPor Float-A-Lyzer.  Dialysed material was then concentrated to a 
volume 10 times less than the starting material using a 10kD cut-off ultrafiltration spin-column.  Samples (10 or 20 µl) 
were run on 4-12% Bis Tris gels and either silver or coomassie stained.  
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4.16 Quantification of purified CCN2 following dialysis and ultrafiltration. 
Previous attempts at quantifying purified CCN2, described in section 4.10, involved the 
measurement of absorbance at 280nm.  This is probably not sensitive enough to measure very 
low concentrations.  Although it was hoped that subsequent protein concentrations would be 
higher (following stable transfection), it was decided to take a different approach to quantify 
purified protein.  Gels were stained with colloidal Coomassie Brilliant Blue G-250, which binds 
to proteins through ionic interactions between dye sulfonic acid groups and positive protein 
amine groups as well as through Van der Waals attractions. Quantitative anaylsis was then 
carried out using Phoretix 1-D gel analysis software.  A fixed volume of purified CCN2, dialysed 
and concentrated 10x, was run on a gel alongside known concentrations of a standard protein.  
In the case of Figure 19, IgG was used as a standard.  To confirm protein concentrations, 
further calibrations were performed using BSA as a standard (data not shown).  Figure 19A 
shows the relative intensities of purified CCN2 compared to known concentrations of IgG.  The 
intensities of the bands as determined by pixel volume were then measured using Phoretix 1-D 
software and data was plotted on a graph (Figure 19B and C).  The relative concentration of 
purified CCN2 could then be determined.  As indicated, a volume of 20 µl of purified material 
contained 550ng.  Therefore the concentration of purified CCN2 was quantified at 
approximately 25 µg/ml.  The final yield of protein obtained was 18.75µg from 600ml of 
conditioned medium.   
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Figure 19.  Quanitification of purified CCN2.  Purified material was dialysed and concentrated. Purified material 
(20 µl) was  then loaded onto a 4-12 % Bis Tris gel alongside known concentrations of a standard protein (IgG).  The 
gel was then coomassie stained to visualise proteins.  Bands were quantified using Phoretix 1D (Nonlinear Dynamics 
Ltd, USA) to determine an approximate concentration of purified CCN2.  
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4.17 Thermostability of purified CCN2. 
Before testing biological activity of purified CCN2, it was important to determine the stability of 
the protein to optimise storage and help maintain the concentration of the protein following 
purification. Purified material was dialysed and aliquots were kept at room temperature or 4 C 
overnight, boiled for 10 minutes, or freeze-thawed three times.  Proteins were run on a gel and 
visualized by silver stain (Figure 20).   Purified CCN2 appeared stable at both room 
temperature (R/T o/n) and 4 C (4 C o/n) for at least 16 hours as indicated by relative 
intensities of bands to the control.  Additionally, repeated freeze-thawing (F/T x 3) of the 
purified material did not appear to affect stability.  As expected, boiling caused loss of protein.   
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Figure 20. Thermostability of purified CCN2.  Purified material was dialysed and was then either kept at room 
temperature or 4 °C overnight, boiled for 10min or freeze-thawed 3 times.  Material (10µl) was then run on a 4-
12% Bis Tris gel and the gel silver stained in order to visualise proteins.  
 
4.18 Localisation of purified CCN2 in the PCM of porcine chondrocytes and explants.  
As described in section 3.7.4, endogenous CCN2 was detected in both porcine chondrocytes 
and explants within the PCM.  Following purification of CCN2, I was interested to confirm this 
localisation using the purified protein.  Chondrocytes were isolated and cultured for 48 hours or 
explants were rested overnight.  Both cells and explants were then incubated for a further 48 
hours in the presence or absence of purified CCN2, processed as previously described, prior to 
being immunostained with antibodies to perlecan and the V5 domain of the purified protein.  
Figure 21 shows localisation of purified CCN2 in chondrocytes.  Perlecan showed typical 
pericellular staining in both control cells and cells incubated in the presence of purified CCN2.  
V5 was only detected in cells incubated in the presence of purified CCN2 and appeared to be 
localised to the PCM.  When images were merged there was significant colocalisation with 
perlecan.  A similar result was seen in porcine explants (Figure 22).  In the absence of purified 
CCN2, there was little or no V5 detected.  However, when incubated in the presence of purified 
CCN2, V5 was again localised to the PCM where it colocalised with perlecan. 
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Figure 21.  Immunolocalisation of CCN2 in stimulated isolated chondrocytes. Chondrocytes were isolated from 
porcine articular cartilage using collagenase, seeded at 2 mill cells/well in a 2 well Lab Tek II chamber slide and rested for 
48h at 37°C to allow accumulation of a PCM.  Cells were then stimulated for a further 48h with purified CCN2 (100ng/ml) 
or medium alone (control). The chondrocytes were fixed in methanol, then incubated with primary antibodies to perlecan 
(1:1000) and V5 (1:1000).  The cells were washed and incubated with secondary FITC labelled antibodies and propidium
iodide (PI).  Fluorescence signals were detected using Ultraview confocal microscopy.  
Perlecan  V5 PI                            Merged
Control 
CCN2 
Figure 22.  Immunolocalisation of CCN2 in porcine explants. Porcine articular cartilage was dissected aseptically from 
the metatarso-phalangeal joints of 3-6 month old pigs obtained fresh from a local abattoir within 24 hours.  Explants were 
cultured for 24h in serum free medium and then stiumlated for a further 48h with purified CCN2 (100ng/ml) or medium 
alone (control).   Explants were then snap frozen and 7 µm frozen sections were cut, fixed in methanol and treated for 1-
2h at 37 °C with chondroitanase ABC.  Sections were then incubated with primary antibodies to perlecan (1:1000) and V5 
(1:1000).  The cells were washed and incubated with secondary FITC labelled antibodies and propidium iodide (PI).  
Fluorescence signals were detected using Ultraview confocal microscopy.  
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4.20 Discussion 
CCN2 has been described as having numerous effects on cells including proliferation, 
differentiation, migration, adhesion, apoptosis and induction of matrix molecules.  It was 
decided to generate recombinant protein with the aim of investigating the role of CCN2 in 
articular cartilage.  This chapter describes the expression and purification of CCN2.  
Optimisation of both expression and purification led to the generation of significant quantities of 
purified CCN2. 
 
Initial experiments involved transient transfection of HeLa cells to generate conditioned 
medium containing secreted CCN2, followed by purification using heparin agarose 
chromatography.  Purification to homogeneity was not possible using this method as indicated 
by the number of contaminating proteins which co-purified with CCN2.  I therefore made use of 
the C-terminal His Tag for purification by nickel agarose chromatography.  This high affinity 
method of purification proved highly specific with little or no contamination with other proteins.  
However, although volumes of up to 500 ml of conditioned medium were used, the 
concentration of purified CCN2 was inadequate for use in investigating the role of the protein.  
It was therefore decided to generate a stably expressing cell line using the pCEP4 vector; 
specifically designed for high-level, constitutive expression in mammalian cells.  Expression 
levels of CCN2 from stably transfected HEK 293 cells were significantly higher than from 
transfected HeLa cells.  CCN2 was specifically purified from HEK 293 cell conditioned medium 
using nickel agarose chromatography and identified by mass spectrometry.  Quantification of 
purified CCN2 indicated a concentration of approximately 25 g/ml.  The fact that I was able to 
generate recombinant protein at such concentrations and with relative ease was somewhat 
surprising considering the low commercial availability of CCN2.  However, accounting for 
results presented in the final chapter, it is likely that the lack of commercially available CCN2 
may reflect the difficulties in determining biological activity of the protein rather than successful 
purification. 
 
Data presented in the previous chapter confirmed the presence of CCN2 within the PCM of 
articular cartilage.  The use of purified CCN2 further confirmed this localisation, and 
colocalisation with perlecan, in both porcine chondrocytes and explants.     
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The ultimate objective of this thesis was to investigate the role of CCN2 in articular cartilage.  
Prior to this, it was necessary to confirm that purified CCN2 was biologically active.  As 
discussed, numerous methods have been published to investigate the effect of CCN2.  The 
next and final chapter of the thesis is concerned with investigating the activity of purified CCN2 
with the aim of determining a role in articular cartilage.      
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5.1 Introduction  
CCN2 is a member of the CCN family of matricellular proteins.  Matricellular proteins are ECM 
proteins that are expressed within the matrix, without serving any structural role.  They are 
thought to function by modulating cellular responses through their ability to interact with 
multiple cell-surface receptors, cytokines, growth factors, proteases, and structural proteins 
(Bornstein and Sage, 2002; Yang et al., 2000).  CCN2 has been described as having multiple 
effects on multiple cell types.  It is implicated in several normal physiological processes, 
including embryonic development and differentiation, endochondral ossification and female 
reproductive tract function in the uterus and ovary (Brigstock et al., 1997; Kireeva et al., 1997; 
Shimo et al., 1999; Wandji et al., 2000).   
 
5.1.1 Function of CCN2 in fibrotic disease 
Many effects of CCN2 are described in the context of the pathogenesis of fibrotic conditions. 
Fibrotic diseases are characterized by excessive production and deposition of collagen (Leask 
and Abraham, 2004). CCN2 is constitutively overexpressed in fibrotic lesions such as in 
scleroderma (Igarashi et al., 1996), atherosclerosis (Oemar et al., 1997), liver (Paradis et al., 
1999), kidney (Ito et al., 1998), lung (Allen et al., 1999), and pancreas (di Mola et al., 2002).  
CCN2 is often described as being a mediator of the downstream effects of TGF-β; which itself 
is considered a central mediator of the fibrotic response (Grotendorst, 1997).  Studies on cells 
such as dermal, renal, gingival and kidney fibroblasts have variously shown effects on 
proliferation and production of extracellular matrix molecules including type I, III and IV 
collagen, and fibronectin, and α5 integrin (Frazier et al., 1996; Gore-Hyer et al., 2002; Heng et 
al., 2006; Lam et al., 2003; Qi et al., 2005).  The majority of these studies were done in vitro, 
using recombinant preparations of CCN2, and some effects were only seen in the presence of 
additional factors such as high glucose or Insulin-Transferrin-Sodium Selenite supplement 
(ITS) (Gore-Hyer et al., 2002; Lam et al., 2003).   
 
A number of studies have investigated the role of CCN2 in mesangial cells, in the context of 
diabetic nephropathy; a progressive kidney disease caused by angiopathy of capillaries in the 
kidney glomeruli.  CCN2 has been shown to promote proliferation and migration of these cells 
as well as inducing their expression of collagen, fibronectin, fibronectin receptor and integrin 
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α5β1 (Crean et al., 2002; Crean et al., 2004; Gore-Hyer et al., 2002; Wahab et al., 2001b; 
Weston et al., 2003).   
 
Studies on CCN2 in smooth muscle have shown that its expression is up to a 100 times greater 
in atherosclerotic blood vessels compared with normal arteries (Oemar et al., 1997).  CCN2 
has been shown to induce both apoptosis and caspase-3 activity in human vascular smooth 
muscle cells (Hishikawa et al., 2000; Hishikawa et al., 1999)  and proliferation, migration and 
expression of MMP-2, type I collagen and fibronectin in rat aortic smooth muscle cells (Fan and 
Karnovsky, 2002; Fan et al., 2000).   
 
5.1.2 The role of CCN2 in signalling 
CCN2 has also been shown to induce phosphorylation of a number of signalling molecules 
including ERK1/2, JNK, ATF2, PKB, SMAD2/3, MKP-1 and Bcl-2 as well as inhibit SMAD7 
phosphorylation (Wahab et al., 2007; Wahab et al., 2005a; Wahab et al., 2005b).  Again, the 
majority of these experiments were done in vitro using recombinant CCN2 protein.  The exact 
mechanism by which CCN2 signals is unclear.  Binding of CCN2 to LRP has been shown to 
result in signalling in myofibroblasts, and direct transport of CCN2 to the nucleus in both 
mesangial and HCS-2/8 cells (Kawata et al., 2006; Wahab et al., 2001a; Yang et al., 2004). In 
addition to binding LRP, CCN2 has also been implicated in the phosphorylation of the 
neurotrophin receptor TrkA, in human mesangial cells. Inhibiton of this receptor inhibited 
CCN2-induced activation of a number of signalling pathways including ERK1/2, JNK and PKB 
(Wahab et al., 2005a). 
 
5.1.3 The role of CCN2 as a cofactor 
Although, the majority of studies investigating the role of CCN2 have focussed on the direct 
action of CCN2 itself, there is a section of the literature that suggests CCN2 acts as a 
modulator of, or co-factor for, other cell signalling molecules.   Abreu et al (2002) showed that 
CCN2 was able to bind to bone morphogenetic protein-4 (BMP-4) and inhibit phosphorylation 
of SMAD1 by inhibiting binding of BMP-4 to its receptor.  The same paper also showed that 
CCN2 was able to potentiate both binding of TGF-β to its receptor and phosphorylation of 
SMAD2.  As mentioned, CCN2 is described as being a down-stream mediator of the effects of 
TGF-β.  A number of studies have shown that blocking the action of CCN2, either by anti-
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CCN2 antibodies, siRNA, or antisense oligonucleotides leads to antagonism of TGF-β effects.  
For example, Kothapallii, et al (1998) showed that while CCN2 alone was unable to mimic 
TGF-β induction of anchorage-independent growth (AIG) on NRK cells, both CCN2 specific 
antibodies and antisense CCN2 were able to inhibit TGF-β induced AIG.  This inhibition was 
reversed when cells were co-stimulated with both CCN2 and TGF-β (Kothapalli et al., 1997).  
CCN2 has also been implicated as a cofactor for both EGF and IGF-2.  Grentendorst et al 
(2004) showed that CCN2, although not active alone, was able to promote the mitogenic 
effects of EGF and the induction of collagen and α-SMA by IGF-2 in NRK cells (Grotendorst et 
al., 2004).  Song et al (2007) (Song et al., 2007) showed that the effects of TGF-β on 
mesenchymal cell condensation could be inhibited by silencing CCN2 expression with either 
siRNA or antisense oligonucleotides.  These studies indicate further a role in either modulating 
or enhancing other growth factor activity, without having a direct effect.  CCN2 has also been 
implicated in modulating Wnt signalling.  Studies on Xenopus embryos have shown that CCN2 
is able to inhibit Wnt signalling through binding to the Wnt-receptor complex, in particular 
through binding to LRP6 (Mercurio et al., 2004). 
 
5.1.4 The role of CCN2 in cartilage 
With regards to the role of CCN2 in cartilage, the majority of studies have been concerned with 
development.  CCN2 -/- mice die within a few days of birth due to severe skeletal dysmorphisms 
including defects within the axial skeleton, shortening of the sterna, deformation of limb 
cartilage and deformation of the craniofacial skeleton. These defects are likely to be due to 
impaired chondrocyte proliferation and extracellular matrix composition within the hypertrophic 
zone (Ivkovic et al., 2003).  Expression of ECM components including aggrecan and link 
protein, and the matrix metalloproteinase MMP-9, are reduced in the growth plate of mutant 
mice; leading to defects in matrix remodelling.  CCN2 -/- mice also show reduced levels of 
VEGF in hypertrophic cartilage, suggesting that CCN2 may also play a role in angiogenesis at 
the growth plate (Ivkovic et al., 2003).  An in vitro study on rabbit growth plate chondrocytes 
showed that CCN2 is able to stimulate proliferation and differentiation of these cells. (Nishida et 
al., 2002) A recent study investigating the role of CCN2 in endochondral ossification suggests 
that CCN2 is able to regulate the proliferation and differentiation of chondrocytes by forming a 
complex with BMP-2 and acting as a modulator of BMP signalling (Maeda et al., 2009). 
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The role of CCN2 in articular cartilage remains unclear due to limited research and conflicting 
reports of the effects of CCN2 on mature cartilage.  Treatment of rabbit articular chondrocytes 
in vitro has been suggested to stimulate gene expression of type II collagen and aggrecan, 
suggesting that CCN2 may be useful for repair of articular cartilage (Nishida et al., 2002). 
However, it is fair to say that these results are not altogether convincing.  Other reports 
investigating the effects of overexpression of CCN2 in mouse knee joints have shown 
increased expression of MMP-3, MMP-13, TIMP-1, ADAMTS-4 and ADAMTS-5 mRNA, and 
increased proteoglycan depletion (Blaney Davidson et al., 2006).  This would imply that CCN2 
has a role in cartilage degeneration.  Whether CCN2 has a protective or degenerative effect on 
articular cartilage remains unclear; thus making it an important area of investigation.  
 
Having successfully purified a substantial amount of CCN2, it was first necessary to confirm 
that the protein was biologically active, before investigating a role in articular cartilage.   
As indicated, a wide variety of assays have been used to investigate CCN2 activity. From the 
literature, it was difficult to identify a specific, or definitive, assay that would confirm biological 
activity.  Therefore, a number of assays were employed to investigate the activity of purified 
CCN2.  
 
5.2 Purified CCN2 did not cause MAPK phosphorylation in porcine chondrocytes. 
As discussed, CCN2 has been shown to cause cellular phosphorylation of a number of 
signalling molecules including mitogen activated protein kinases (MAPKs).  These include; both 
p38 and ERK1/2 in a human epithelial cell line (Nagai et al., 2008), ERK1/2, p38 and JNK in rat 
neonatal cardiomyocytes (Hayata et al., 2008) and JNK, ERK1/2, but not p38 in mesangial 
cells (Wahab et al., 2007).  Kubota et al, (2006) showed that recombinant CCN2 was able to 
induce phosphorylation of JNK, ERK and p38 in the human chondrosarcoma cell line, HCS-2/8 
(Kubota et al., 2006).  Phosphorylation of ERK and p38 in HCS-2/8 cells was also shown by 
Yoshimichi et al, (2001) (Yosimichi et al., 2001). While looking at the combinational effects of 
CCN2 and BMP2, Maeda et al, (2009) showed phosphorylation of both p38 and ERK in 
primary chondrocytes isolated from the ventral half of the rib cages of E18.5 mouse embryos 
(Maeda et al., 2009).  Methods for investigating MAPK activation in primary porcine 
chondrocytes have been well characterised within our laboratory (Vincent et al., 2002; Vincent 
et al., 2004).  Evidence in the literature suggested it was reasonable to investigate the effect of 
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purified CCN2 on MAPK in porcine chondrocytes.  FGF-2 has been previously shown to cause 
phosphorylation of both ERK1/2 and p38 in porcine chondrocytes so was used as a positive 
control (Vincent, 2002; Vincent et al., 2004).  In the first instance, porcine chondrocytes were 
stimulated for 20 minutes with FGF-2 (100ng/ml) and purified CCN2 at both 50 and 100ng/ml 
(Figure 1A).  FGF-2 caused a typically strong activation of ERK1/2 as detected with a phospho-
specific antibody.  There did not appear to be any effect with 50ng/ml of CCN2, however there 
was possibly a weak effect with 100ng/ml.  Porcine chondrocytes were therefore stimulated 
with 400ng/ml of purified CCN2 (Figure 1B).  Again, FGF-2 showed a strong ERK1/2 activation, 
however there was no effect using purified CCN2 at a high concentration.  In addition to 
ERK1/2, phosphorylation of p38 was also investigated.  The membrane was stripped and 
reprobed with an antibody to phosphorylated p38 (Figure 1B, panel 2).  As expected, FGF-2 
caused phosphorylation of p38.  However, purifed CCN2 at 400ng/ml was unable to induce 
phosphorylation above the control (unstimulated cells).  In both cases, an antibody to total-
ERK1/2 was used as a loading control. 
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Figure 1.  Purified CCN2 does not activate MAPK in isolated porcine chondrocytes. Chondrocytes  were isolated from 
porcine articular cartilage using collagenase.  Cells (1 x 106/well of a 24 well plate) were rested overnight, serum starved for 4h 
and stimulated for 20mins with either FGF (100ng/ml) or CCN2 (50, 100 or 400ng/ml).  Cell lysates were then immunoblotted
with antibodies to phosphorylated ERK, phosphorylated p-38, or total ERK as a loading control.   
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5.3 Purified CCN2 did not affect protein expression in porcine chondrocytes. 
CCN2 has been reported to affect the expression of a number of matrix proteins including 
collagen type I and II, fibronectin, and aggrecan, as well as molecules involved in matrix 
remodelling including MMP-1, MMP-2, MMP-3, and TIMP-1 (Blaney Davidson et al., 2006; 
Chen et al., 2001; Fan and Karnovsky, 2002; Frazier et al., 1996; McLennan et al., 2004).  In 
the context of the role of CCN2 in cartilage, overexpression of CCN2 in the synovial lining of 
mouse knee joints led to an increase in expression of MMP-3, MMP-13, ADAMTS-4 and 5, and 
TIMP-1 (Blaney Davidson et al., 2006).  Metabolic labelling with 35S [Met/Cys] of porcine 
chondrocytes is an established method for investigating protein expression within our 
laboratory.  The expression patterns following stimulation of chondrocytes with both 
inflammatory cytokines and growth factors have previously been characterised by mass 
spectrometry for identification of proteins (Vincent et al., 2002).  Both IL-1 and FGF-2 have 
induced expression of a number of proteins such as type II collagen pro-peptide, MMP-3, 
MMP-1 and TIMP-1 (Vincent et al., 2004).  Therefore it was decided to investigate whether 
stimulation of porcine chondrocytes with purified CCN2 would reveal changes in the expression 
pattern.  Chondrocytes were stimulated with FGF-2, as a positive control, and purified CCN2 at 
100 and 400ng/ml (Figure 2).  As previously identified by mass spectrometry, FGF-2 induced 
the secretion of both MMP-1 and TIMP-1.  Neither concentration of CCN2 appeared to show 
any difference in the pattern of protein expression compared to the control (unstimulated cells).   
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Figure 2  Chondrocyte protein expression following stimulation with purified CCN2 is not similar to FGF-2. 
Isolated chondrocytes (1million cells per treatment)  were serum-starved for 2 hours , then stimulated for 16h with 
either FGF-2 (100ng/ml) or purified CCN2 (100 or 400ng/ml). Following the stimulation period the cells were 
pulsed for 6h with 15μCi/well radiolabelled [methionine/cysteine] in methionine/cysteine-free medium. Cell media 
were resolved on 4-12% Bis Tris gel, the gel was silver-stained and dried. Radiolabelled bands were visualized by 
autoradiography.  
 
 
5.4 Purified CCN2 does not affect Wnt signalling in porcine chondrocytes. 
Another proposed effect of CCN2 is in the modulation of Wnt signalling. Constitutive 
expression of CCN2 in murine C3H10T1/2 multipotential mesenchymal cells inhibited Wnt3A 
induced osteoblast differentiation, suggesting a role in the transduction of Wnt3A signalling 
(Luo et al., 2004).  Overexpression of CCN2 was shown to inhibit Xwnt8 induction of secondary 
axes in Xenopus embryos.  This modulation of canonical Wnt signalling was attributed to the 
ability of CCN2 to bind to both LRP6 and Frizzled8; both members of the Wnt signalling 
complex (Mercurio et al., 2004).  Overexpression of CCN2 in murine bone marrow stromal cells 
caused a decrease in Wnt-3A-induced accumulation of β-catenin (Smerdel-Ramoya et al., 
2008a).  Interestingly, heparin has been shown to activate Wnt-signalling in two in vitro 
neuronal models, implicating a role for HSPGs in regulating Wnt signalling in the nervous 
system (Colombres et al., 2008).  The ability of CCN2 to bind HSPGs has previously been 
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discussed. It could be hypothesised that another mechanism by which CCN2 modulates Wnt 
signalling is through binding to HSPGs.   
Wnt signalling regulates a variety of biological processes including embryonic development, 
body patterning, tissue morphogenesis, and tumorigenesis.  There are two classes of Wnt 
ligands; the Wnt-1 class (for example Wnt-1, -3A, -7A, and 8), which activates the canonical 
Wnt pathway; and the Wnt-5 class (for example Wnt-5A, -4 and -11), which activates the 
noncanonical pathway.  In the canonical Wnt pathway, Wnt ligands bind to transmembrane 
receptors of the Frizzled family and the co-receptor lipoprotein-related proteins 5 and 6 (LRP-
5/6).  This causes phosphorylation of Dishevelled (Dvl), which in turn causes inhibition of 
glycogen synthase kinase (GSK)-3β.  In the absence of Wnt signalling GSK-3β is involved in 
phosphorylating β-catenin, resulting in proteasomal degradation.  Inhibition of GSK-3β upon 
Wnt signalling leads to an accumulation of β-catenin in the cytosol which travels to the nucleus 
where it acts as a co-activator with Tcf/Lef transcription factors.  Transcriptional activity 
regulates the expression of a number of target genes including MMPs (Clevers, 2006). 
Noncanonical Wnt signalling does not require LRP-5 and LRP-6 and acts via a β-catenin 
independent mechanism that increases intracellular Ca2+ concentrations or controls cell polarity 
by activation of Rho GTPases.  (Montcouquiol et al., 2006).  The role of Wnt signalling in 
chondrogenesis and cartilage development has been well studied. Wnt signalling components 
have been shown to both positively and negatively regulate chondrogenesis, as well as 
maturation and differentiation of hypertrophic chondrocytes (Chun et al., 2008). The role of Wnt 
signalling in articular cartilage, or specifically cartilage degeneration is less understood. A 
number of Wnt signalling components have been identified as being upregulated in OA 
chondrocytes including known antagonists of Wnt signalling FrzB-2 and FrzB-3, and the Wnt 
ligands Wnt-7A and Wnt-16 (Dell'accio et al., 2008; James et al., 2000; Loughlin et al., 2004; 
Nakamura et al., 2005). Additionally β-catenin has been shown to accumulate following 
cartilage injury (Dell'accio et al., 2008) and in OA cartilage (Kim et al., 2002) and inhibiting β-
catenin degradation led to cessation of cartilage-specific ECM molecule synthesis (Ryu et al., 
2002).  Accumulation of β-catenin has been shown to induce expression of COX-2, an 
important enzyme in inflammatory responses (Kim et al., 2002).  Both Wnt-3A -5A and- 7A 
have been shown to suppress type II collagen expression in chondrocytes, possibly due to a 
decrease in expression of the transcription factor Sox-9 (Hwang et al., 2004; Hwang et al., 
2005; Ryu and Chun, 2006).  It is possible that CCN2 acts to regulate Wnt induced 
degeneration of cartilage in OA.   
 Chapter 5                                Investigating the function of purified CCN2      
 
166 
 
It was decided to investigate the ability of CCN2 to inhibit Wnt signalling in porcine 
chondrocytes.  Porcine chondrocytes were stimulated with Wnt-3A, in the presence of absence 
of purified CCN2. Activation of Wnt signalling was determined by the detection of β-catenin in 
cell lysates (Figure 3).  It can be seen that Wnt-3A induced β-catenin stabilization, whereas 
CCN2 alone did not appear to induce β-catenin above the control.  Co-stimulation with CCN2 
did not appear to show any inhibiton of Wnt-3A induced β-catenin.  It is fair to say that the 
concentration of Wnt-3A used in this experiment was high.  As a consequence, it may be 
possible that any inhibitory effect of CCN2 was not significant enough to be detected.  
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Figure 3. Purified CCN2 does not inhibit wnt signalling in porcine articular chondrocytes. Porcine 
chondrocytes were isolated from porcine articular cartilage using collagenase.  Cells (1 x 106/well of a 24 well plate)  
were rested overnight, serum starved for 16h and stimulated for 5h with either wnt3A (250ng/ml) or CCN2 (200ng/ml) 
alone, or in combination.  Cell lystates were immunoblotted for β-catenin.
 
5.5 Purified CCN2 alone had no effect on gene expression in human dermal fibroblasts 
In an attempt to investigate further the biological activity of purified CCN2, I initially focussed on 
the effect of CCN2 on gene expression in fibroblasts.  CCN2 has been implicated in the 
pathogenesis of many fibrotic conditions. The majority of work looking at the effect of CCN2 in 
dermal fibroblasts has been done in the context of scleroderma and therefore has focussed on 
sclerodermal fibroblasts.  However, experiments performed specifically on normal human 
dermal fibroblasts have shown that recombinant CCN2 increases expression of both type I 
collagen and fibronectin (Shi-wen et al., 2000; Twigg et al., 2002).  TGF-β is known to be a 
potent inducer of matrix genes in fibroblasts, including both type I collagen and fibronectin 
(Ignotz and Massague, 1986; Raghow et al., 1987).  If as described, CCN2 acts as a 
downstream mediator of TGF- β, it could be hypothesised that direct stimulation with CCN2 
would result in a similar increase in gene expression. Figure 4 shows the effect on gene 
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expression by purified CCN2 in normal human dermal fibroblasts.    Using quantitative real-time 
PCR, levels of mRNA expression of type I collagen and fibronectin were measured relative to 
the housekeeping gene, GAPDH.  TGF-β3 induced a three-fold change in type I collagen 
expression and a seven-fold change in fibronectin expression, relative to the control 
(unstimulated cells).  However, purified CCN2 did not appear to increase either type I collagen 
or fibronectin expression, above the control.  This result would suggest that purified CCN2 was 
not exhibiting biological activity.  However, TGF-β is a potent inducer of CCN2 itself and CCN2 
is described as being a downstream-mediator of TGF-β activity in fibroblasts (Gore-Hyer et al., 
2002; Grotendorst, 1997; Leask and Abraham, 2003; Leask and Abraham, 2004).  This raised 
the question as to whether TGF-β signalling, upstream of CCN2 expression, was in fact 
required for CCN2 to demonstrate an effect.  This will be addressed further later in this chapter.   
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Figure 4. Purified CCN2 alone has no effect on matrix gene expression in human dermal fibroblasts.  
Normal human dermal fibroblasts were seeded at a density of 1.8 x 105 cells/well and rested for 24h. Cells were the 
serum starved overnight and stimulated for a further 24h with TGF-β3 (5ng/ml) or purified CCN2 (100ng/ml).  Total 
RNA was extracted and expression of type I collagen and fibronectin was obtained by real-time PCR.  All genes 
were normalized to GAPDH, calibrated to mRNA from control (unstimulated) cells and expressed as fold change. 
Results shown are the mean values for three experiments, (with one sample per experiment); the error bars 
represent the standard error of the mean. 
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5.6 Purified CCN2 alone had no effect on gene expression in murine mesenchymal stem 
cells.  
Another role proposed for CCN2 is in condensation of a mesenchymal stem cell line. Song et 
al, (2007) showed that silencing of CCN2 expression in C3H10T1/2 cells, using both siRNA 
and antisense nucleotides, was able to inhibit the effects of TGF-β on MSC condensation as 
determined by a reverse in the downregulation of Sox-9, and upregulation of fibronectin mRNA 
expression. (Song et al., 2007). It was hypothesised that direct stimulation with purified CCN2 
would mimic those effects seen with TGF-β.  Murine mesenchymal stem cells have previously 
been prepared in our laboratory for study of cell markers (Vaghjiani et al., 2009).  In the 
absence of C3H10T1/2 cells, a murine mesenchymal stem cell clone previously isolated was 
used.  As described in Song et al, murine MSCs were cultured using a micromass culture 
system, commonly used for induction of chondrogenesis.  Cells were then stimulated for 48 
hours with TGF-β3 or purified CCN2 alone.  Quantitative real-time PCR was used to measure 
expression of Sox-9 and type I collagen mRNA, relative to GAPDH.  It should be noted that 
Song et al, 2007 described an upregulation of type I collagen following stimulation with TGF-β.  
It can be seen in Figure 5 that TGF-β resulted in a 75% decrease in Sox-9 mRNA expression 
relative to the control, in accordance with that previously seen.  Purified CCN2 alone did not 
appear to have a significant effect on Sox-9 mRNA, although expression was decreased by 
approximately 25%.  In contrast to reported effects on type I collagen, stimulation with TGF-β 
resulted in a 50% decrease in mRNA expression.  Purified CCN2 alone had no significant 
effect on type I collagen expression.  The effect of TGF-β on type I collagen expression is 
difficult to explain.  Differentiation of mesenchymal stem cells into a chondrocytic lineage is 
thought to be preceded by prechondrogenic condensation whereby mesenchymal stem cells 
aggregate before initiating cartilage matrix deposition (Kosher et al., 1986).  Prechondrogenic 
mesenchymal cells have been shown to synthesise type I collagen.  As chondrogenic 
differentiation occurs, there is an initiation in the synthesis of cartilage-characteristic type II 
collagen and cessation of type I collagen synthesis (von der Mark, 1980).  The expression 
patterns of the transcription factor Sox-9, implicate a role during the very early stages of 
chondrogenesis, although it is not clear whether Sox-9 is specifically involved in 
prechondrogenic condensation (Wright et al., 1995).  The main role proposed for Sox-9 is in 
the induction of type II collagen (Col21A), with the expression of Sox-9 slightly preceding that 
of Col21A (Lefebvre and de Crombrugghe, 1998).  It is likely that timing is critical in expression 
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of genes involved in both condensation and subsequent differentiation events.  It is possible 
that the decrease in type I collagen expression occurs earlier than the indicated 48 hour time 
point and is sustained up to and beyond this point.  The decrease in Sox-9 expression seen at 
48 hours may precede a subsequent increase in Sox-9, and type II collagen expression.  
Alternatively induction of Sox-9 may also occur earlier than 48 hours, followed by a subsequent 
decrease in expression, as demonstrated.  It is also possibly that the culture system used 
influences the effect on gene expression.  It has been shown that treatment of human 
mesenchymal stem cells cultured in monolayer, with recombinant CCN2, led to an increase in 
type I collagen expression (Lee et al., 2006).  The expression of type II collagen was not 
investigated in the context of this experiment; however it is possible that the expression pattern 
of type II collagen may further shed light on the temporal sequence of gene expression. 
 
As discussed, inhibiting expression of TGF-β induced CCN2 was shown to inhibit gene 
expression in a murine mesenchymal stem cell line (Song et al., 2007).  Therefore the effects 
seen with TGF-β may represent direct downstream effects of CCN2.  However, the fact that 
purified CCN2 alone did not have any significant effect on gene expression in murine MSCs 
either suggested the protein was inactive, or again raised the question as to whether the 
presence of, or specific signalling via TGF-β was necessary for purified CCN2 to exhibit an 
effect. 
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Figure 5. Purified CCN2 alone has no effect on matrix gene expression in murine mesenchymal cells.  
Murine mesenchymal cells were seeded in micromass cultures at a density of 2 x 105 cells/well and stimulated 
for 48h  with TGF-β3 (5ng/ml) or purified CCN2 (100ng/ml).  Total RNA was extracted and expression of sox -9 
type I collagen was obtained by real-time PCR.  All genes were normalized to GAPDH, calibrated to mRNA 
from control (unstimulated) cells and expressed as fold change. Results shown are the mean values for three 
experiments, (with one sample per experiment); the error bars represent the standard error of the mean. 
 
 
5.7 Purified CCN2 did not exhibit any effect when used in combination with a high 
concentration of TGF-β. 
To investigate whether the presence of TGF-β was required for purified CCN2 to exhibit any 
effect, normal human dermal fibroblasts were stimulated with purified CCN2 in combination 
with TGF-β3 in a preliminary experiment.  As before, the effect on gene expression of type I 
collagen and fibronectin was measured. In addition, gene expression of CCN2, which is known 
to be upregulated by TGF-β and CCN2 itself in fibroblasts, was also measured (Abraham et al., 
2000; Twigg et al., 2002).  As expected, TGF-β alone increased expression of all three genes, 
with CCN2 being upregulated most significantly (Figure 6).  The combination of TGF-β with 
purified CCN2 at 10, 50 or 100ng/ml did not result in any significant change in relative gene 
expression compared to TGF-β alone.  This could be interpreted as lack of activity by purified 
CCN2.  However, TGF-β alone at 5ng/ml most likely reflected a maximal response by TGF-β 
and therefore may have masked any changes induced by addition of purified CCN2. 
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Figure 6. Purified CCN2 does not  affect gene expression induced by a high concentration of TGF-β
in normal human dermal fibroblasts.  Normal human dermal fibroblasts were seeded at a density of 1.8 x 
105 cells/well and rested for 24h. Cells were then serum starved overnight and stimulated for a further 24h 
with TGF-β3 (5 ng/ml) alone or in the presence of CCN2 (10, 50 or 100ng/ml).  Total RNA was extracted 
and expression of CCN2, type I collagen and fibronectin was obtained by real -time PCR.  All genes were 
normalized to GAPDH, calibrated to mRNA from control (unstimulated) cells and expressed as fold change.  
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5. 8 Purified CCN2 potentiates the effect of TGF-β in normal human dermal fibroblasts. 
To determine whether purified CCN2 exhibited activity in the presence of TGF-β at a minimal 
dose, it was first necessary to determine the lowest dose necessary to demonstrate a TGF-β 
effect.  Figure 7 shows a dose dependent effect of TGF-β on gene expression of CCN2, type I 
collagen and fibronectin.  As before, TGF-β at a concentration of 5ng/ml showed an increase in 
CCN2 expression by approximately 30 fold, with a 2.5 and 6 fold increase in type I collagen 
and fibronectin respectively.  From these results, it was decided that a good suboptimal dose 
was between 0.1 and 0.5ng/ml of TGF-β. 
 
Normal human dermal fibroblasts were stimulated with TGF-β at a concentration of 0.2ng/ml 
alone or in the presence of purified CCN2 (Figure 8).  As before, TGF-β at 0.2ng/ml produced a 
minimal response which in the presence of purified CCN2 appeared to be slightly upregulated 
for all three genes.  The increase in expression of CCN2 mRNA was not statistically significant, 
although the changes in type I collagen and fibronectin were.  Such a small potentiation of 
TGF-β induced gene expression did not confirm with any certainty biological act ivity of purified 
CCN2.  It was possible that a higher concentration of purified CCN2 would induce a more 
significant potentiation.  It was also possible that the effect of adding purified CCN2 was limited 
due to the presence of high levels of endogenously secreted CCN2.  This will be addressed 
further later within this chapter.  
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Figure 7. TGF-β3 has a dose dependent effect on gene expression in human dermal fibroblasts.  Normal 
human dermal fibroblasts were seeded at a density of 1.8 x 105 cells/well and rested for 24h. Cells were then 
serum starved overnight and stimulated for a further 24h with TGF-β3 (0.1, 0.5, 1 or  5 ng/ml).  Total RNA was 
extracted and expression of CCN2, type I collagen and fibronectin was obtained by real-time PCR.  All genes were 
normalized to GAPDH, calibrated to mRNA from control (unstimulated) cells and expressed as fold change. Each 
bar represent the mean values for two experiments, with one sample per experiment. 
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Figure 8. Purified CCN2 potentiates the effect of TGF-β on gene expression in fibroblasts.  Normal human 
dermal fibroblasts were seeded at a density of 1.8 x 105 cells/well and rested for 24h. Cells were then serum starved 
overnight and stimulated for a further 24h with TGF-β3 (0.2 ng/ml) and CCN2 (25ng/ml) alone, or in combination.  
Total RNA was extracted and expression of CCN2, type I collagen and fibronectin was obtained by real-time PCR.  
All genes were normalized to GAPDH, calibrated to mRNA from control (unstimulated) cells and expressed as fold 
change. Results shown are the mean values for three experiments (with one sample per experiment); the error bars 
represent the standard error of the mean. Significance was calculated using a one way ANOVA test followed by 
Bonferroni’s multiple comparison test. ns= p value of >0.05 (not significant), *= p ≤ 0.05 (significant), **= p ≤ (very 
significant), ***= p ≤ 0.001 (extremely significant).   
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5.9 Purified CCN2 potentiates the effect of TGF-β in mesenchymal stem cells. 
Purified CCN2 alone did not appear to have any significant effect on gene expression in murine 
MSCs.  In an attempt to confirm the potentiation seen in fibroblasts, the effect of TGF-β in 
combination with purified CCN2 on MSCs was investigated.  As with fibroblasts, it was first 
necessary to determine the minimal concentration of TGF-β required to demonstrate an effect 
on gene expression.  TGF-β induced a dose dependent effect on gene expression of CCN2, 
Sox-9 and type I collagen (Figure 9 ).  As demonstrated in fibroblasts, the minimal dose of 
TGF-β required to change gene expression appeared to be somewhere between 0.1 and 
0.5ng/ml.   
 
The effect on gene expression following stimulation of murine MSCs with TGF-β at 0.2ng/ml 
alone or in the presence of purified CCN2 was investigated (Figure 10).   In the case of CCN2 
mRNA expression, TGF-β alone showed a minimal effect.  This was approximately doubled in 
the presence of purified CCN2.  Sox-9 mRNA expression was suppressed to 50% of control, in 
the presence of low concentration TGF-β.  However, this suppression was potentiated to 25% 
of control in the presence of purified CCN2.  Type I collagen mRNA expression was 
suppressed from 75% to 25% of control in the presence of TGF-β and purified CCN2.  The 
changes in gene expression seen with the combination of both TGF-β and CCN2 were shown 
to be statistically significant for all three genes.  In comparison with results shown in fibroblasts, 
the effect on murine MSCs was certainly more convincing. In fact, this result was the first to 
imply with any certainty that purified CCN2 was biologically active and showed that the effect 
on gene expression in murine MSCs at least, was dependent on the presence of TGF-β.   
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Figure 9. TGF-β3 has a dose dependent effect on gene expression in murine mesenchymal cells. Murine 
MSCs were seeded in micromass culture at a density of 2 x 105 cells/well and stimulated for 48h with TGF-β3 (0.1, 
0.5, 1 or  5 ng/ml).  Total RNA was extracted and expression of CCN2, sox-9 and type I collagen was obtained by 
real-time PCR.  All genes were normalized to GAPDH, calibrated to mRNA from control (unstimulated) cells and 
expressed as fold change. Results shown are the mean values for two experiments, with one sample per 
experiment. 
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Figure 10. Purified CCN2 potentiates the effect of TGF-β on gene expression in murine mesenchymal cells. 
Murine MSCs were seeded in micromass culture at a density of 2 x 105 cells/well and stimulated for 48h with TGF-
β3 (0.2 ng/ml) and CCN2 (100 ng/ml) alone, or in combination.  Total RNA was extracted and expression of CCN2,  
sox-9 and type I collagen was obtained by real-time PCR.  All genes were normalized to GAPDH, calibrated to 
mRNA from control (unstimulated) cells and expressed as fold change. Results shown are the mean values for four 
experiments (with one sample per experiment); the error bars represent the standard error of the mean. Significance 
was calculated using a one way ANOVA test followed by Bonferroni’s multiple comparison test. (** =p≤ 0.01). n=4  
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5.10 Purified CCN2 inhibits TGF-β induced expression of Sox-9 protein in mesenchymal 
stem cells.   
To confirm further the effect seen on gene expression using a TGF-β and purified CCN2 in 
combination, I investigated the corresponding Sox-9 protein expression.  Murine MSCs were 
stimulated as in the previous experiment.  Figure 11 shows detection of Sox-9 protein within 
cell lysates.  Stimulation of murine MSCs with TGF-β appeared to induce expression of Sox-9 
protein above the control (Figure 11(TGF-β)).  The combination of TGF-β and purified CCN2 
led to a decrease in expression of Sox-9 compared withTGF-β alone.  This result would appear 
to conflict with corresponding Sox-9 mRNA levels although it is possible that once again, the 
temporal sequence of events in these mesenchymal micromass cultures is critical; not only the 
sequence of mRNA changes over time, but also the relationship between mRNA and protein 
levels.  At the very least we are able to conclude that CCN2 is modifying TGF-β activity. 
 
64
36
50
C
   
 
Sox-9
ERK
Stimulus T
G
F
   
 
T
G
F
/C
C
N
2 
   
C
C
N
2 
   
Figure 11. Purified CCN2 inhibits TGF-β induction of sox-9 protein at 48 hours.  Murine MSCs were seeded 
in micromass culture at a density of 2 x 105 cells/well and stimulated for 48h with TGF-β3 (0.2ng/ml)  andCCN2 
(100ng/ml) alone, or in combination or left unstimulated (C). Cell lysates were then immunoblotted for sox-9 and 
Total-ERK as a loading control.  Result shown is a represenative result from two separate experiments. 
 
 
 
 
 
 
 Chapter 5                                Investigating the function of purified CCN2      
 
179 
 
5.11 Purified CCN2 potentiates TGF-β phosphorylation of SMAD-2 in mesenchymal stem 
cells. 
CCN2 has been claimed to activate a number of signalling molecules including SMAD proteins. 
SMADs are essential in the transduction of intracellular signals downstream of TGF-β 
superfamily ligands.  Binding of TGF-β superfamily members to cognate transmembrane 
receptor kinases leads to activation of SMADs.  SMADs are able to transduce the signal from 
the membrane, in addition to directly regulating gene expression (Schmierer and Hill, 2007).  
TGF-β specifically phosphorylates SMAD-2 and -3 which then form a heterodimer with SMAD-4 
(Schnaper et al., 2002). This complex is then translocated to the nucleus where it regulates 
expression of a number of target genes including type I collagen, TIMP-1, CCN2 and integrin 
β5 (Verrecchia and Mauviel, 2002).  TGF-β signalling is controlled by a negative feedback 
mechanism involving inhibitory SMADs including SMAD7.  SMAD7 is thought to regulate 
signalling via a number of mechanisms including competitive binding of TGF-β receptors, 
induction of receptor dephosphorylation and receptor degradation.  A detailed review of the 
literature shows that the role of CCN2 in the activation of SMAD proteins has only been 
demonstrated in the context of a potentiation of TGF-β signalling.  Studies on renal fibroblasts 
showed that TGF-β was able to induce phosphorylation of SMAD-2 after 15 minutes; however 
recombinant CCN2 alone did not induce pSMAD-2 until 24 hours.  It was suggested that this 
delay in induction by CCN2 was due to a basal secretion of TGF-β interacting progressively 
with recombinant CCN2 rather than a direct induction by CCN2 itself (Qi et al., 2005).  Studies 
on human mesangial cells showed recombinant CCN2 alone was unable to induce 
phosphorylation of SMAD-2; however when used in combination with TGF-β, CCN2 enhanced 
TGF-β induced phosphorylation.  CCN2 was also shown to directly inhibit SMAD-7 
phosphorylation. It was suggested that the potentiation of TGF-β induced phosphorylation of 
SMAD-2, was due to CCN2 directly blocking the negative feedback loop provided by SMAD-7, 
allowing continued activation of TGF-β signalling (Wahab et al., 2005b).  Experiments on 
human proximal tubule cells showed that silencing of CCN2 mRNA led to a decrease in both 
the secretion of active TGF-β and phosphorylation of SMAD-2 (Qi et al., 2007).  As mentioned 
previously, Abreu et al (2002) showed that at low TGF-β concentrations, CCN2 was able to 
potentiate phosphorylation of SMAD-2 induced by TGF-β in foetal mink lung cells.  CCN2 
alone, or in combination with TGF-β at a higher concentration was unable to demonstrate the 
same effects (Abreu et al., 2002).   
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I investigated whether purified CCN2 was able to potentiate TGF-β phosphorylation of SMAD-
2.  Given that previous experiments on fibroblasts showed minimal effects on gene expression 
compared to that seen in murine MSCs, it was decided to investigate SMAD-2 phosphorylation 
in mesenchymal cells.  Firstly, the ability of TGF-β to induce phosphorylation of SMAD-2 in 
murine MSCs was confirmed (Figure 12).  TGF-β showed a dose dependent effect on 
phosphorylation, with significant detection of pSMAD-2 even at 0.5ng/ml of TGF-β.   
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Figure 12. TGF-β has a dose dependent effect on phospho-smad2 signalling in murine mesenchymal cells. Murine 
MSCs were seeded in micromass culture at a density of 2 x 105 cells/well, serum starved for 5h and stimulated for 
1h with TGF-β3 (5, 1 or 0.5 ng/ml).  Cell lysates were then precipitated using an SDS-PAGE clean-up kit and 
immunoblotted for phospho-smad2.
 
From the results of the dose response experiment, it was decided to use a concentration of 
0.2ng/ml to cause a minimal response by TGF-β. The effect of TGF-β in combination with 
purified CCN2 was investigated (Figure 13).  TGF-β at a concentration of 5ng/ml was used as a 
positive control and caused strong activation of pSMAD-2, whereas TGF-β at 0.2ng/ml caused 
a weak activation, barely detectable above control levels. No effect was seen with purified 
CCN2 alone.  However, when used in combination with TGF-β, a clear potentiation of TGF-β 
induction of pSMAD-2 was demonstrated.  An antibody to ERK1/2 was used as a loading 
control.  This potentiation of TGF-β signalling further confirmed that purified CCN2 had 
biological activity although without further investigation, the exact mechanism by which CCN2 
enhanced the activity of TGF-β remained unclear.   Qi et al (2005) showed a sustained 
phosphorylation of SMAD-2, up to 24 hours, by TGF-β in human proximal tubule cells and 
cortical fibroblasts (Qi et al., 2005).  It may be interesting to determine whether the potentiating 
effect of CCN2 on TGF- β is also sustained or is in fact transient by measuring activation of 
pSMAD-2 over a time course.  A transient effect may suggest that CCN2 is acting indirectly to 
potentiate TGF-β through activation of another factor such as SMAD-7 whereas a sustained 
activation may suggest that CCN2 is acting directly on TGF-β itself.     
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Figure 13. Purified CCN2 potentiaties TGF-β induction of phospho-smad2 in murine mesenchymal cells. Murine 
MSCs were seeded in micromass culture at a density of 2 x 105 cells/well, serum starved overnight and stimulated for 
1h with TGF-β3 (5 or 0.2ng/ml) and CCN2 (10ng/ml) alone, or in combination.  Cell lysates were then precipitated 
using an SDS-PAGE clean-up kit and immunoblotted for phospho-smad2. and total ERK.  Result shown is a 
representative result from three separate experiments. 
36
50
 
 
5.12 CCN2 is constitutively expressed in normal human dermal fibroblasts. 
The reason that purified CCN2 was able to exhibit an effect in murine MSCs but not dermal 
fibroblasts was unclear. One possibility was that constitutive tissue expression of CCN2 
masked the in vitro expression data.  CCN2 is not thought to be constitutively expressed in 
normal dermal fibroblasts.  In scleroderma, no CCN2 mRNA was detected by in situ 
hybridization in cultured human fibroblasts (Igarashi et al., 1996; Igarashi et al., 1995).  Also, 
while investigating the role of TNF-α in blocking induction of CCN2, expression of CCN2 
protein was not found in normal dermal fibroblasts in the absence of TGF-β stimulation 
(Abraham et al., 2000).  In contrast to these reports, one study investigating the inhibition of 
CCN2 by ultraviolet radiation was able to show expression of CCN2 in normal skin fibroblasts 
at both the mRNA and protein level by RT-PCR and western blotting of conditioned media 
(Quan et al., 2002). In view of what I had already shown in porcine chondrocytes; namely that 
constitutive expression was high, especially in the presence of heparin, I hypothesised that 
different levels of constitutive expression may account for changes on in vitro responses in 
different cells.   Fibroblasts and murine MSCs were seeded at the same density and cultured 
for 24 or 48 hours respectively; corresponding to the incubation times in previous experiments.  
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Experiments were performed in the presence or absence of heparin.  Conditioned medium 
from fibroblasts and MSCs was immunoblotted with an antibody to CCN2 (Figure 14).  CCN2 
was undetectable in the conditioned medium of MSCs, even in the presence of heparin.  In the 
absence of heparin, CCN2 was not detected in the medium of fibroblasts, however when 
incubated with heparin there appeared to be substantial accumulation of CCN2 into the 
medium similar to that seen in chondrocytes.  This apparent constitutive expression of CCN2 
by fibroblasts, but not MSCs, would support the hypothesis that the expression of CCN2 at 
relatively high basal levels acts to potentiate TGF-β-induced gene expression in fibroblasts.  
Adding exogenous CCN2 therefore has no additional effect.  In the case of murine MSCs, the 
lack of detectable endogenous CCN2 expression means that a significant potentiating effect by 
exogenous CCN2 is realised.    
 
 
 
36
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Figure 14.  Fibroblasts release more CCN2 than murine MSCs.  Both murine MSCs and normal human dermal 
fibroblasts were seeded at a density of 2 x 105 cells/well. Cells were incubated with or without 100µg/ml heparin for 
48h or 24h respectively.  Conditioned medium (50µl of 1 ml) was then collected and immunoblotted for CCN2.  
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5.13 Discussion 
Following generation of purified CCN2, it was necessary to confirm biological activity.  The 
wide variety of effects of CCN2 reported in the literature made it difficult to select a definitive 
assay to show activity.  Therefore, a number of assays were considered and investigated.  The 
data presented in this chapter demonstrates the difficulties in identifying an appropriate assay, 
confirms biological activity of purified CCN2 and indicates a role for CCN2 in potentiating the 
effects of TGF-β. 
 
I have shown that purified CCN2 was unable to activate the MAPKs, ERK 1/2 or p38, in 
primary porcine chondrocytes.  Reports in the literature have shown that recombinant CCN2 
activates both ERK1/2 and p38 in the chondrosarcoma cell line, HCS-2/8 (Yosimichi et al., 
2001).  Another recent report showed phosphorylation of these two MAPKs in mouse 
chondrocytes, isolated from rib cages of E18.5 mouse embryos (Maeda et al., 2009).  Cell type 
may be critical in determining the effects seen by CCN2.  It is possible that the use of a cell line 
or embryonic chondrocytes may respond differently than articular chondrocytes.  In view of 
data presented in the latter part of this chapter, it is possible that the effects reported are a 
consequence of a potentiation of TGF-β or other growth factor effects, rather than a direct 
effect by CCN2 itself.  It is unclear as to whether TGF-β is constitutively expressed in HCS-2/8 
cells.  Expression of TGF-β is thought to be high in the hypertrophic zones of developing 
cartilage (Horner et al., 1998). The fact that mouse costal chondrocytes are described as 
maintaining a hypertrophic morphology during culture may suggest constitutive expression of 
TGF-β (Ishizeki et al., 2003). TGF-β is known to induce phosphorylation of ERK1/2 and p38 in 
a number of chondrocytic cell lines and primary articular chondrocytes (Poleni et al., 2007; 
Qureshi et al., 2005; Watanabe et al., 2001).  It is obviously difficult to determine whether such 
reported effects of CCN2 are in fact representing enhancement of TGF-β effects.  It may be 
interesting to investigate this hypothesis using porcine articular chondrocytes.  Although the 
effects of TGF-β on articular cartilage have been widely studied, it is unclear to what level TGF-
β is expressed within this tissue.  Previous studies within our laboratory were unable to identify 
TGF-β following proteomic analysis of secreted proteins from porcine articular cartilage 
(Hermansson, M; Thesis).  It could be hypothesised that purified CCN2 was unable to exhibit 
any positive effect due to a lack of endogenous TGF-β, or active TGFβ, within this system.  It 
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would be, therefore, interesting to investigate the effect on MAPK phosphorylation using a 
combination of recombinant TGF-β and purified CCN2. 
 
Purified CCN2 did not affect expression of secreted proteins as determined by metabolic 
labelling.  This again may be a reflection of the ability of CCN2 to act as a cofactor for other 
regulatory molecules within articular cartilage.  CCN2 has been shown to bind to and modulate 
signalling of BMP-2.  Stimulation of primary mouse chondrocytes with BMP-2 and CCN2 in 
combination led to an increase in gene expression of aggrecan, type II and type X collagen 
compared with BMP-2 alone (Maeda et al., 2009).  The effects on protein expression by either 
TGF-β or BMP-2, using metabolic labelling, have never been investigated within our laboratory.  
It may be interesting to use this method to determine both the effects of TGF-β and BMP-2, 
and any potentiating effects of purified CCN2. 
 
I have shown that purified CCN2 did not appear to have any inhibitory effect on Wnt signalling 
in porcine articular chondrocytes. As mentioned, it is possible that the concentration of 
recombinant Wnt3A used in described experiments may have been too high; masking any 
inhibitory effect exhibited by purified CCN2. However, the specific role of CCN2 in modulating 
Wnt signalling is unclear.  Evidence from Xenopus embryos have shown inhibition of Wnt 
signalling following overexpression of CCN2.  In the same study, CCN2 was shown to bind to 
LRP6 and Frizzled8; both members of the Wnt signalling complex.  It was hypothesised that 
CCN2 was able to inhibit Wnt signalling by acting as a receptor antagonist (Mercurio et al., 
2004). Both LRP-5 and -6 are described as Wnt co-receptors, whereas other LRP receptors 
have not been implicated.  It is unclear as to the specificity of LRP expression on porcine 
articular chondrocytes; however, the fact that Wnt3A causes accumulation of β-catenin would 
imply expression of both LRP-5/-6.  One study showed LRP-1 to be expressed in articular 
cartilage and the colocalisation of LRP-1 and CCN2 in HCS-2/8 cells (Kawata et al., 2006).  It 
is possible that CCN2 is unable to bind LRP-5/-6 in chondrocytes.  Data presented in section 
3.7.2 would suggest that CCN2 expressed from porcine chondrocytes is able to bind LRP; 
however, again the specificity of the LRP was unknown.  To clarify a potential role for CCN2 in 
modulating Wnt signalling in articular cartilage, it would be necessary to determine both 
expression of LRP -5/-6 and the ability of purified CCN2 to bind these receptors.      
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While trying to confirm activity of purified CCN2, I investigated the effect of purified CCN2 on 
gene expression in fibroblasts.  Results indicated that purified CCN2 alone was unable to 
mediate any effect.  Evidence in the literature to suggest a role for CCN2 as a cofactor for 
TGF-β signalling led me to investigate the effect of purified CCN2 in combination with TGF-β.  
Purified CCN2 was unable to demonstrate any effect when used in combination with a high 
dose of TGF-β.  However, when a minimal concentration of TGF-β was used, purified CCN2 
was able to potentiate the effects of TGF-β.  Although statistically significant, the increase was 
marginal.  Contrary to the majority of reports, CCN2 appeared to be constitutively expressed in 
normal human dermal fibroblasts, although by western blot was only detected in the medium in 
the presence of heparin.  It could be hypothesised that the presence of endogenous CCN2 
may have prevented purified CCN2 from being able to exhibit any significant potentiation of 
TGF-β effects.  It is therefore likely that any effect by purified CCN2 is highly dependent on 
endogenous expression of CCN2 itself.  Inhibiting the expression of endogenous CCN2, 
through the use of siRNA for example, may allow this hypothesis to be investigated further. 
 
Another assay considered while investigating the activity of purified CCN2 was the effect on 
gene expression in murine MSCs.  As shown in human dermal fibroblasts, purified CCN2 alone 
did not exhibit any significant effect on gene expression.  However, in combination with a low 
dose of TGF-β, a significant potentiation of TGF-β induction of CCN2 mRNA and suppression 
of both Sox-9 and type I collagen mRNA expression was demonstrated. As discussed, the 
more significant effect on TGF-β activity seen in MSCs compared to fibroblasts was likely due 
to the apparent difference in endogenous expression of CCN2.  Further confirmation of a 
potentiating effect on TGF-β signalling came from data presented showing that the combination 
of TGF-β and purified CCN2 increased phosphorylation of SMAD-2.  Although previously 
demonstrated in both mesangial cells and fetal mink lung cells, the potentiation of TGF-β 
phosphorylation of SMAD-2 in mesenchymal stem cells has not previously been shown.  It is 
possible that this implies a specific role for CCN2 in the potentiation of TGF-β induced 
chondrogenesis of MSCs.  
 
It is difficult to identify the exact mechanism by which purified CCN2 is able to potentiate TGF-β 
activity.  A number of potential mechanisms have been described in the literature.  In the 
context of the effect on mesangial cells, the increase in phosphorylation of SMAD-2/3 was 
attributed to the inhibition of SMAD-7 by CCN2 (Wahab et al., 2005b).  As mentioned, SMAD-7 
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is induced by TGF-β and involved in negatively regulating TGF-β signalling (Schmierer and Hill, 
2007).  It would be interesting to determine whether purified CCN2 was able to directly affect 
SMAD-7 in mesenchymal cells, possibly explaining the increase in phosphorylation of SMAD-2.  
This needs to be investigated in future experiments.   
 
Another potential mechanism by which CCN2 may potentiate TGF-β activity is in facilitating 
TGF-β signalling directly, rather than through inhibition of a negative regulator.  Abreu et al. 
(2002) showed that CCN2 increased binding of [125 I] TGF-β to recombinant TGF-βRII in 
solution.  CCN2 also increased binding of [125 I] TGF-β to endogenous receptors on the cell 
surface of cultured cells as well as increasing crosslinking of TGF-β to all three TGF-β 
interacting proteins (TGF-βRI, TGF-βRII and beta-gylcan).  This may indicate a role for CCN2 
as a chaperone to modify the conformation or solubility of TGF-β, and facilitate presentation to 
its cognate receptors (Abreu et al., 2002).  The same study showed that the cysteine-rich (CR) 
domain II of CCN2 designated the von Willebrand type c domain, showed homology with CR 
domains of a number of proteins including thrombospondin-1 (TSP-1) and chordin.  Surface 
plasmon resonance showed that CCN2 could bind both BMP-4 and TGF-β directly through its 
CR domain (Abreu et al., 2002).  A number of studies showed that BMP-7 acts as an 
endogenous antagonist of TGF-β (Wang et al., 2003; Wang and Hirschberg, 2004; Zeisberg et 
al., 2003).  It has been suggested that CCN2 inhibits receptor binding and signalling of BMP-7 
blocking its ability to antagonise TGF-β (Gressner and Gressner, 2008) 
 
Although not previously described, other properties attributed to CCN2 may be responsible for 
potentiation of TGF-β.  For example, the ability of CCN2 itself to bind integrins may somehow 
facilitate binding of integrins to LAP, allowing release of active TGF-β.  Also, the fact that 
module III of CCN2 contains sequences sharing identity with the TSP-1 repeat (Planque and 
Perbal, 2003) may implicate CCN2 in binding to LAP in a similar manner to TSP-1 itself.  
Alternatively, CCN2 may be directly involved in facilitating binding of TGF-β to its receptor, 
following activation.  This may occur again through the ability of CCN2 to bind integrins at the 
cell-surface.  CCN2 may bind to TGF-β directly through its CR domain (Abreu et al., 2002) and 
the localisation of CCN2 within the PCM may be important in facilitating presentation of TGF-β 
to receptors at the cell surface.  To investigate these hypotheses it may firstly be interesting to 
determine the localisation of TGF-β within cartilage and determine whether it does in fact 
colocalise with CCN2 in the PCM.  Interestingly, Chen et al. (2007) have shown a potential role 
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for HS proteoglycans in the regulation of TGF-β by modulating binding of the LTBP to the ECM.  
Heparin was shown to increase binding of LTBP to fibronectin coated plates and the addition of 
exogenous heparin to cell cultures was shown to inhibit the assembly of LTBP within the 
matrix.   It is possible that CCN2 competes for binding to HSPGs, whether within the matrix, or 
at the cell surface, preventing assembly of LTBP within the matrix and possibly allowing 
conversion of TGF-β to the active form.   
 
Although it is obvious from the literature that CCN2 plays a role in TGF-β activity, evidence that 
embryonic fibroblasts from CCN2 null mice were still able to exhibit TGF-β induced activation of 
SMAD pathways, implies that there are multiple factors involved in TGF-β activation and 
signalling (Mori et al., 2008).  Indeed it is likely that CCN2 itself has multiple roles in addition to 
the potentiation of TGF-β signalling, including described modulatory roles in both BMP and Wnt 
signalling.   
 
In regards to the role of CCN2 in articular cartilage, evidence showing that purified CCN2 had 
no effect on MAPK activation or protein synthesis may imply that CCN2 does not have a direct 
effect but acts as a co-factor for other molecules.  Given the literature, it would be interesting to 
investigate the effect of using a combination of CCN2 with such molecules as TGF-β, BMP-2 or 
activin A.  Activin A is another member of the TGF-β superfamily of proteins and is known to be 
upregulated in OA (Hermansson et al., 2004).  The role of activin A in articular cartilage is 
unclear; however it is able to suppress IL-1 induced aggrecanolysis (Alexander et al., 2007).  
Given the affinity of CCN2 for other TGF-β family members, it is reasonable to suggest that 
CCN2 may modulate activity of activin A and therefore may be interesting to investigate.  
However, given the data presented on human dermal fibroblasts, the use of purified CCN2 in 
determining the role of CCN2 in cartilage may be limited.  The inability to demonstrate any 
significant effect with purified CCN2 on dermal fibroblasts has been attributed to the 
constitutive expression of CCN2 in these cells.  Therefore, as shown in Chapter 3, Figure 22, 
the relatively high constitutive expression of CCN2 in both chondrocytes and explants may 
prevent the elucidation of a specific effect on cartilage using purified CCN2.  To overcome this 
problem, it may be necessary to inhibit endogenous expression of CCN2 using siRNA or 
antisense oligonucleotides.  Alternatively, the use of purified CCN2 on cartilage from a tissue-
specific CCN2 knockout mouse may enable a more specific understanding of the role of CCN2.  
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6.0 Concluding comments 
At the beginning of the PhD, I set out to study the presence of novel regulatory molecules 
within the PCM of articular cartilage.  Using both electron and confocal microscopy, I was able 
to further define the PCM as a distinct zone of matrix containing key molecules such as type VI 
collagen, perlecan, hyaluronan.  I also showed that aggrecan is localised within the PCM of 
young, but not mature, articular cartilage suggesting a role for the PCM in mediating assembly 
of aggrecan aggregates in developing cartilage.  I found that the use of proteomics to identify 
novel proteins within PCM of isolated chondrons was not a sensitive enough method.  
Therefore I concentrated on the presence of a candidate regulatory molecule, CCN2, which 
was detected by western blot in isolated chondrons.   
 
I confirmed the presence of CCN2 within the PCM, bound to perlecan, of both human and 
porcine articular cartilage using confocal microscopy.  I also demonstrated that porcine 
chondrocytes actively secrete CCN2; a process that may involve both LRP and heparan 
sulphated proteoglycans.   
 
To determine a role for CCN2 in articular cartilage, I initially attempted purification of the protein 
following transient transfection of HeLa cells, using both heparin and metal affinity 
chromatography.   Unfortunately the concentration of expressed and purified protein was 
insufficient for biological use.  Therefore I generated a stably expressing cell line and used 
metal affinity chromatography to successfully purify CCN2 at a sufficient concentration. 
 
To test the activity of purified CCN2, I investigated a number of biological assays.  I was unable 
to demonstrate any effect of the protein on articular chondrocytes or human dermal fibroblasts.  
However, I demonstrated that purified CCN2 was able to potentiate the effects of TGF-β in 
murine mesenchymal stem cells suggesting a role for CCN2 in cartilage development.  I 
showed that whilst mesenchymal stem cells did not constitutively express CCN2, both 
fibroblasts and chondrocytes showed high constitutive expression levels.  This would explain 
why the effect of purified CCN2 on chondrocytes and fibroblasts was negligible and highlights 
the need for generation of CCN2-/- mice to determine a specific role of CCN2 articular cartilage.  
Our group are in the process of acquiring floxed CCN2 mice with which the plan will be to 
develop cartilage specific conditional knock-out mice.  Future work will then address the in vivo 
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role of CCN2 in articular cartilage, as well as providing cartilage explants with which the role of 
CCN2 in vitro can be examined.
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